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PREAMBLE
It is important that the medical profession play a significant
role in critically evaluating the use of diagnostic procedures
and therapies in the management or prevention of disease
states. Rigorous and expert analysis of the available data
documenting relative benefits and risks of those procedures
and therapies can produce helpful guidelines that improve
the effectiveness of care, optimize patient outcomes, and
affect the overall cost of care favorably by focusing resources
on the most effective strategies.
The American College of Cardiology (ACC) and the
American Heart Association (AHA) have jointly engaged
in the production of such guidelines in the area of cardio-
vascular disease since 1980. The ACC/AHA Task Force on
Practice Guidelines, whose charge is to develop and revise
practice guidelines for important cardiovascular diseases and
procedures, directs this effort. The Task Force is pleased to
have this guideline co-sponsored by the European Society of
Cardiology (ESC). This is the first such joint effort. The
Task Force wishes to acknowledge the important contribu-
tions of Jean-Pierre L. Bassand, MD, FESC, the previous
chair of the ESC Scientific and Clinical Initiatives Com-
mittee, who helped initiate this joint effort. Experts in the
subject under consideration have been selected from all 3
organizations to examine subject-specific data and write
guidelines. The process includes additional representatives
from other medical practitioner and specialty groups where
appropriate. Writing groups are specifically charged to
perform a formal literature review, weigh the strength of
evidence for or against a particular treatment or procedure,
and include estimates of expected health outcomes where
data exist. Patient-specific modifiers, comorbidities, and
issues of patient preference that might influence the choice
of particular tests or therapies are considered, as well as
frequency of follow-up and cost-effectiveness.
The ACC/AHA Task Force on Practice Guidelines and
the ESC make every effort to avoid any actual or potential
conflicts of interest that might arise as a result of an outside
relationship or personal interest of a member of the writing
panel. Specifically, all members of the writing panel are
asked to provide disclosure statements of all such relation-
ships that might be perceived as real or potential conflicts of
interest. These statements are reported orally to all members
of the writing panel at the first meeting and updated as
changes occur.
These practice guidelines are intended to assist physicians
in clinical decision making by describing a range of generally
acceptable approaches for the diagnosis, management, or
prevention of specific diseases or conditions. These guide-
lines attempt to define practices that meet the needs of most
patients in most circumstances. The physician and patient
must make the ultimate judgment regarding care of a
particular patient in light of general information and specific
circumstances.
The executive summary and recommendations are pub-
lished in the October issue of the Journal of the American
College of Cardiology and the October 23 issue of Circulation.
The full text of these guidelines is published in the mid-
October issue of the European Heart Journal. Reprints of the
full text guidelines are available from the ESC; single
reprints of the executive summary are available from the
ACC; bulk reprints of the full text and executive summary
are available from the AHA. These guidelines are available
on the ACC, AHA, ESC and NASPE World Wide Web
sites. The guidelines have been officially endorsed by the
North American Society of Pacing and Electrophysiology.
Raymond J. Gibbons, MD,
FACC
Chair, ACC/AHA
Task Force on
Practice Guidelines
Werner W. Klein, MD,
FACC, FESC
Chair, ESC Committee
for Practice Guidelines
and Policy Conferences
I. INTRODUCTION
A. Organization of Committee and Evidence Review
Atrial fibrillation (AF) is the most common sustained
rhythm disturbance. Its prevalence is increasing along with
the age of the population. AF is often associated with
structural heart disease, but a substantial proportion of
patients with AF have no detectable heart disease. Hemo-
dynamic impairment and thromboembolic events related to
AF result in significant morbidity, mortality, and cost.
Accordingly, the American College of Cardiology (ACC),
the American Heart Association (AHA), and the European
Society of Cardiology (ESC) created a committee to estab-
lish guidelines for better management of this frequent and
complex arrhythmia.
The committee was composed of 8 members representing
the ACC and AHA, 4 members representing the ESC, 1
member from the North American Society of Pacing and
Electrophysiology (NASPE), and a representative of the
Johns Hopkins University Evidence-Based Practice Center
representing the Agency for Healthcare Research and Qual-
ity’s report on Atrial Fibrillation in the Elderly. This
document was reviewed by 3 reviewers nominated by the
ACC, 3 nominated by the AHA, and 3 nominated by the
ESC, as well as by the ACC Clinical Electrophysiology
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Committee, the AHA ECG and Arrhythmia Committee,
NASPE, and 25 additional reviewers nominated by the
writing committee. The document was approved for publi-
cation by the governing bodies of the ACC, AHA, and
ESC and officially endorsed by NASPE. These guidelines
will be reviewed annually by the task force and will be
considered current unless the task force revises or withdraws
them from distribution.
The ACC/AHA/ESC Committee to Develop Guide-
lines for the Management of Patients With Atrial Fibrilla-
tion conducted a comprehensive review of the relevant
literature from 1980 to June 2000. Literature searches were
conducted in the following databases: PubMed/Medline,
EMBASE, the Cochrane Library (including the Cochrane
Database of Systematic Reviews and the Cochrane Con-
trolled Trials Registry), and Best Evidence. Searches were
limited to English language sources and to human subjects.
Major search terms included atrial fibrillation, aged, atrial
remodeling, atrioventricular conduction, atrioventricular
node, cardioversion, classification, clinical trial, complica-
tions, concealed conduction, cost-effectiveness, defibrillator,
demographics, epidemiology, heart failure (HF), hemody-
namics, human, hyperthyroidism, hypothyroidism, meta-
analysis, myocardial infarction, nomenclature, pharmacol-
ogy, postoperative, pregnancy, pulmonary disease, quality of
life, rate control, risks, sinus rhythm, symptoms, and
tachycardia-mediated cardiomyopathy.
Recommendations are evidence based and derived pri-
marily from published data. The weight of evidence was
ranked highest (A) when the data were derived from
multiple randomized clinical trials and intermediate (B)
when based on a limited number of randomized trials,
nonrandomized studies, or observational registries. The
lowest rank (C) was given when the primary basis for the
recommendation was expert consensus.
Recommendations follow the format of previous ACC/
AHA guidelines for classifying indications,
summarizing both the evidence and expert opinion:
Class I:
Conditions for which there is evidence for and/or
general agreement that the procedure or treatment is
useful and effective.
Class II:
Conditions for which there is conflicting evidence
and/or a divergence of opinion about the usefulness/
efficacy of a procedure or treatment.
Class IIa:
The weight of evidence or opinion is in favor of the
procedure or treatment.
Class IIb:
Usefulness/efficacy is less well established by evidence
or opinion.
Class III:
Conditions for which there is evidence and/or general
agreement that the procedure or treatment is not
useful/effective and in some cases may be harmful.
B. Contents of These Guidelines
These guidelines first present a comprehensive review of the
latest information about the definition, classification, epi-
demiology, mechanisms, and clinical characteristics of AF.
The management of this complex and potentially dangerous
arrhythmia is then reviewed. This includes conversion to
and maintenance of sinus rhythm, control of heart rate, and
prevention of thromboembolism. The treatment algorithms
include pharmacological and nonpharmacological antiar-
rhythmic approaches, as well as antithrombotic strategies
thought to be most appropriate for each particular patient’s
condition. Overall, this is a consensus document that
attempts to reconcile evidence and opinion from both sides
of the Atlantic Ocean. The pharmacological and nonphar-
macological antiarrhythmic approaches discussed may in-
clude some drugs and devices that do not have the approval
of governmental regulatory agencies. Additional informa-
tion may be obtained from the package inserts.
Because atrial flutter can precede or coexist with AF,
special consideration is given in each of these sections to this
arrhythmia. There are important differences in the mecha-
nisms of AF and atrial flutter, and the body of evidence
available to support therapeutic recommendations is distinct
for the 2 arrhythmias. Atrial flutter is not addressed com-
prehensively in these guidelines but will be addressed in the
upcoming ACC/AHA/ESC Guidelines on the Manage-
ment of Patients With Supraventricular Arrhythmias.
II. DEFINITION
A. Atrial Fibrillation
Atrial fibrillation is a supraventricular tachyarrhythmia
characterized by uncoordinated atrial activation with con-
sequent deterioration of atrial mechanical function. On the
electrocardiogram (ECG), AF is described by the replace-
ment of consistent P waves by rapid oscillations or fibrilla-
tory waves that vary in size, shape, and timing, associated
with an irregular, frequently rapid ventricular response when
atrioventricular (AV) conduction is intact (1). The ventric-
ular response to AF depends on electrophysiological prop-
erties of the AV node, the level of vagal and sympathetic
tone, and the action of drugs (2) (Fig. 1). Regular RR
intervals are possible in the presence of AV block or
interference due to ventricular or junctional tachycardia. In
patients with electronic pacemakers, diagnosis of AF may
require temporary inhibition of the pacemaker to expose
atrial fibrillatory activity (3). A rapid, irregular, sustained,
wide-QRS-complex tachycardia strongly suggests AF with
conduction over an accessory pathway or AF with underly-
ing bundle-branch block. Extremely rapid rates (over 200
bpm) suggest the presence of an accessory pathway.
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B. Related Arrhythmias
Atrial fibrillation may occur in isolation or in association
with other arrhythmias, most commonly atrial flutter or
atrial tachycardia. Atrial flutter may arise during treatment
with antiarrhythmic agents prescribed to prevent recurrent
AF. Atrial flutter is a more organized arrhythmia than AF
and is characterized by a saw-tooth pattern of regular atrial
activation called flutter (f) waves on the ECG, particularly
visible in leads II, III, and aVF, without an isoelectric
baseline between deflections (Fig. 2). In the untreated state,
the atrial rate typically ranges from 240 to 320 beats per
minute, with f waves inverted in ECG leads II, III, and aVF
and upright in lead V1. The wave of activation in the right
atrium (RA) may be reversed, resulting in f waves that are
upright in leads II, III, and aVF and inverted in lead V1.
Atrial flutter commonly occurs with 2:1 AV block, resulting
in a ventricular rate of 120 to 160 beats per minute, most
characteristically about 150 beats per minute. Several types
of atrial flutter have been distinguished, but no consistent
nomenclature has been widely accepted. Atrial flutter may
degenerate into AF, AF may initiate atrial flutter, or the
ECG pattern may alternate between atrial flutter and AF,
reflecting changing activation of the atria.
Other atrial tachycardias, AV reentrant tachycardias, and
AV nodal reentrant tachycardias may also trigger AF. In
other atrial tachycardias, P waves are readily identified and
separated by an isoelectric baseline in 1 or more ECG leads.
The morphology of the P waves may help localize the origin
of the tachycardias. A unique type of atrial tachycardia has
recently been identified that commonly originates in the
pulmonary veins but may arise elsewhere (4), is rapid
(typically faster than 250 beats per minute), and often
degenerates into AF. Electrophysiological studies with in-
tracardiac mapping may help differentiate the various types
of atrial arrhythmias and elucidate their mechanisms.
III. CLASSIFICATION
Atrial fibrillation has a heterogeneous clinical presentation,
occurring in the presence or absence of detectable heart
disease or related symptoms. Various classification systems
have been proposed for AF. One scheme is based on the
ECG presentation (1–3). Another is based on epicardial (5)
or endocavitary recordings or noncontact mapping of atrial
electrical activity. Several clinical classification schemes have
also been proposed, but none fully accounts for all aspects of
AF (6–9). To be clinically useful, a classification system
must be based on a sufficient number of features and carry
specific therapeutic implications.
An episode of AF may be self-limited or require medical
intervention for termination. Over time, the pattern of AF
may be defined in terms of the number of episodes,
duration, frequency, mode of onset and possible triggers,
and response to therapy, but these features may be impos-
sible to discern when AF is first encountered in an individ-
ual patient. Although the pattern of the arrhythmia can
change over time, it may be of clinical value to characterize
the arrhythmia at a given moment.
Assorted labels have been used to describe the pattern of
AF, including acute, chronic, paroxysmal, intermittent,
constant, persistent, and permanent, but the vagaries of
Figure 1. Standard 12-lead surface electrocardiogram showing atrial fibrillation with a controlled rate of ventricular response.
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definitions make it difficult to compare studies of AF in
terms of the effectiveness of therapeutic strategies based on
these designations. The classification scheme recommended
in this document represents a consensus driven by a desire
for simplicity and clinical relevance.
The clinician should distinguish a first-detected episode
of AF, whether or not it is symptomatic or self-limited,
recognizing that there may be uncertainty about the dura-
tion of the episode and about previous undetected episodes
(Fig. 3). When a patient has had 2 or more episodes, AF is
considered recurrent. If the arrhythmia terminates sponta-
neously, recurrent AF is designated paroxysmal; when
sustained, AF is designated persistent. In the latter case,
termination with pharmacological therapy or electrical car-
dioversion does not change the designation. Persistent AF
may be either the first presentation of the arrhythmia or the
Figure 2. Standard 12-lead surface electrocardiogram showing typical atrial flutter with variable atrioventricular conduction. The recording chart speed and
deflection sensitivity are the same as for Fig. 1.
Figure 3. Patterns of atrial fibrillation. 1, episodes that generally last less than or equal to 7 days (most less than 24 h); 2, usually more than 7 days; 3,
cardioversion failed or not attempted; and 4, either paroxysmal or persistent AF may be recurrent.
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culmination of recurrent episodes of paroxysmal AF. The
category of persistent AF also includes cases of long-
standing AF (e.g., greater than 1 year) in which cardiover-
sion has not been indicated or attempted, usually leading to
permanent AF (Fig. 3).
The terminology defined in the preceding paragraph
applies to episodes of AF that lasts more than 30 seconds
and that are unrelated to a reversible cause. Secondary AF
that occurs in the setting of acute myocardial infarction
(MI), cardiac surgery, pericarditis, myocarditis, hyperthy-
roidism, pulmonary embolism, pneumonia, or acute pulmo-
nary disease is considered separately, because AF is less
likely to recur once the precipitating condition is resolved.
In these settings, AF is not the primary problem, and
treatment of the underlying disorder concurrently with
management of the episode of AF usually results in termi-
nation of the arrhythmia without recurrence.
The term “lone AF” has been variously defined but
generally applies to young individuals (under 60 years of
age) without clinical or echocardiographic evidence of car-
diopulmonary disease (10). These patients have a favorable
prognosis with respect to thromboembolism and mortality.
As time goes by, however, patients move out of the lone AF
category by virtue of aging or the development of cardiac
abnormalities such as enlargement of the left atrium (LA),
and the risks of thromboembolism and mortality rise ac-
cordingly. Lone AF is distinguished from other forms of
idiopathic AF because of the criteria of patient age and the
absence of identified cardiovascular pathology. By conven-
tion, the term nonvalvular AF is restricted to cases in which
the rhythm disturbance occurs in the absence of rheumatic
mitral valve disease or a prosthetic heart valve.
IV. EPIDEMIOLOGY AND PROGNOSIS
Atrial fibrillation is the most common arrhythmia encoun-
tered in clinical practice, accounting for approximately one
third of hospitalizations for cardiac rhythm disturbance. It
has been estimated that 2.2 million Americans have parox-
ysmal or persistent AF (11). Most of the data regarding the
epidemiology, prognosis, and quality of life in AF have been
obtained in North America and western Europe.
A. Prevalence
The prevalence of AF is estimated at 0.4% of the general
population, increasing with age (12). Cross-sectional studies
have found the prevalence to be less than 1% in those under
60 years of age and greater than 6% in those over 80 years
(13–15) (Fig. 4). The age-adjusted prevalence is higher in
men (15,16). Based on limited data, the age-adjusted risk of
developing AF in blacks appears to be less than half that in
whites (17,18).
In population-based studies, the frequency of AF in
patients with no history of cardiopulmonary disease (lone
AF) was less than 12% of all cases of AF (Fig. 5) (10,15,19,20).
In some series, however, the observed frequency of lone AF
was over 30% (21,22). AF is prevalent in patients with
congestive HF or valvular heart disease and increases in
prevalence with the severity of these conditions (Table 1).
B. Incidence
In prospective studies, the incidence of AF increased from
less than 0.1% per year in those under 40 years of age to
greater than 1.5% per year in women over 80 years of age
and greater than 2% per year in men over 80 years of age
(17,23,24) (Fig. 6). The age-adjusted incidence increased
over a 30-year period in the Framingham Study (23), and
this may have implications for the future impact of AF on
the population. During 38 years of follow-up in the Fra-
mingham Study, 20.6% of men who developed AF had
congestive HF at inclusion vs. 3.2% of those without AF;
the corresponding incidences in women were 26.0% and
2.9% (25). In patients referred for treatment of HF, the 2-
to 3-year incidence of AF was 5% to 10% (17,26,27). The
incidence of AF may be lower in HF patients treated with
angiotensin converting enzyme inhibitors (28).
C. Prognosis
The rate of ischemic stroke among patients with nonrheu-
matic AF averages 5% per year, which is between 2 and 7
times that of people without AF (13,14,21,23,24,28) (Fig.
7). One of every 6 strokes occurs in patients with AF (29).
Additionally, when transient ischemic attacks and clinically
occult “silent” strokes detected radiographically are consid-
ered, the rate of brain ischemia accompanying nonvalvular
AF exceeds 7% per year (25,30–33). In patients with
rheumatic heart disease and AF, stroke risk was increased
17-fold compared with age-matched controls in the Fra-
mingham Heart Study (34), and attributable risk was 5
times greater than in those with nonrheumatic AF (14).
Atrial fibrillation doubled the risk of stroke in the Manitoba
Follow-up Study independently of other risk factors (24),
and the relative risks for stroke in nonrheumatic AF were
6.9% and 2.3% in the Whitehall and the Regional Heart
studies, respectively. Among AF patients from general
practices in France, the ALFA Study (Etude en Activite´
Figure 4. Prevalence of AF in 2 American epidemiological studies.
Framingham indicates the Framingham Heart Study (14), CHS, Cardio-
vascular Health Study (15).
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Liberale sur le Fibrillation Auriculaire) found a 2.4% inci-
dence of thromboembolism over a mean of 8.6 months of
follow-up (21). The risk of stroke increases with age; in the
Framingham Study, the annual risk of stroke attributable to
AF increased from 1.5% in participants aged 50 to 59 years
to 23.5% for those aged 80 to 89 years (14).
The mortality rate of patients with AF is about double
that of patients in normal sinus rhythm and is linked with
the severity of underlying heart disease (13,16,24) (Fig. 7).
About two thirds of the 3.7% mortality over 8.6 months in
the ALFA study was attributed to cardiovascular causes
(21). In patients with mild to moderate HF, however, the
data are mixed. The V-HeFT studies (Veterans Adminis-
tration Heart Failure Trials) did not find increased mortality
among patients with concomitant AF (35), whereas in the
SOLVD trial (Studies of Left Ventricular Dysfunction),
mortality was 34% for those with AF vs. 23% for patients in
sinus rhythm (p less than 0.001) (36). The difference was
attributed mainly to an increased number of deaths due to
HF rather than to thromboembolism.
V. PATHOPHYSIOLOGICAL MECHANISMS
A. Atrial Factors
1. Pathology of the Atrium in Patients With AF. Pa-
tients with persistent AF predominate in most pathological
studies, and only limited information is available about
anatomic changes associated with paroxysmal AF. The atria
of patients with AF display structural abnormalities beyond
the changes caused by underlying heart disease (38). His-
tological examination has shown patchy fibrosis with juxta-
position of normal and diseased atrial fibers, which may
account for nonhomogeneity of atrial refractoriness (39,40).
Fibrosis or fatty infiltration may also affect the sinus node
and may be a reaction to inflammatory or degenerative
processes that are difficult to detect. The role of inflamma-
tion in the pathogenesis of AF has not yet been evaluated,
but histological changes consistent with myocarditis were
reported in 66% of atrial biopsy specimens from patients
with lone AF (40). Infiltration of the atrial myocardium may
occur in amyloidosis, sarcoidosis, and hemochromatosis.
Atrial fiber hypertrophy has been described as a major
Figure 6. Incidence of atrial fibrillation in 2 American epidemiological
studies. Framingham indicates the Framingham Heart Study (23), and
CHS indicates Cardiovascular Health Study (17).
Table 1. Prevalence of Atrial Fibrillation in Patients With
Heart Failure
Predominant
NYHA Type
Prevalence
of AF, % Study, y
I 4 SOLVD-prevention (1992)
II–III 10–26 SOLVD-treatment (1991)
CHF-STAT (1995)
MERIT-HF (1999)
Diamond (1999)
III–IV 20–29 Middlekauff (1991)
Stevenson (1996)
GESICA (1994)
IV 50 CONSENSUS (1987)
NYHA, New York Heart Association; AF indicates atrial fibrillation; SOLVD,
Studies of Left Ventricular Dysfunction; CHF-STAT, Survival Trial of Antiarrhyth-
mic Therapy in Congestive Heart Failure; MERIT-HF, Metoprolol CR/XL Ran-
domized Intervention Trial in Congestive Heart Failure; GESICA, Grupo Estudio
de la Sobrevida en la Insufficienca Cardiaca en Argentina (V); and CONSENSUS,
Co-operative North Scandinavian Enalapril Survival Study.
Figure 5. Estimated prevalence of AF in relation to age in the United States, based on 4 population-based surveys. The median age of AF patients is about
75 years. Approximately 70% are between 65 and 85 years old. The overall number of men and women with AF is about equal, but approximately 60%
of AF patients over age 75 years are female prevalence, age, distribution, and gender of patients with atrial fibrillation analysis and implications. Vol. 155,
pp. 469–73, © 1995 American Medical Association (37).
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feature or sometimes the sole histological change in AF
patients (39). Atrial hypertrophy and dilatation may be
either a cause or a consequence of persistent AF, because
progressive atrial enlargement has been demonstrated echo-
cardiographically in patients with AF (41). A recent exper-
imental study showed that HF facilitates the induction of
sustained AF, mediated by extensive interstitial fibrosis (42).
In most patients, however, it is not possible to identify the
underlying anatomic process responsible for the arrhythmia.
A role for autoimmune mechanisms in genetically predis-
posed patients has been suggested by high serum levels of
antibodies against myosin heavy chains in patients with
paroxysmal AF without identified heart disease (43). This is
of particular interest because the prevalence of heart disease
is generally lower in patients with paroxysmal AF than in
those with permanent AF.
2. Mechanisms of AF. Theories of the mechanism of AF
involve 2 main processes: enhanced automaticity in 1 or
several rapidly depolarizing foci and reentry involving 1 or
more circuits (44,45) (Fig. 8). A focal origin of AF is
supported by experimental models of aconitine-induced and
pacing-induced AF (46,47) in which the arrhythmia per-
sisted only in isolated regions of atrial myocardium. Rapidly
firing atrial foci, located most often in the superior pulmo-
nary veins, may initiate AF in susceptible patients (4,48).
Patients may have more than 1 pulmonary vein focus
capable of engendering AF (48); foci also occur in the RA
and infrequently in the superior vena cava or coronary sinus
(4,48,49). Histological studies have demonstrated cardiac
muscle with preserved electrical properties extending into
the pulmonary veins (50–55). Whether this represents a
particular form of AF or a triggering arrhythmia is not clear,
nor has the importance of this mechanism of induction
among various subsets of AF patients been evaluated suffi-
ciently. The focal origin appears to be more important in
patients with paroxysmal AF than in those with persistent
AF, and ablation of such foci may be curative (4) (see
Section VIII-E-7, Nonpharmacological Correction of AF).
The multiple-wavelet hypothesis as the mechanism of
reentrant AF was advanced by Moe and colleagues (44,56),
who proposed that fractionation of the wave fronts as they
propagate through the atria results in self-perpetuating
“daughter wavelets.” The number of wavelets present at any
time depends on the refractory period, mass, and conduc-
tion velocity in different parts of the atria. A large atrial mass
with a short refractory period and delayed conduction may
Figure 7. Relative risk of stroke and mortality in patients with AF compared with patients without AF. Source data from the Framingham Heart Study
(16), Regional Heart Study (13), Whitehall study (13), and Manitoba study (24).
Figure 8. Principal electrophysiological mechanisms of atrial fibrillation. A, Focal activation. The initiating focus (indicated by the asterisk) often lies within the
region of the pulmonary veins. The resulting wavelets represent fibrillatory conduction, as in multiple-wavelet reentry. B, Multiple-wavelet reentry. Wavelets
(indicated by arrows) randomly reenter tissue previously activated by them or by another wavelet. The routes the wavelets travel vary. LA indicates left atrium; PV,
pulmonary vein; ICV, inferior vena cava; SCV, superior vena cava; and RA, right atrium. Reproduced with permission from Konings KTS (64).
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harbor an increased number of wavelets, favoring sustained
AF. Simultaneous recordings from multiple electrodes have
confirmed the multiple-wavelet hypothesis in canine atria
(45,57), and similar observations have been reported in
humans (58,59).
Although the patterns of activation underlying the irreg-
ular atrial electrical activity of AF have traditionally been
described as disorganized or random, recent evidence has
emerged that AF is spatially organized. High-resolution
video imaging, ECG recordings, and spectral analysis dur-
ing propagation of AF in sheep hearts identified sequential
wave fronts with temporal periodicity and spatial patterns of
propagation that appear to arise from reentry in anatomi-
cally or functionally determined circuits (60). Unlike other
arrhythmias, in which a single reentrant circuit is typically
identified, AF may involve several circuits (5,61). The
length of the path through which the depolarization wave
front must travel, as well as its conduction velocity and
refractoriness, is influenced by atrial enlargement, which
may favor the development of AF. On the basis of mapping
studies of patients undergoing surgery for the Wolff-
Parkinson-White (WPW) syndrome, 3 patterns of induced
AF have been identified (5). Type I AF involves single wave
fronts propagating across the RA. Type II AF involves 1 or
2 wave fronts, and type III AF is characterized by multiple
activation wavelets propagating in different directions. An-
isotropy related to the orientation of atrial fibers and
pectinate muscles within the atria has been investigated by
video imaging and mapping (62), with observations of
heterogeneous breakthrough patterns over the epicardium,
wave collisions, and incomplete reentry. Evolving nonfluo-
roscopic 3-dimensional electroanatomic recording systems
are expected to provide additional information about the
mechanisms engendering AF that will allow more precise
characterization of its electrophysiological origins (63) (Ta-
ble 2). Ultimately, a better understanding of the diverse
electrophysiological mechanisms responsible for the genesis
and maintenance of AF will lead to the development of
effective preventive measures.
A. ATRIAL ELECTRICAL REMODELING. Pharmacological or
electrical cardioversion of AF has a higher success rate when
AF has been present for less than 24 h (65), whereas a
longer duration of AF reduces the likelihood of restoring
and maintaining sinus rhythm. These observations gave rise
to the adage that “atrial fibrillation begets atrial fibrillation.”
This notion (that atrial fibrillation tends to perpetuate itself)
has recently found experimental support in a goat model
using an automatic atrial fibrillator that detected spontane-
ous termination of induced AF and reinduced the dysrhyth-
mia by delivering a burst of electrical stimuli (66). Initially,
electrically induced AF terminated spontaneously. After
repeated inductions, however, the episodes became progres-
sively more sustained until AF persisted at a more rapid
atrial rate (66). The increasing propensity to AF was related
to progressive shortening of effective refractory periods with
increasing episode duration, a phenomenon known as elec-
trophysiological remodeling. These measurements support
clinical observations (67) that the atrial effective refractory
period in patients with paroxysmal AF is short and that
refractoriness fails to adapt to rate, particularly during
bradycardia. Further confirmation has come from record-
ings of action potentials in isolated tissue from fibrillating
atria and in patients after cardioversion (68). The duration
of atrial monophasic action potentials in AF patients was
shorter after cardioversion and was correlated with instabil-
ity of the sinus mechanism (69). Decreased inward current
through L-type calcium channels probably plays an impor-
tant role in action potential shortening (70).
Electrophysiological remodeling that takes place in the
atria within the first 24 h after the onset of AF involves
shortening of the effective atrial refractory periods. Resto-
ration of electrical refractoriness by prompt cardioversion of
AF might explain the higher success rate of early interven-
tion (66). Calcium channel blockade may inhibit the atrial
remodeling that occurs during AF (71–73). Prolonged
periods of AF may also disturb atrial contractile function,
and recovery of atrial mechanical function may depend on
the duration of AF. After a long period of persistent AF,
recovery of atrial contraction can be delayed for days or even
weeks after sinus rhythm has been restored. This has
important implications for the duration of anticoagulation
after cardioversion. (See Section VIII-G, Preventing
Thromboembolism.) Electrophysiological studies in dogs
and preliminary human data suggest that prolonged AF may
lengthen sinus node recovery time (74,75). The implication
is that in some patients with the tachycardia-bradycardia
syndrome, AF may be partly responsible for sinus node
dysfunction.
B. OTHER ELECTROPHYSIOLOGICAL FACTORS. Other fac-
tors involved in the induction or maintenance of AF include
premature beats, autonomic nervous system activity, atrial
ischemia (76), atrial stretch (77), anisotropic conduction
(78), and aging. In animal experiments, induction of AF
increases oxygen consumption in atrial myocardium (76). In
human studies (79,80), refractory periods and conduction
velocities are not homogeneous in AF patients, and disper-
Table 2. Anatomic and Electrophysiological Factors Promoting
the Initiation and/or Maintenance of AF
Anatomic Factors Electrophysiological Factors
Ion channel expression Shortened atrial effective refractory periods
Altered gap junction
distribution
Atrial myocyte calcium overload
Altered sympathetic
innervation
Atrial myocyte triggered activity or
automaticity
Atrial dilatation Decreased atrial conduction velocity
Pulmonary vein
dilatation
Nonhomogeneity of atrial refractoriness
Atrial myocyte apoptosis Dispersion of conduction
Interstitial fibrosis Supersensitivity to catecholamines and
acetylcholine
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sion of refractoriness has been linked to the inducibility and
persistence of AF (70). Slowing of conduction is also
involved in dispersion of atrial refractoriness, particularly in
structurally diseased hearts (80), and interruption of sym-
pathetic and parasympathetic fibers increases the sensitivity
of atrial tissue to catecholamines and acetylcholine (77).
A critical mass of atrial tissue appears necessary to sustain
AF. This may account for the effectiveness of the maze
operation (58,81,82) and of catheter ablation of atrial
myocardium with linear lesions. Both methods reduce the
mass of contiguous atrial tissue to a point that inhibits
sustained AF. Once it is initiated, maintenance of AF may
involve specific requirements for the size of the atria and the
distance between depolarization wave fronts. When the
wavelength (45) exceeds the length of the path, the dys-
rhythmia stops. For an electrical impulse to propagate
around an area of block, conduction must be slow enough to
allow the fibers ahead to recover excitability. A short
refractory period or slow conduction shortens the excitation
wavelength and thus sustains reentry.
Atrial fibrillation may result from increased vagal tone,
which leads to episodes during sleep or after meals, most
often in patients without organic heart disease. In dog
models, vagal denervation of the atria prevents induction of
AF (83). In contrast, exercise, emotion, surgical stress, or
infusion of isoproterenol may provoke catecholamine-
induced AF. One or the other of these mechanisms may
predominate in a given patient, but the mode of initiation of
AF may vary over time, which makes it difficult to distin-
guish one type from another based on the history of a single
episode. The role of the autonomic nervous system in AF
patients has been examined with measurements of heart rate
variability, which revealed features of vagal or adrenergic
predominance (84).
Even when other factors are involved in AF, premature
beats are important initiating events in most cases (4,85,86).
Just as rapid ventricular tachycardia may degenerate into
ventricular fibrillation, other types of supraventricular tachy-
cardia may degenerate into AF (tachycardia-induced tachy-
cardia) (87). It is important to recognize this mechanism of
AF induction, because elimination of the initiating arrhyth-
mia may abolish AF. AV node reentry and AV reentry are
examples of arrhythmias that cause AF and are often easily
cured by radiofrequency catheter ablation (88–90).
B. AV Conduction
1. General Aspects. In the absence of an accessory path-
way or His-Purkinje dysfunction, the AV node limits
conduction during AF (90). There appear to be 2 distinct
atrial inputs to the AV node, one directed posteriorly via the
crista terminalis and the other anteriorly via the interatrial
septum. Studies on rabbit AV nodal preparations showed
that during AF, propagation of impulses through the AV
node to the His bundle depended in part on the relative
timing of the anterior and posterior septal activation inputs
to the AV node (91). Other factors affecting conduction
through the AV node are its intrinsic refractoriness, con-
cealed conduction, and autonomic tone. Concealed conduc-
tion, which occurs when atrial impulses traverse part of the
AV node but do not conduct to the ventricle, plays a
prominent role in determining the ventricular response
during AF (56,92,93). These impulses alter AV nodal
refractoriness, slowing or blocking subsequent atrial im-
pulses. Moe and colleagues (56) explained that the irregu-
larity of ventricular response during AF was caused in part
by concealed AV nodal conduction. When the atrial rate
during AF is relatively slow, the ventricular rate tends to
increase. Alternatively, an increased atrial rate is associated
with a slower ventricular rate.
AV nodal conduction is also affected by autonomic tone
(92,94,95). Increased parasympathetic and decreased sym-
pathetic tone exert negative dromotropic effects on AV
nodal conduction; the opposite is true in states of decreased
parasympathetic and increased sympathetic tone. Vagal tone
also enhances the negative dromotropic effects of concealed
conduction in the AV node (94,95). Fluctuations in auto-
nomic tone can produce disparate ventricular responses to
AF in a given patient. For example, a patient may exhibit
slow ventricular rates during sleep but an accelerated ven-
tricular response during exercise. Digitalis, which slows
ventricular rate during AF predominantly by increasing
vagal tone, may control heart rate at rest but is much less
effective during activity. These wide swings in rate due to
variations in autonomic tone often create therapeutic chal-
lenges.
The conducted QRS complexes during AF are narrow
unless there is fixed or rate-related bundle-branch block or
an accessory pathway (see below). Aberrant conduction
occurs commonly during AF, facilitated by the irregularity
of the ventricular response. This often results in a long
interval followed by a relatively short interval, with the QRS
complex that closes the short interval aberrantly conducted
(Ashman phenomenon) (96).
2. AV Conduction in the WPW Syndrome. Accessory
pathways are muscle connections between the atrium and
ventricle that have the capacity to conduct rapidly in many
individuals. Unlike conduction through the AV node, con-
duction over an accessory pathway during AF can result in
a very rapid ventricular response that may be fatal (2,97).
Concealed conduction over accessory pathways (98) likely
plays a lesser role than the AV node to limit the ventricular
response. Whereas a substantial increase in sympathetic
tone may increase the preexcited ventricular response, alter-
ations in vagal tone appear to have little effect on conduction
over accessory pathways.
Transition of AV reentry into AF in patients with the
WPW syndrome can produce a rapid ventricular response
that degenerates into ventricular fibrillation leading to
sudden cardiac death (97,99). Drugs such as digitalis,
calcium channel antagonists, and beta-blockers, which are
usually given to slow conduction across the AV node during
AF, do not block conduction over the accessory pathway
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and may even enhance conduction, resulting in hypotension
or cardiac arrest (100). During AF with intermittent con-
duction over an accessory pathway, drugs such as calcium
channel blockers that impair conduction predominantly
through the AV node may result in an accelerated preex-
cited ventricular response because of the loss of concealed
retrograde conduction into the accessory pathway.
C. Myocardial and Hemodynamic Consequences of AF
During AF, 3 factors can affect hemodynamic function: loss
of synchronous atrial mechanical activity, irregularity of
ventricular response, and inappropriately rapid heart rate. A
marked decrease in cardiac output may occur with the loss
of atrial contraction, especially in patients with impaired
diastolic ventricular filling, hypertension, mitral stenosis,
hypertrophic cardiomyopathy (HCM), or restrictive cardio-
myopathy. The variation in RR intervals during AF may
also result in hemodynamic impairment. In a canine model
with complete heart block, cardiac output fell by approxi-
mately 9% during irregular ventricular pacing at the same
mean cycle length as a regularly paced rhythm (101).
Importantly, mitral regurgitation was observed only during
the irregularly paced rhythm. Cardiac cycle irregularity
during AF can also decrease cardiac output in human
subjects (102). In fact, myocardial contractility is not con-
stant during AF. When left ventricular (LV) pressure and
volume were measured continuously in 6 patients, cycle-to-
cycle changes in myocardial contractility were observed in
AF because of force-interval relationships associated with
cycle length (103). Thus, both the loss of AV synchrony and
the irregularity of the ventricular response adversely affect
hemodynamics during AF. Although it might seem that
restoration of sinus rhythm would result in improved
hemodynamic characteristics, this is not always the case
(104,105).
A persistently rapid atrial rate can adversely affect atrial
mechanical function (tachycardia-induced atrial cardiomy-
opathy) (2,106). In dogs subjected to sustained rapid atrial
pacing, electrophysiological, anatomic, and pathological
changes occur over time, including increased mitochondrial
size, disruption of sarcoplasmic reticulum, biatrial enlarge-
ment, and decreased atrial refractoriness (106). Persistence
of AF in chronically instrumented goat atria is associated
with marked structural abnormalities in atrial myocytes and
progressive but reversible electrophysiological changes, so
sustained AF develops much more readily (66,106,107).
Such changes in atrial tissue may explain the delayed
recovery of atrial contractility in patients after cardioversion
to sinus rhythm. In a study of persistent AF, mean LA
volume increased over time from 45 to 64 cm3, and RA
volume increased from 49 to 66 cm3 (108). In another study,
restoration and maintenance of sinus rhythm decreased RA
and LA volumes (109). Moreover, transesophageal echocar-
diography (TEE) has demonstrated that LA appendage
(LAA) blood flow velocity and contractile function recover
over time after cardioversion, which suggests a reversible
atrial cardiomyopathy (110,111).
Beyond the effects on atrial function, a persistently
elevated ventricular rate during AF—greater than or equal
to 130 beats per minute in one study (112)—can produce
dilated ventricular cardiomyopathy (tachycardia-induced
cardiomyopathy) (2,112–115). It is critically important to
recognize this cause of cardiomyopathy, because control of
the ventricular response may lead to partial or even complete
reversal of the myopathic process. Patients may present with
HF as the initial manifestation of AF; HF may thus be a
consequence of rather than the cause of AF, offering an
avenue for remarkable improvement in LV function. In one
study, the median LV ejection fraction increased from 25%
to 52% (113) with rate control. This has important impli-
cations for the timing of measurements of ventricular
performance in patients with AF, because a reduced ejection
fraction during or in the days or weeks following tachycardia
may not accurately reflect ventricular function after the rate
has been controlled. A variety of hypotheses have been
proposed to explain tachycardia-mediated cardiomyopathy
that involve myocardial energy depletion, ischemia, abnor-
malities of calcium regulation, and remodeling, but the
actual mechanisms responsible for this disorder are still
unclear (116).
D. Thromboembolism
Although ischemic stroke and systemic arterial occlusion in
AF are generally attributed to embolism of thrombus from
the LA, the pathogenesis of thromboembolism is complex
(117). Up to 25% of AF-associated strokes may be due to
intrinsic cerebrovascular diseases, other cardiac sources of
embolism, or atheromatous pathology in the proximal aorta
(118,119). The frequency of stroke related to AF increases
with age to 36% per year for patients aged 80 to 89 years
(14). About half of all elderly AF patients have chronic
hypertension (a major risk factor for cerebrovascular disease)
(28), and approximately 12% harbor cervical carotid artery
stenosis. Carotid atherosclerosis is not substantially more
prevalent in AF patients with stroke than in patients
without AF, however, and is probably a relatively minor
contributing factor (120).
1. Pathophysiology of Thrombus Formation. LA throm-
bus formation begins with Virchow’s conditions of stasis,
endothelial dysfunction, and a hypercoagulable state. The
hemodynamic and hemostatic mechanisms responsible for
clinical thromboembolism in AF have been elucidated by
serial imaging and coagulation studies. Thrombus associ-
ated with AF arises most frequently in the LAA, which
cannot be regularly examined by precordial (transthoracic)
echocardiography (121). Transesophageal Doppler echocar-
diography provides a sensitive and specific method to assess
LAA function (122) and to detect thrombotic material.
Thrombi are more often encountered in AF patients with
ischemic stroke than in those without stroke (123). Serial
TEE studies of the LA (124) and LAA (125) during
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conversion of AF to sinus rhythm have demonstrated
reduced LAA flow velocities related to loss of organized
mechanical contraction during AF. This substrate of de-
creased flow within the LA/LAA has been associated with
spontaneous echo contrast, thrombus formation, and em-
bolic events (126–132). LAA flow velocities are lower in
patients with atrial flutter than what is usually seen with
normal sinus rhythm but are higher than with AF. Whether
this accounts for the slightly lower prevalence of LAA
thrombus and perhaps a lower rate of thromboembolism
associated with atrial flutter is uncertain. Although conven-
tional clinical management is based on the presumption that
thrombus formation requires continuation of AF for ap-
proximately 48 h, thrombi have been identified by TEE
within shorter intervals (133,134). (See Section VIII-G-
1-c, Therapeutic Implications.)
Endothelial dysfunction has been difficult to demonstrate
as a distinct mechanism contributing to thrombus formation
in patients with AF, although systemic and atrial tissue
levels of von Willebrand factor are elevated in some patients
(135–138). Similarly, AF has been associated with bio-
chemical markers of coagulation and platelet activation that
may reflect a systemic hypercoagulable state (135,136,139–
141). Both persistent and paroxysmal AF have been asso-
ciated with increased systemic fibrinogen and fibrin
D-dimer levels, which indicates active intravascular throm-
bogenesis (135,136,140–142). Elevated thromboglobulin
and platelet factor 4 levels in selected patients with AF
indicate platelet activation (135,140,143), but these data are
less robust, in line with the lower efficacy of platelet-
inhibitor drugs for prevention of thromboembolism in
clinical trials of antithrombotic therapy for AF. These
biochemical markers of coagulation and platelet activation
do not distinguish between a reactive process secondary to
intravascular coagulation and a primary hypercoagulable
state. The levels of some of these markers of coagulation
activity fall to normal during anticoagulation therapy (139),
and some markers increase immediately after conversion to
sinus rhythm and then normalize (144).
In patients with rheumatic mitral stenosis undergoing
transseptal catheterization for mitral balloon valvuloplasty, a
regional type of coagulopathy has been demonstrated in the
LA. Levels of fibrinopeptide A, thrombin/antithrombin III
complex, and prothrombin fragment F1.2 are increased in
the LA compared with levels in the RA and femoral vein,
which indicates regional activation of the coagulation cas-
cade (145,146). Whether such elevations are related to AF
through LA pressure overload or some other mechanism has
not been determined, but the regional coagulopathy was
associated with spontaneous echo contrast in the LA (146).
In contrast, incompetence of the mitral valve reduces stasis
in the LAA and is associated with less coagulation activity
(147).
Spontaneous echo contrast is a complex phenomenon
that is dependent in vitro on blood flow velocity and serum
proteins, including fibrinogen, and hematocrit (148). In
patients with AF, independent predictors of spontaneous
echo contrast include LA size, LAA flow velocity (126,149),
LV dysfunction, fibrinogen level (132), hematocrit
(131,132), and aortic atherosclerosis (131,132,148,150).
This hemorheologic phenomenon may represent an echo-
cardiographic surrogate for regional coagulopathy and is of
clinical value, particularly when dense, for identifying AF
patients at high risk for thromboembolism (148). The utility
of this finding for prospective risk stratification for throm-
boembolism beyond that achieved by clinical assessment,
however, has not yet been determined.
Contrary to the prevalent concept that systemic antico-
agulation for 4 weeks results in endocardial adherence and
organization of LAA thrombus, TEE studies have verified
resolution of thrombus in the majority of patients (151).
Similar observations have defined the dynamic nature of
LA/LAA dysfunction on conversion of AF, which provides
a mechanistic rationale for anticoagulation for several weeks
before and after successful cardioversion. Conversely, in-
creased flow within the LA in patients with mitral regur-
gitation has been associated with less prevalent LA sponta-
neous echo contrast (152,153) and fewer thromboembolic
events, even in the presence of LA enlargement (154).
2. Clinical Implications. Because the pathophysiology of
thromboembolism in patients with AF is uncertain, the
mechanisms linking risk factors to ischemic stroke in AF are
also incompletely defined. The strong association between
hypertension and stroke in AF is probably mediated pri-
marily by embolism originating in the LAA (119), but
hypertension also increases the risk of noncardioembolic
strokes in AF (119,155). Hypertension in AF patients is
associated with reduced LAA flow velocity, spontaneous
echo contrast, and thrombus formation (148,149,156). Ven-
tricular diastolic dysfunction might underlie the effect of
hypertension on LA dynamics, but this relationship is still
speculative (157,158). Whether sustained control of sys-
temic hypertension lowers the risk for cardioembolic stroke
in AF patients is a vital question, because ventricular
diastolic abnormalities associated with hypertension in the
elderly are often multifactorial and difficult to reverse
(158,159).
The effect of advancing age in increasing stroke risk in
AF is multifactorial. In patients with AF, aging is associated
with LA enlargement, reduced LAA flow velocity, and
spontaneous echo contrast, all of which predispose to LA
thrombus formation (41,148,149). Additionally, age is a risk
factor for atherosclerosis, including complex aortic arch
plaque, and is associated with stroke independently of AF
(150). Levels of prothrombin activation fragment F1.2, an
index of in vivo thrombin generation, increase with age in
the general population (160–162) and in those with AF
(11,163), which suggests an age-related prothrombotic di-
athesis. In the Stroke Prevention in Atrial Fibrillation
(SPAF) studies, age was a more potent risk factor when
combined with other risk factors such as hypertension or
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female gender (163), placing women over age 75 years with
AF at particular risk for cardioembolic strokes (164).
LV systolic dysfunction, as indicated by a history of HF
or transthoracic echocardiographic measurements, predicts
ischemic stroke in AF patients who receive no antithrom-
botic therapy (165–168) but not in moderate-risk AF
patients given aspirin (163,169). Mechanistic inferences are
contradictory; LV systolic dysfunction has been associated
both with LA thrombus and with noncardioembolic strokes
in AF patients (119,170).
In summary, complex thromboembolic mechanisms are
operative in AF and involve the interplay of factors related
to LA/LAA stasis, endothelial dysfunction, and systemic
and possibly local hypercoagulability.
VI. ASSOCIATED CONDITIONS, CLINICAL
MANIFESTATIONS, AND QUALITY OF LIFE
A. Causes and Associated Conditions
1. Acute Causes of AF. Atrial fibrillation may be related to
acute, temporary causes, including alcohol intake (“holiday
heart syndrome”), surgery, electrocution, MI, pericarditis,
myocarditis, pulmonary embolism or other pulmonary dis-
eases, and hyperthyroidism or other metabolic disorders. In
such cases, successful treatment of the underlying condition
may eliminate AF. Atrial fibrillation that develops in the
setting of an acute MI portends an adverse prognosis
compared with preinfarct AF or sinus rhythm (171). Atrial
fibrillation may be associated with another supraventricular
tachycardia, the WPW syndrome, or AV nodal reentrant
tachycardias, and treatment of these primary arrhythmias
reduces the incidence of recurrent AF (87). Atrial fibrilla-
tion is a common early postoperative complication of
cardiac or thoracic surgery.
2. AF Without Associated Heart Disease. The concept
that AF is not a disease by itself and should instead be
considered a sign of underlying cardiac disease is reinforced
by the fact that it has so many causes. Arguing to the
contrary, approximately 30% to 45% of paroxysmal cases
and 20% to 25% of persistent cases of AF occur in younger
patients without demonstrable underlying disease (lone AF)
(19,21,22). Atrial fibrillation can present as an isolated (48)
or familial (172) arrhythmia, although an underlying disease
may appear over time. Although this may reduce the relative
incidence of lone AF in the elderly, development of heart
disease in older patients may be coincidental and unrelated
to AF.
3. AF With Associated Heart Disease. Specific cardio-
vascular conditions associated with AF include valvular
heart disease (most often mitral valve disease), coronary
artery disease (CAD), and hypertension, particularly when
LV hypertrophy is present. In addition, AF may be associ-
ated with HCM or dilated cardiomyopathy or congenital
heart disease, especially atrial septal defect in adults. Sinus
node disease, ventricular preexcitation, and supraventricular
tachycardias may also underlie AF. The list of etiologies also
includes restrictive cardiomyopathies (such as amyloidosis,
hemochromatosis, and endomyocardial fibrosis), cardiac
tumors, and constrictive pericarditis. Other heart diseases,
such as mitral valve prolapse even without mitral regurgita-
tion, calcification of the mitral annulus, cor pulmonale, and
idiopathic dilation of the RA, have been associated with a
high incidence of AF. Atrial fibrillation is commonly
encountered in patients with the sleep apnea syndrome, but
whether the arrhythmia is provoked by hypoxia or other
biochemical abnormality or mediated by changes in pulmo-
nary dynamics or RA factors has not been determined.
Table 3 shows a list of associated heart diseases in the
contemporary population of the ALFA study (21).
4. Neurogenic AF. The autonomic nervous system may
trigger AF in susceptible patients through heightened vagal
or adrenergic tone. Many patients experience onset of AF
during periods of enhanced parasympathetic or sympathetic
tone, and Coumel described a group of patients that he
characterized in terms of a vagal or adrenergic form of AF
(173). Vagal AF is characterized by 1) a prevalence that is
approximately 4 times greater in men than in women; 2) age
approximately 40 to 50 years at onset; 3) frequent associa-
tion with lone AF; 4) little tendency to progress to perma-
nent AF; 5) occurrence at night, during rest, after eating, or
after ingestion of alcohol; and 6) antecedent progressive
bradycardia. Because heart rate is relatively slow during the
episode of AF, most patients complain of irregularity rather
than dyspnea, lightheadedness, or syncope. Importantly,
both adrenergic blocking drugs and digitalis may increase
the frequency of vagally mediated AF.
Like vagal AF, the age of patients with adrenergic AF is
usually about 50 years at onset, and most do not exhibit
structural heart disease. In contrast, as originally described
by Coumel (173) and subsequently verified by others,
adrenergic AF has the following features: 1) a lower
incidence than vagally mediated AF; 2) onset predomi-
nantly during the daytime; 3) provocation by exercise or
emotional stress; 4) polyuria as a common correlate; 5) onset
typically associated with a specific sinus rate for a given
patient; and 6) no gender differences. In contrast to vagally
induced AF, beta-blockers are usually the treatment of
choice for AF of the adrenergic type.
Scant data are available on neurogenic AF, which is
relatively rare as a pure entity. Although patients with pure
vagal or adrenergic AF are uncommon, when the clinical
history reveals a pattern of onset of AF that has features of
one or the other of these syndromes, the clinician may be
able to select agents that are more likely to prevent recurrent
episodes.
B. Clinical Manifestations
Atrial fibrillation may be symptomatic or asymptomatic,
even in the same patient. The dysrhythmia may present for
the first time with an embolic complication or exacerbation
of HF, but most patients with AF complain of palpitations,
chest pain, dyspnea, fatigue, lightheadedness, or syncope.
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The association of polyuria with AF may be mediated by
release of atrial natriuretic peptide. Atrial fibrillation may be
associated with a fast ventricular response, leading to
tachycardia-mediated cardiomyopathy, especially in patients
who are unaware of the arrhythmia. Syncope is an uncom-
mon but serious complication that is usually associated with
sinus node dysfunction or hemodynamic obstruction, such
as valvular aortic stenosis, HCM, cerebrovascular disease, or
an accessory AV pathway. Symptoms vary with the ventric-
ular rate, underlying functional status, duration of AF, and
individual patient perceptions.
C. Quality of Life
Although strokes certainly account for much of the func-
tional impairment associated with AF, the rhythm distur-
bance can also decrease quality of life directly. In the SPAF
study cohort, Ganiats et al. (174) found the New York
Heart Association functional classification, developed for
HF, to be an insensitive index of quality of life in patients
with AF. In another study (175), 47 (68%) of 69 patients
with paroxysmal AF considered the dysrhythmia disruptive
of their lives, but this perception was not associated with
either the frequency or duration of symptoms.
Little is known of the direct effects of antiarrhythmic and
rate control therapy on quality of life. In the Canadian Trial
of Atrial Fibrillation (CTAF) study, quality of life improved
after pharmacological treatment, whether this involved ami-
odarone, propafenone, or sotalol (176). The postcardiover-
sion EMERALD (European and Australian Multicenter
Evaluation Research on Atrial Dofetilide) study (177)
showed that dofetilide improved quality of life 1 month
after electrical cardioversion. The AFFIRM trial (Atrial
Fibrillation Follow-up Investigation of Rhythm Manage-
ment), still in progress, is comparing maintenance of sinus
rhythm with rate control in patients with AF and addressing
many facets of quality of life, as has been done in the smaller
PIAF (Pharmacological Intervention in Atrial Fibrillation)
study (178,179).
In selected patients, radiofrequency catheter ablation of
the AV node and pacemaker insertion decreased subjective
symptoms of AF and improved quality-of-life scores com-
pared with medical therapy (180–185). Baseline quality-of-
life scores appear to be lower for patients with atrial flutter
Table 3. Demographics and Associated Conditions Among Patients With Atrial Fibrillation in
the ALFA Study
Total
Population
Paroxysmal
AF
Chronic
AF
Recent-
Onset
AF
No. of patients 756 167 389 200
Age, y 68.6 65.9 69.9 68.1
Male/female ratio 436/320 91/76 237/152 108/92
Body weight, kg 72.5 72.3 72.4 73
Height, cm 168.4 169.2 168 168.3
Time from first episode of AF, mo 47.3 39.4 65.7 NA
Duration of current episode of AF, mo NA NA 54 NA
Underlying heart disease, n (%)
Coronary artery disease* 126 (16.6) 20 (11.9) 69 (17.7) 37 (18.5)
Hypertensive heart disease 162 (21.4) 28 (16.7) 84 (21.5) 50 (25.0)
Valvular (rheumatic) 115 (15.2) 16 (9.5) 76 (19.5) 23 (11.5)
Dilated cardiomyopathy 70 (9.2) 4 (2.3) 49 (12.5) 17 (8.5)
Hypertrophic cardiomyopathy 37 (4.8) 5 (2.9) 14 (3.5) 18 (9.0)
Nonrheumatic valvular (mitral valve
prolapse, other)
25 (3.3) 9 (5.3) 10 (2.5) 6 (3.0)
Cardiomyopathy (other) 9 (1.2) 1 (0.6) 6 (1.5) 2 (1.0)
Sinus node dysfunction 9 (1.2) 3 (1.8) 5 (1.3) 1 (0.5)
Miscellaneous 28 (3.7) 10 (6.0) 13 (3.3) 5 (2.5)
None 222 (29.3) 77 (46.1) 90 (23.1) 55 (27.5)
Other predisposing or associated factors, n (%)
Hyperthyroidism 24 (3.1) 6 (3.5) 9 (2.3) 9 (4.5)
Hypertension 298 (39.4) 59 (35.3) 148 (38.0) 91 (45.5)
Bronchopulmonary disease 85 (11.2) 16 (9.5) 50 (12.9) 19 (9.5)
Diabetes 81 (10.7) 12 (7.1) 51 (13.1) 18 (9.0)
Congestive HF 226 (29.8) 24 (14.3) 166 (42.6) 36 (18.0)
Prior embolic events 64 (8.4) 14 (8.3) 42 (10.8) 8 (4.0)
Left atrial size, mm 43.8 40 46.5 41.5
Left ventricular ejection fraction, % 58.7 63.3 56.9 58.4
ALFA indicates Etude en Activite´ Liberale sur le Fibrillation Auriclaire (21); AF, atrial fibrillation; NA denotes not applicable
or available; HF, heart failure. Persistent AF includes both patients with recent-onset AF and chronic AF. Recent-onset AF was
defined as persistent AF of between 7 and 30 days’ duration. Chronic AF was defined as persistent AF more than 30 days’
duration. Patients in whom the diagnosis was definite and those in whom it was probable were included. Modified with
permission from Levy S et al., Characterization of different subsets of atrial fibrillation in general practice in France: the ALFA
Study, Vol. 99, pp. 3028–35, © 1999 by Lippincott Williams & Wilkins.
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and fibrillation than for those with other arrhythmias who
are undergoing radiofrequency ablation (186). A meta-
analysis of 10 published studies of patients with AF (187)
found improvement in both symptoms and quality-of-life
scores after ablation and pacing. Although these studies
followed highly selected patients who remained in AF, such
consistent improvement suggests that quality of life was
impaired at baseline (before intervention). Two studies have
described improvement in symptoms and quality of life after
radiofrequency catheter ablation of atrial flutter (188,189).
Long-term oral anticoagulant therapy, which involves
frequent blood testing and multiple drug interactions, is
another factor with important implications for the quality of
life of AF patients. Gage et al. (190) quantified this as a
mean 1.3% decrease in utility, a measure of quality of life
used in quantitative decision analysis. Eleven patients (16%)
felt that their quality of life would be greater with aspirin
than with oral anticoagulants, despite its lesser efficacy.
Protheroe et al. (191), using decision analysis to assess
patient preferences, found that only 59 (61%) of 97 patients
preferred anticoagulation therapy to no treatment, a con-
siderably smaller proportion than that for whom treatment
has been recommended according to published guidelines.
These comparisons could be influenced in the future by the
development of more convenient approaches to antithrom-
botic therapy.
VII. CLINICAL EVALUATION
A. Minimum Evaluation of the Patient With AF
1. Clinical History and Physical Examination. The initial
evaluation of a patient with suspected or proven AF includes
characterizing the pattern of the arrhythmia as paroxysmal
or persistent, determining its cause, and defining associated
cardiac and extracardiac factors (Table 4). A careful history
will result in a well-planned, focused workup that serves as
an effective guide to therapy (2). The workup of an AF
patient can usually take place and therapy can be initiated in
1 outpatient encounter. Delay occurs when the rhythm has
not been specifically documented and additional monitoring
is necessary.
As emphasized, AF may present with a wide array of
symptoms. (See Section VI, Associated Conditions, Clinical
Manifestations, and Quality of Life.) Factors contributing
to symptoms include the rate and irregularity of the ven-
tricular response and the loss of atrial contribution to
ventricular filling. Patients with atrial flutter and a regular
pulse, even if rapid, are less often symptomatic than in
patients with AF (192).
Typically, AF occurs in patients with underlying heart
disease, usually hypertensive heart disease (24,193). (See
Section VI, Associated Conditions, Clinical Manifestations,
and Quality of Life.) Atherosclerotic heart disease or val-
vular heart diseases are also common substrates, whereas
pulmonary pathology, preexcitation syndromes, and thyroid
disease are less frequent causes that should still be sought
(194). Because reports of genetic transmission of AF have
been published, the family history is becoming important as
well (172). The setting in which the physician initially
encounters the AF patient may be a clue to its origin.
Patients seen in the hospital emergency department tend to
have a higher incidence of organic heart disease than those
seen in an ambulatory clinic setting, where the incidence of
lone AF can be higher than 30% (21) (Table 3).
Although various environmental triggers can initiate
episodes of AF, this aspect may not emerge from the initial
history given spontaneously by the patient and often re-
quires specific inquiry. Commonly mentioned triggers in-
clude alcohol, sleep deprivation, and emotional stress, but
vagally mediated AF episodes may occur during sleep or
after a large meal and are more likely to arise during a period
of rest after a period of stress. Stimulants such as caffeine or
exercise may also precipitate AF.
Patients with paroxysmal AF may be particularly fright-
ened by the symptoms, and the initial physician encounter
must be complete and reassuring. Even when the patient
with AF is relatively asymptomatic, the interview should
include an effort to characterize the episodes in terms of
onset and duration. The clinician should determine whether
the onset and termination of palpitations is abrupt or
gradual; the former favors AF or another supraventricular
tachyarrhythmia, whereas the latter suggests a mechanism
other than AF, including sinus tachycardia. As the arrhyth-
mia begins, is the pulse regular or irregular? If it begins as a
regular rhythm and then becomes irregular, another atrial
arrhythmia should be considered, such as one involving a
bypass tract. Are there associated symptoms? Dyspnea may
indicate underlying heart disease, whereas angina pectoris
points toward CAD. Syncope may be associated with AF,
but ventricular arrhythmias should not be overlooked as a
possible cause. The patient may relate the onset of AF to
environmental factors including food, drink, emotional
stress, sleep, or other details. Some of these factors may
indicate a provocative vagal component; vagally mediated
AF is also suggested when a beta-blocker or digitalis has
increased the tendency to AF (173). Finally, an effort should
be made to quantify the episodes in terms of frequency and
duration, because AF episodes tend to become more fre-
quent and more symptomatic over time.
The physical examination may suggest AF on the basis of
irregular pulse, irregular jugular venous pulsations, and
variation in the loudness of the first heart sound. Examina-
tion may also disclose associated valvular heart disease,
myocardial abnormalities, or HF. The findings on exami-
nation are similar in patients with atrial flutter, except that
the rhythm may be regular and rapid venous oscillations
may occasionally be visible in the jugular pulse.
2. Investigations. The diagnosis of AF requires ECG
documentation by at least single-lead ECG recording dur-
ing the dysrhythmia, which may be facilitated by review of
emergency department records, Holter monitoring, or tran-
stelephonic or telemetric recordings. A portable ECG
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recording tool may help establish the diagnosis in cases of
paroxysmal AF and provide a permanent ECG record of the
dysrhythmia. If episodes are frequent, then a 24-h Holter
monitor can be used. If episodes are infrequent, then an
event recorder, which allows the patient to transmit the
ECG to a recording facility when the arrhythmia occurs,
may be more useful.
A chest radiograph may detect enlargement of the cardiac
chambers and HF but is valuable mostly for detection of
intrinsic pulmonary pathology and evaluation of the pulmo-
nary vasculature. It is less important than echocardiography
for the routine evaluation of patients with AF. Two-
dimensional transthoracic echocardiography should be ac-
quired during the initial workup of all AF patients to
determine LA and LV dimensions and LV wall thickness
and function and to exclude occult valvular or pericardial
disease or HCM. LV systolic and diastolic performance
help guide decisions regarding antiarrhythmic and anti-
Table 4. Minimum and Additional Clinical Evaluation in Patients With Atrial Fibrillation
Minimum evaluation
1. History and physical examination, to define
c The presence and nature of symptoms associated with AF
c The clinical type of AF (first episode, paroxysmal, persistent, or permanent)
c The onset of the first symptomatic attack or date of discovery of AF
c The frequency, duration, precipitating factors, and modes of termination of AF
c The response to any pharmacological agents that have been administered
c The presence of any underlying heart disease or other reversible conditions (e.g., hyperthyroidism or
alcohol consumption)
2. Electrocardiogram, to identify
c Rhythm (verify AF)
c LV hypertrophy
c P-wave duration and morphology or fibrillatory waves
c Preexcitation
c Bundle-branch block
c Prior MI
c Other atrial arrhythmias
c To measure and follow the RR, QRS, and QT intervals in conjunction with antiarrhythmic drug
therapy
3. Chest radiograph, to evaluate
c The lung parenchyma, when clinical findings suggest an abnormality
c The pulmonary vasculature, when clinical findings suggest an abnormality
4. Echocardiogram, to identify
c Valvular heart disease
c Left and right atrial size
c LV size and function
c Peak RV pressure (pulmonary hypertension)
c LV hypertrophy
c LA thrombus (low sensitivity)
c Pericardial disease
5. Blood tests of thyroid function
c For a first episode of AF, when the ventricular rate is difficult to control, or when AF recurs
unexpectedly after cardioversion
Additional testing
c One or several tests may be necessary
1. Exercise testing
c If the adequacy of rate control is in question (permanent AF)
c To reproduce exercise-induced AF
c To exclude ischemia before treatment of selected patients with a type IC antiarrhythmic drug
2. Holter monitoring or event recording
c If diagnosis of the type of arrhythmia is in question
c As a means of evaluating rate control
3. Transesophageal echocardiography
c To identify LA thrombus (in the LA appendage)
c To guide cardioversion
4. Electrophysiological study
c To clarify the mechanism of wide-QRS-complex tachycardia
c To identify a predisposing arrhythmia such as atrial flutter or paroxysmal supraventricular tachycardia
c Seeking sites for curative ablation or AV conduction block/modification
AF indicates atrial fibrillation; LV, left ventricular; MI, myocardial infarction; RV, right ventricular; LA, left atrial; and AV,
atrioventricular. Type IC refers to the Vaughan Williams classification of antiarrhythmic drugs (see Table 9).
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thrombotic therapy. Thrombus should be sought in the LA
but is seldom detected without TEE (121,127,195).
Blood tests are routine but can be abbreviated. It is
important that thyroid function, serum electrolytes, and the
hemogram be measured at least once (196).
B. Additional Investigation of Selected Patients With AF
1. Holter Monitoring and Exercise Testing. Aside from
the use of Holter monitoring to establish the diagnosis of
AF, this technique and treadmill stress testing will better
evaluate the adequacy of rate control over time than a
resting ECG (197). Exercise testing should be performed if
myocardial ischemia is suspected or if type IC antiarrhyth-
mic drug therapy is planned.
2. Transesophageal Echocardiography. TEE places high-
frequency ultrasound transducers in close proximity to the
heart to provide high-quality images of cardiac structure
(198) and function (199). It is the most sensitive and specific
technique to detect sources and potential mechanisms for
cardiogenic embolism (200) and has been used in AF to
stratify patients in terms of stroke risk and to guide
cardioversion. (See Section VIII-G, Preventing Thrombo-
embolism.) TEE of patients with AF before cardioversion
has shown an LA or LAA thrombus in 5% to 15%
(195,201). Detection of LA/LAA thrombus in the setting
of stroke or systemic embolism is convincing evidence of a
cardiogenic mechanism (134).
Several TEE features have been associated with throm-
boembolism in patients with nonvalvular AF, including
LA/LAA thrombus, LA/LAA spontaneous echo contrast,
reduced LAA flow velocity, and aortic atheromatous abnor-
malities (156). Although these features are associated with
cardiogenic embolism (169,202), further prospective inves-
tigation is needed to compare these TEE findings with
clinical and transthoracic echocardiographic predictors of
thromboembolism.
TEE has also been used to exclude LA/LAA thrombus
before elective cardioversion (203,204). In a multicenter
observational study, however, 17 cases of thromboembolism
in AF patients were reported after conversion to sinus
rhythm even after TEE showed no LA/LAA thrombus
(205). All of the strokes occurred relatively soon after
cardioversion in patients who did not receive therapeutic
anticoagulation. These observations reinforce the need to
maintain therapeutic anticoagulation in patients with AF
undergoing cardioversion even when no thrombus is iden-
tified by TEE. For patients with AF of greater than 48 h
duration, a TEE-guided strategy and the traditional strategy
of anticoagulation for 3 weeks before and 4 weeks after
elective cardioversion resulted in similar rates of thrombo-
embolism (less than 1%) during the 8 weeks after random-
ization (201). (See Section VIII-G-3, Conversion to Sinus
Rhythm and Thromboembolism.)
3. Electrophysiological Study. An electrophysiological
study is rarely needed to establish the diagnosis of AF but
may be useful for other reasons. In patients with paroxysmal
AF, an electrophysiological study may help define the
mechanism of AF, which is especially important when
curative catheter ablation is considered for selected patients.
The cause of AF may be a rapidly firing focus, commonly in
or near the pulmonary vein(s), or the result of a regular
supraventricular tachycardia such as AV reentry, AV node
reentry, or atrial flutter that degenerates into AF
(tachycardia-induced tachycardia). (See Section V, Patho-
physiological Mechanisms.) Electrophysiological studies
may be helpful when sinus node dysfunction is suspected
and to clarify the mechanism of wide QRS complexes
during AF, particularly when the ventricular response is
rapid. Rate control by catheter ablation or modification of
AV conduction requires electrophysiological study, as does
selection of patients for pacemaker therapy to prevent AF.
VIII. MANAGEMENT
The major issues in management of patients with AF are
related to the arrhythmia itself and to prevention of throm-
boembolism. In patients with persistent AF, there are
fundamentally 2 ways to manage the dysrhythmia: to restore
and maintain sinus rhythm or to allow AF to continue and
ensure that the ventricular rate is controlled. Although this
decision must be faced often by clinicians because AF is
common, remarkably little research has been conducted in
the form of controlled trials of antiarrhythmic drugs that
take into account the various mechanisms and patterns of
AF. Management strategies and therapeutic algorithms
must be based on the scant evidence available. Information
on prevention of thromboembolism is more substantial,
however, enabling recommendations to be based on a higher
level of evidence.
A. Rhythm Control vs. Heart Rate Control
Reasons for restoration and maintenance of sinus rhythm in
patients with AF include relief of symptoms, prevention of
embolism, and avoidance of cardiomyopathy (Table 5). The
decision to convert AF (as opposed to controlling the rate
and allowing AF to continue) is commonly intended to
alleviate all these problems, but evidence documenting the
extent to which restoration and maintenance of sinus
rhythm achieves these goals is sparse. Conversion to and
maintenance of sinus rhythm offers the theoretical advan-
tages of reducing the risk of thromboembolism and conse-
quently the need for chronic anticoagulation, but drugs used
to control heart rate are generally considered safer than
those with an antiarrhythmic effect. The relative merit of
these 2 approaches—rhythm control vs. rate control—is the
subject of ongoing clinical trials (178,179). Limited avail-
Table 5. Objectives of Rhythm Control in Patients With
Atrial Fibrillation
Relief of symptoms such as palpitations, fatigue, and dyspnea
Prevention of thromboembolism
Prevention of tachycardia-induced myocardial remodeling and HF
HF indicates heart failure.
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able data suggest no clear advantage of one approach over
the other (179), but a more complete answer awaits the
results of studies in progress.
B. Cardioversion
1. Basis for Cardioversion of AF. Cardioversion is often
performed electively to restore sinus rhythm in patients with
persistent AF. The need for cardioversion may be immedi-
ate, however, when the arrhythmia is the main factor
responsible for acute HF, hypotension, or worsening of
angina pectoris in a patient with CAD. Nevertheless,
cardioversion carries a risk of thromboembolism unless
anticoagulation prophylaxis is initiated before the proce-
dure, and this risk appears greatest when the arrhythmia has
been present more than 48 h.
2. Methods of Cardioversion. Cardioversion may be
achieved by means of drugs or electrical shocks. Drugs were
commonly used before electrical cardioversion became a stan-
dard procedure. The development of new drugs has increased
the popularity of pharmacological cardioversion, although
some disadvantages persist, including the risk of drug-induced
torsade de pointes ventricular tachycardia or other serious
arrhythmias. Pharmacological cardioversion is still less effective
than electrical cardioversion, but the latter requires conscious
sedation or anesthesia, whereas the former does not.
There is no evidence that the risk of thromboembolism or
stroke differs between pharmacological and electrical meth-
ods of cardioversion. The recommendations for anticoagu-
lation at the time of cardioversion are the same for both
methods, as outlined in Section VIII-G, Preventing
Thromboembolism.
C. Pharmacological Cardioversion
Pharmacological cardioversion has been the subject of in-
tense research for over a decade. Although pharmacological
and electrical cardioversion have not been compared di-
rectly, pharmacological approaches appear to be simpler but
less efficacious than electrical cardioversion. In selected
cases, pharmacological cardioversion may even be attempted
at home. The major risk is the toxicity of antiarrhythmic
drugs. In this section, emphasis is given to studies in which
drugs were administered over short periods of time specif-
ically to restore sinus rhythm. The quality of available
evidence is limited by small samples, lack of standard
inclusion criteria, variable intervals from drug administra-
tion to assessment of outcome, and arbitrary dose selection.
In developing these guidelines, placebo-controlled trials of
pharmacological cardioversion have been emphasized, but
trials in which the control group was given another antiar-
rhythmic drug have also been considered.
Pharmacological cardioversion appears to be most effec-
tive when initiated within 7 days after the onset of AF
(206–209). Most such patients have a first documented
episode of AF or an unknown pattern of AF at the time of
treatment. (See Section III, Classification.) A large propor-
tion of patients with recent-onset AF experience spontane-
ous cardioversion within 24 to 48 h (210–212). Spontane-
ous conversion is less frequent in patients with AF of longer
duration (greater than 7 days) before treatment was begun,
and the efficacy of pharmacological cardioversion is also
markedly reduced in patients with persistent AF.
Some drugs have a delayed onset of action, and conver-
sion may not occur for several days (213). In some studies,
drug treatment abbreviated the interval to cardioversion
compared with placebo without affecting the proportion of
patients who remained in sinus rhythm after 24 h (211).
Pharmacological cardioversion may accelerate the restora-
tion of sinus rhythm in patients with recent-onset AF, but
the advantage over placebo is quite modest after 24 to 48 h,
and it is much less effective (and with some drugs ineffec-
tive) in patients with persistent AF.
The relative efficacy of various drugs differs for pharma-
cological cardioversion of AF and atrial flutter, yet many
studies of drug therapy for AF have included patients with
atrial flutter. The dose, route, and rapidity of administration
influence efficacy, and this has been considered as much as
possible in developing these guidelines. The designs of
randomized trials have seldom fully accounted for concom-
itant medications, on the assumption that such treatment
would be equally distributed among groups. Several inves-
tigators have generated multiple reports, and it is not always
clear when these involve distinct or overlapping patient
cohorts. Diligence in reporting adverse effects varies be-
tween trials, but toxicity has been considered in the recom-
mendations that follow. Special populations, such as those
with AF after recent heart surgery or MI, are addressed later
(Section VIII-H, Special Considerations).
The potential interactions of antiarrhythmic drugs with oral
anticoagulants (either increasing or decreasing the anticoagu-
lant effect) are always an issue when these drugs are added or
withdrawn from the treatment regimen. The problem is
amplified when anticoagulation is initiated in preparation for
elective cardioversion. Addition of an antiarrhythmic drug to
enhance the likelihood that sinus rhythm will be restored and
maintained may perturb the intensity of anticoagulation be-
yond the intended therapeutic range, raising the risk of
bleeding or thromboembolic complications.
A summary of recommendations concerning the use of
pharmacological agents for cardioversion of AF is presented
in Tables 6, 7, and 8. Algorithms for pharmacological
management of AF are given in Figs. 9, 10, 11, and 12.
Considerations specific to individual agents are summarized
below. The antiarrhythmic drugs listed have been approved
by federal regulatory agencies in the United States and
Europe for clinical use, but their use for the treatment of AF
has not been approved in all cases. Furthermore, not all
agents are approved for use in each country. Within each
category, drugs are listed alphabetically. The recommenda-
tions given in this document are based on published data
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and do not necessarily adhere to the regulations and labeling
requirements of governmental agencies.
1. Agents With Proven Efficacy.
A. AMIODARONE. Data on amiodarone are confusing be-
cause the drug may be given intravenously, orally, or by both
routes concurrently. The drug is modestly effective for
pharmacological cardioversion of recent-onset AF (214) but
acts less rapidly and probably less effectively than other
agents. The conversion rate in patients with AF for longer
than 7 days is limited, however, and restoration of sinus
rhythm may not occur for days or weeks. Amiodarone is
effective for controlling the rate of ventricular response to
AF. Both amiodarone and dofetilide (administered sepa-
rately) have been proven effective for conversion of persis-
tent AF in placebo-controlled trials (214–216). Limited
information suggests that amiodarone is equally effective for
conversion of AF and atrial flutter. Adverse effects include
bradycardia, hypotension, visual disturbances, nausea, and
constipation after oral administration and phlebitis after
peripheral intravenous administration. Serious toxicity has
been reported, including 1 death due to bradycardia ending
in cardiac arrest (210,213,214,217–225).
B. DOFETILIDE. Dofetilide, given orally, is more effective
than placebo for pharmacological cardioversion of AF that
has persisted longer than 1 week, but available studies
have not further stratified patients on the basis of the
duration of the dysrhythmia. Dofetilide appears to be more
effective for cardioversion of atrial flutter than of AF. A
response may take days or weeks when the drug is given
orally, and the intravenous form is investigational
(215,216,226–228).
C. FLECAINIDE. Flecainide administered orally or intrave-
nously was effective for pharmacological cardioversion of
recent-onset AF in placebo-controlled trials. It has not been
evaluated extensively in patients with persistent AF, but
available information suggests lower efficacy in this setting.
Limited data suggest that flecainide may be more effective
for conversion of AF than of atrial flutter. A response
usually occurs within 3 h after oral administration and 1 h
Table 6. Recommendations for Pharmacological Cardioversion of Atrial Fibrillation of Less Than or Equal to 7 Days’ Duration
Drug*
Route of
Administration
Type of
Recommendation
Level of
Evidence References
Agents with proven efficacy
Dofetilide Oral I A 215, 216, 226–228, 261
Flecainide Oral or intravenous I A 206–208, 210, 220, 229–233
Ibutilide Intravenous I A 234–239
Propafenone Oral or intravenous I A 208, 211, 212, 221, 229, 230, 233,
240–249
Amiodarone Oral or intravenous IIa A 210, 213, 214, 217–225, 262
Quinidine Oral IIb B 206, 208, 209, 211, 218, 219, 247,
250, 251
Less effective or incompletely studied agents
Procainamide Intravenous IIb C 234, 236, 259
Digoxin Oral or intravenous III A 211, 222, 229, 249, 255–258
Sotalol Oral or intravenous III A 237, 250, 251, 256, 260
*The doses of medications used in these studies may not be the same as those recommended by the manufacturers. Drugs are listed alphabetically within each category of
recommendation and level of evidence.
Table 7. Recommendations for Pharmacological Cardioversion of Atrial Fibrillation of More Than 7 Days’ Duration
Drug*
Route of
Administration
Type of
Recommendation
Level of
Evidence References
Agents proven effective
Dofetilide Oral I A 215, 216, 226–228, 261
Amiodarone Oral or intravenous IIa A 210, 213, 214, 217–225, 262
Ibutilide Intravenous IIa A 234–239
Flecainide Oral IIb B 206–208, 210, 220, 229–233
Propafenone Oral or intravenous IIb B 208, 211, 212, 221, 229,
230, 233, 240–249
Quinidine Oral IIb B 206, 208, 209, 211, 218,
219, 247, 250, 251
Less effective or incompletely studied agents
Procainamide Intravenous IIb C 234, 236, 259
Sotalol Oral or intravenous III A 237, 250, 251, 256, 260
Digoxin Oral or intravenous III C 211, 222, 229, 249,
255–258
*The doses of medications used in these studies may not be the same as recommended in Table 8 or by the manufacturers. Drugs are listed alphabetically within each category
of recommendation and level of evidence.
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after intravenous administration. Arrhythmias, including
atrial flutter with rapid ventricular rates and bradycardia
after conversion, are relatively frequent adverse effects.
Transient hypotension and mild neurological side effects
may also occur. Overall, adverse reactions have been re-
ported slightly more frequently with flecainide than with
propafenone, and these drugs should be given cautiously or
avoided entirely in patients with underlying organic heart
disease involving abnormal ventricular function (206–
208,210,220,229–233).
D. IBUTILIDE. In placebo-controlled trials, intravenous
ibutilide has proved effective for pharmacological cardiover-
sion within a few weeks after onset of AF. Available data are
insufficient to establish its efficacy for conversion of persis-
tent AF of longer duration. Ibutilide is more effective for
conversion of atrial flutter than of AF. An effect may be
expected within 1 h after administration. There is a small
but definite risk of torsade de pointes ventricular tachycar-
dia, so serum concentrations of potassium and magne-
sium should be measured before administration of ibuti-
lide, and patients should be monitored for at least 4 h
afterward. Hypotension is an infrequent adverse response
(234 –239).
E. PROPAFENONE. Placebo-controlled trials have verified
that propafenone, given orally or intravenously, is effective
for pharmacological cardioversion of recent-onset AF. Lim-
ited data suggest that efficacy is reduced in patients with
persistent AF, for conversion of atrial flutter, and in patients
with structural heart disease. The effect occurs between 2
and 6 h after oral administration and earlier after intrave-
nous injection. Adverse effects are uncommon but include
rapid atrial flutter, ventricular tachycardia, intraventricular
conduction disturbances, hypotension, and bradycardia at
conversion. Available data on the use of various regimens of
propafenone loading in patients with organic heart disease
are scant. This agent should be used cautiously or not at all
for conversion of AF in such cases and should be avoided in
patients with congestive HF or obstructive lung disease
(208,211,212,221,229–233,240–249).
F. QUINIDINE. Quinidine is usually administered after
digoxin or verapamil has been given to control the ventric-
Table 8. Recommended Doses of Drugs Proven Effective for Pharmacological Cardioversion of Atrial Fibrillation
Drug*
Route of
Administration Dosage** Potential Adverse Effects References
Amiodarone Oral Inpatient: 1.2–1.8 g per day in divided dose
until 10 g total, then 200–400 mg per day
maintenance or 30 mg/kg as single dose
Hypotension, bradycardia, QT
prolongation, torsade de pointes
(rare), GI upset, constipation,
phlebitis (IV)
210, 213, 214,
217–225, 262
Outpatient: 600–800 mg per day divided dose
until 10 g total, then 200–400 mg per day
maintenance
Intravenous/oral 5–7 mg/kg over 30–60 min, then 1.2–1.8 g per
day continuous IV or in divided oral doses
until 10 g total, then 200–400 mg per day
maintenance
Dofetilide Oral Creatinine clearance
(mL/min)
Dose
(mcg BID)
QT prolongation, torsade de pointes;
adjust dose for renal function, body
size, and age
215, 216, 226–228,
261
.60 500
40–60 250
20–40 125
,20 Contraindicated
Flecainide Oral 200–300 mg† Hypotension, rapidly conducting
atrial flutter
206–208, 210, 220,
229–233
Intravenous 1.5–3.0 mg/kg over 10–20 min†
Ibutilide Intravenous 1 mg over 10 min; repeat 1 mg when necessary QT prolongation, torsade de pointes 234–239
Propafenone Oral 450–600 mg Hypotension, rapidly conducting
atrial flutter
208, 211, 212, 221,
229, 230, 233,
240–249
Intravenous 1.5–2.0 mg/kg over 10–20 min†
Quinidine‡ Oral 0.75–1.5 g in divided doses over 6–12 h, usually
with a rate-slowing drug
QT prolongation, torsade de pointes,
GI upset, hypotension
206, 208, 209, 211,
218, 219, 247,
250, 251
GI indicates gastrointestinal; IV, intravenous; BID, twice a day.
*Drugs are listed alphabetically.
**Dosages given in the table may differ from those recommended by the manufacturers.
†Insufficient data are available on which to base specific recommendations for the use of one loading regimen over another for patients with ischemic heart disease or impaired
left ventricular function, and these drugs should be used cautiously or not at all in such patients.
‡The use of quinidine loading to achieve pharmacological conversion of atrial fibrillation is controversial, and safer methods are available with the alternative agents listed in
the table. Quinidine should be used with caution.
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ular response rate. It is probably as effective as most other
drugs for pharmacological cardioversion of recent-onset AF
and is sometimes effective for correction of persistent AF.
No distinction can be made between its efficacy for AF and
atrial flutter. Potential adverse effects of quinidine include
QT-interval prolongation that may precede torsade de
pointes ventricular tachycardia, nausea, diarrhea, fever, he-
patic dysfunction, thrombocytopenia, and hemolytic ane-
mia. During the initiation of quinidine therapy, hypoten-
sion and acceleration of the ventricular response to AF may
occur on a vagolytic basis. A clinical response may be
expected 2 to 6 h after administration (206,208,211,218,
219,247,250–252).
2. Less Effective or Incompletely Studied Agents.
A. BETA-BLOCKERS. When given intravenously, the short-
acting beta-blocker esmolol may have modest efficacy for
pharmacological cardioversion of recent-onset AF, but this
has not been established by comparison with placebo.
Esmolol acts rapidly, however, to control the rate of
ventricular response to AF. It is not useful in patients with
persistent AF, and there are no data comparing its relative
efficacy for atrial flutter and AF. A response may be
expected within 1 h. Hypotension and bronchospasm are
the major adverse effects of esmolol and other beta-blockers
(209,253).
B. CALCIUM CHANNEL ANTAGONISTS (VERAPAMIL AND DIL-
TIAZEM). The calcium channel antagonist verapamil has
not been shown to be effective for pharmacological cardio-
version of recent-onset or persistent AF, but it acts rapidly
to control the rate of ventricular response (208,209,224,
232,246). Negative inotropic effects contribute to toxicity,
which includes hypotension.
The calcium channel antagonist diltiazem has not been
shown to be effective for pharmacological cardioversion of
Figure 9. Pharmacological management of patients with newly discovered atrial fibrillation. AF indicates atrial fibrillation; HF, heart failure.
Figure 10. Pharmacological management of patients with recurrent par-
oxysmal atrial fibrillation. AF indicates atrial fibrillation. *See Fig. 11.
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recent-onset or long-standing AF, but like verapamil, it is
effective for control of heart rate (254).
C. DIGOXIN. Digitalis glycosides are generally no more
effective than placebo for conversion of recent-onset AF to
sinus rhythm. Digoxin may prolong the duration of episodes
of paroxysmal AF in some patients (255), and it has not
been evaluated adequately in patients with persistent AF
except to achieve rate control. Digoxin has few adverse
effects after acute administration in therapeutic doses, aside
from AV block and acceleration of ventricular ectopy
(211,222,229,249,255–258).
D. DISOPYRAMIDE. Disopyramide has not been tested ade-
quately but may be effective when administered intrave-
nously (254). Adverse effects include dryness of mucosal
membranes, especially of the mouth; constipation; urinary
retention; and depression of LV contractility. The latter
reaction makes it a relatively unattractive option for phar-
macological conversion of AF.
E. PROCAINAMIDE. Intravenous procainamide has been
used extensively for conversion of AF within 24 h of onset,
and several studies suggest that it may be superior to placebo
(234,236,259). Procainamide appears to be less useful than
some other drugs and has not been tested adequately in
patients with persistent AF. Hypotension is the major
adverse effect after intravenous administration of procain-
amide.
F. SOTALOL. Contrary to its relative efficacy for mainte-
nance of sinus rhythm, sotalol has no proven efficacy for
pharmacological cardioversion of recent-onset or persistent
AF when given either orally or intravenously. It does,
however, control the heart rate (237,250,251,256,260).
An issue related to pharmacological cardioversion that
arises frequently is whether the antiarrhythmic drug should
be started in the hospital or on an outpatient basis. The
major concern is the potential for serious adverse effects,
Figure 11. Antiarrhythmic drug therapy to maintain sinus rhythm in patients with recurrent paroxysmal or persistent atrial fibrillation. Drugs are listed
alphabetically and not in order of suggested use. *For adrenergic atrial fibrillation, beta-blockers or sotalol are the initial drugs of choice. †Consider
nonpharmacological options to maintain sinus rhythm if drug failure occurs. HF indicates heart failure; CAD, coronary artery disease; and LVH, left
ventricular hypertrophy.
Figure 12. Pharmacological management of patients with recurrent per-
sistent or permanent atrial fibrillation. *See Fig. 11. Initiate drug therapy
before cardioversion to reduce the likelihood of early recurrence of AF.
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including torsade de pointes ventricular tachycardia. With
the exception of those involving low-dose oral amiodarone
(225), virtually all studies of pharmacological cardioversion
have been limited to hospitalized patients. (For a more
extensive discussion of out-of-hospital initiation of antiar-
rhythmic agents, see Section VIII-E-4, Out-of-Hospital
Initiation of Antiarrhythmic Drugs in Patients With AF.)
D. Electrical Cardioversion
1. Terminology. Direct-current cardioversion involves de-
livery of an electrical shock synchronized with the intrinsic
activity of the heart, usually by sensing the R wave of the
ECG. This technique ensures that electrical stimulation
does not occur during the vulnerable phase of the cardiac
cycle, from 60 to 80 ms before to 20 to 30 ms after the apex
of the T wave (263). Electrical cardioversion is used to
normalize all abnormal cardiac rhythms except ventricular
fibrillation. The term defibrillation implies an asynchronous
discharge, which is appropriate for correction of ventricular
fibrillation but not for AF.
2. Technical Aspects. Successful cardioversion of AF de-
pends on the nature of the underlying heart disease and the
current density delivered to the atrial myocardium. The
latter, in turn, depends on the voltage of the defibrillator
capacitor, the output waveform, the size and position of the
electrode paddles, and transthoracic impedance. The cur-
rent density delivered decreases as the impedance increases
for a given paddle surface area. The impedance (264) is
related to the size and composition of the electrode paddles,
the contact medium between the electrodes and the skin,
the distance between the paddles, body size, phase of the
respiratory cycle, number of shocks delivered, and interval
between shocks. Proper attention to each of these variables
is important for successful cardioversion.
The electrical resistance between the electrode paddles
and the skin should be minimized by the use of electrolyte-
impregnated pads. Pulmonary tissue between the paddles
and the heart inhibits conduction of current, so shocks
delivered during expiration and with chest compression
deliver higher levels of energy to the heart. Large electrode
paddles result in lower impedance than smaller ones, but
when the paddles are too large, current density through
cardiac tissue is insufficient to achieve cardioversion,
whereas undersized paddles may produce too much current
density and cause injury. Animal experiments have shown
that the optimum diameter is one that approximates the
cross-sectional area of the heart. No definite information
has been developed regarding the best paddle size for the
specific cardioversion of AF, but a diameter of 8 to 12 cm
(264) is generally recommended.
Because the combination of high impedance and low
energy reduces the likelihood of successful cardioversion, it
has been suggested that impedance be measured to shorten
the duration of the procedure, reduce adverse responses, and
improve outcome (265,266). Kerber et al. (267) described a
technique for automatic impedance-adjusted energy delivery
in which energy is automatically increased when the imped-
ance exceeds 70 ohms and claimed improved efficacy in
patients with high transthoracic impedances.
The output waveform also influences the amount of
energy delivered to the heart during electrical cardioversion.
Most equipment used for external cardioversion has a
monophasic waveform. In a randomized trial that compared
cardioversion with a standard damped sine-wave monopha-
sic waveform with cardioversion applying a rectilinear bi-
phasic waveform, the 77 patients treated with monophasic
shocks had a cumulative success rate of 79%, whereas 94%
of 88 subjects cardioverted with biphasic shocks were
successfully converted to sinus rhythm. Patients in the latter
group required less energy for cardioversion. Independent
correlates of successful conversion were rectilinear biphasic
shocks, thoracic impedance, and the duration of AF (268).
In their original description of cardioversion, Lown et al.
(269,270) indicated that an anterior-posterior electrode
configuration was superior to anterior-anterior positioning,
but others disagree (264,271,272). Anterior-posterior posi-
tioning allows enough current to reach a sufficient mass of
atrial myocardium to effect defibrillation when the pathol-
ogy associated with AF involves both the RA and the LA
(as in patients with atrial septal defect or cardiomyopathy),
because the resulting force field encompasses part of the RA
wall. A drawback of this configuration is the comparatively
wide electrode separation and the amount of pulmonary
tissue between the anterior paddle and the heart, particularly
in patients with emphysema. Placing the anterior electrode
to the left of the sternum reduces electrode separation and
the amount of interposed pulmonary tissue. The superiority
of one electrode position over another has not been firmly
established, but the paddles should be placed directly against
the chest wall, under rather than over breast tissue.
Other paddle positions result in less effective current flow
through crucial parts of the heart, and their use is discour-
aged (264). In a randomized controlled study of 301 subjects
undergoing elective external cardioversion, patients were
allocated to anterior-lateral (ventricular apex and right
infraclavicular) or anterior-posterior (sternum and left scap-
ular) paddle positions (273). The overall success (adding the
outcome of low-energy shocks to that of high-energy
shocks) was greater with the anterior-posterior configura-
tion (87%) than with the anterior-lateral alignment (76%),
and the energy requirement was lower with the anterior-
posterior paddle configuration. Because the optimum pad-
dle configuration for a given patient is not known before
cardioversion, the clinician should consider an alternative
arrangement if the initial position proves unsuccessful.
3. Clinical Aspects. Cardioversion is performed with the
patient having fasted and under adequate general anesthesia
to avoid pain related to delivery of the electrical shock.
Short-acting anesthetic drugs or agents that produce con-
scious sedation are preferred, because cardioversion patients
should recover rapidly after the procedure and usually do not
require overnight hospitalization (274).
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The electric shock should be properly synchronized with
the QRS complex, which calls for triggering by monitoring
the R wave with an appropriately selected lead. In addition
to R-wave amplitude, it is important that the monitored
lead give a good view of P waves, which facilitates assess-
ment of the outcome of the procedure. The initial energy
delivered with a monophasic waveform may be low (50 J)
for cardioversion of atrial flutter. Higher energy is required
for AF cardioversion, starting with at least 200 J. The
energy output is increased successively in increments of 100
J until a maximum of 400 J is reached. Some physicians
begin with higher energies to reduce the number of shocks
(and thus the total energy) delivered. Lower energies are
required with a biphasic waveform. To avoid myocardial
damage, the interval between 2 consecutive shocks should
not be less than 1 minute (275).
In a recent study (276), 64 patients were randomly
assigned to initial monophasic waveform energies of 100,
200, or 360 J. Higher initial energy was significantly more
effective than lower levels (immediate success rates were
14% with 100, 39% with 200, and 95% with 360 J,
respectively), resulting in fewer shocks and less cumulative
energy when 360 J was delivered initially. These data
indicate that an initial shock of 100 J is often too low, and
an initial energy of 200 J or greater is recommended for
electrical cardioversion of AF. Devices that deliver current
with a biphasic waveform are available, and these appear to
achieve cardioversion at lower energy levels than those using
a monophasic waveform.
Rates of electrical cardioversion of AF vary from 70% to
90% (277–279). This variability is explained in part by
differences in patient characteristics and in part by the
definition of success. The interval at which the result is
evaluated ranges in the literature from immediately after
cardioversion to several days afterward. Restoration and
maintenance of sinus rhythm are less likely to occur through
cardioversion when AF has been present for longer than a
year than in patients with AF of shorter duration.
Over time, the proportion of AF caused by rheumatic
heart disease has declined and the average age of the
population has increased (277,279,280), whereas the inci-
dence of lone AF has remained constant. These factors
make it difficult to compare recent and older data on the
outcome of cardioversion. In a large consecutive series of
patients undergoing cardioversion of AF, 24% were classi-
fied as having ischemic heart disease, 24% rheumatic valvu-
lar disease, 15% lone AF, 11% hypertension, 10% cardio-
myopathy, 8% nonrheumatic valvular disease, 6% congenital
heart disease, and 2% treated hyperthyroidism (277). Sev-
enty percent of the patients were in sinus rhythm 24 h after
cardioversion. Multivariate analysis revealed that short du-
ration of AF, presence of atrial flutter, and younger age were
independent predictors of success, whereas LA enlarge-
ment, underlying heart disease, and cardiomegaly predicted
failure. These authors developed a scheme expressing the
likelihood of success to facilitate clinical decision making
and improve cost-effectiveness by avoiding cardioversion in
patients unlikely to sustain sinus rhythm.
The primary success rate as measured 3 days after
cardioversion in 100 consecutive subjects (279) was 86%;
this increased to 94% when the procedure was repeated
during treatment with quinidine or disopyramide after an
initial failure to convert the rhythm. Only 23% of the
patients remained in sinus rhythm after 1 year and 16% after
2 years; in those who relapsed, repeated cardioversion with
antiarrhythmic medication resulted in sinus rhythm in 40%
and 33% after 1 and 2 years, respectively. For patients who
relapsed again, a third cardioversion resulted in sinus
rhythm in 54% at 1 year and 41% at 2 years. Thus, sinus
rhythm can be restored in a substantial proportion of
patients by direct-current cardioversion, but the rate of
relapse is high unless concomitant antiarrhythmic drug
therapy is given (Fig. 13). For patients for whom initial
attempts at cardioversion fail, available adjunctive strategies
include alternative electrode positions, concomitant admin-
istration of intravenous ibutilide, and delivery of higher
energy with the use of 2 defibrillators. It is anticipated that
external cardioversion with a biphasic shock waveform will
reduce the need for these adjunctive maneuvers.
4. Transvenous Electrical Cardioversion. A technique for
delivering high-energy (200 to 300 J) direct current inter-
nally for cardioversion of AF was introduced by Le´vy et al.
in 1988 (281,282), using an RA catheter and a backplate. In
Figure 13. Arrhythmia-free survival after electrical cardioversion in pa-
tients with persistent atrial fibrillation. The lower curve represents outcome
after a single shock when no prophylactic drug therapy was given. The
upper curve depicts the outcome with repeated electrical cardioversions in
conjunction with antiarrhythmic drug prophylaxis. ECV indicates electrical
cardioversion; SR, sinus rhythm. Reproduced with permission from van
Gelder et al., Arch Intern Med 1996;156:2585–92, © 1996, American
Medical Association (304).
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a randomized trial, internal cardioversion was superior to
external countershock, particularly in obese patients and
patients with chronic obstructive lung disease, but the
frequency of recurrence of AF over the long term did not
differ between the 2 methods. A monophasic shock wave-
form was used for external cardioversion in the study; use of
a biphasic waveform would likely necessitate internal car-
dioversion considerably less frequently. Other techniques
for internal cardioversion apply low-energy (less than 20 J)
shocks via a large-surface cathodal electrode in the RA and
an anode in the coronary sinus or left pulmonary artery
(283–286). These techniques have been successful for res-
toration of sinus rhythm in 70% to 90% of mixed cohorts,
including those who did not respond to external cardiover-
sion (285–287). Low-energy internal cardioversion does not
require general anesthesia but is performed under sedation.
Indications might include implanted pacemakers, defibril-
lators, or drug infusion pumps, but these are presently under
investigation.
5. Electrical Cardioversion in Patients With Implanted
Pacemakers and Defibrillators. Cardioversion of patients
with implanted pacemaker and defibrillator devices is fea-
sible and safe when appropriate precautions are taken to
prevent damage. Pacemaker generators and defibrillators are
designed with circuits protected against sudden external
electrical discharges, but programmed data may nevertheless
be altered by sudden current surges. Electricity conducted
along an implanted electrode lead to the endocardium may
cause myocardial injury associated with a temporary or
permanent increase in stimulation threshold. When pro-
nounced, this may cause exit block that results in failure of
ventricular capture. The implanted device should be inter-
rogated immediately before and after cardioversion to verify
appropriate pacemaker function and should be repro-
grammed if necessary to increase generator output. Devices
are typically implanted anteriorly, and the paddles used for
external cardioversion should be positioned as distant as
possible from them, preferably in the anterior-posterior
configuration. The risk of exit block is greatest when one
paddle is positioned near the impulse generator and the
other over the cardiac apex, or lower with the anterior-
posterior electrode configuration and in pacemakers with
bipolar lead systems (288,289). Low-energy internal cardio-
version in patients with implanted pacemakers and elec-
trodes positioned in the RA and coronary sinus or left
pulmonary artery does not interfere with pacemaker func-
tion (290).
6. Risks and Complications. The risks of electrical car-
dioversion are mainly related to embolic events and cardiac
arrhythmias.
A. EMBOLISM. Thromboembolic events have been reported
in between 1% and 7% of patients who did not receive
prophylactic anticoagulation before cardioversion of AF
(291,292). Prophylactic antithrombotic therapy is discussed
below.
B. ARRHYTHMIAS. Various benign arrhythmias may arise
after cardioversion that commonly subside spontaneously,
especially ventricular and supraventricular premature beats,
bradycardia, and short periods of sinus arrest (293). More
dangerous arrhythmias, such as ventricular tachycardia and
fibrillation, may be precipitated in patients with hypokale-
mia or digitalis intoxication (294,295). Serum potassium
levels should be in the normal range for safe, effective
cardioversion. Cardioversion is contraindicated in cases of
digitalis toxicity because the ventricular tachyarrhythmias
that are provoked may be difficult to terminate. A serum
digitalis level in the therapeutic range does not exclude
clinical toxicity but is not generally associated with malig-
nant ventricular arrhythmias during cardioversion (296), so
it is not routinely necessary to interrupt digoxin use before
elective cardioversion of AF. It is important to exclude
clinical and ECG signs of digitalis excess and to delay
cardioversion until the toxic state has been eliminated,
which usually requires more than 24 h.
In patients with long-standing AF, cardioversion com-
monly unmasks underlying sinus node dysfunction. A slow
ventricular response to AF in the absence of drugs that slow
conduction across the AV node may indicate an intrinsic
conduction defect. The patient should be evaluated before
cardioversion with these issues in mind to avoid symptom-
atic bradycardia (297). When this risk is anticipated, a
transvenous or transcutaneous pacemaker can be used pro-
phylactically.
C. MYOCARDIAL INJURY. Animal experiments show a wide
margin of safety between the energy required for cardiover-
sion of AF and that associated with clinically relevant
myocardial depression (298,299). Even without apparent
myocardial damage, however, transient ST-segment eleva-
tion may appear on the ECG after cardioversion (300,301),
and blood levels of creatine kinase may rise. In a study of 72
elective cardioversion attempts involving an average energy
greater than 400 J (range 50 to 1280 J), serum troponin-T
and -I levels did not rise significantly. There was a small
increase in creatinine kinase-MB mass levels above the
proportion attributable to skeletal muscle trauma in 10% of
patients, and this was related to the energy delivered (302).
Myocardial damage, even on a microscopic level, related to
direct-current cardioversion has not been confirmed and is
probably not clinically significant.
Before electrical cardioversion, prophylactic drug therapy
to prevent early recurrence of AF should be considered
individually for each patient. For example, a patient with
lone AF of relatively short duration is less likely to develop
early recurrence than a patient with heart disease and a
longer duration of AF. The latter patient stands to gain
more potential benefit from prophylactic antiarrhythmic
drug therapy before cardioversion. Should relapse (particu-
larly early relapse) occur, antiarrhythmic therapy is recom-
mended in conjunction with the second attempt. Further
cardioversion is of limited value, and patients should be
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selected carefully. In patients who are highly symptomatic,
for example, infrequently repeated cardioversion may be an
acceptable approach.
Recommendations for Pharmacological or Electrical
Cardioversion of AF
Class I
1. Immediate electrical cardioversion in patients with
paroxysmal AF and a rapid ventricular response
who have ECG evidence of acute MI or symptom-
atic hypotension, angina, or HF that does not
respond promptly to pharmacological measures.
(Level of Evidence: C)
2. Cardioversion in patients without hemodynamic
instability when symptoms of AF are unacceptable.
(Level of Evidence: C)
Class IIa
1. Pharmacological or electrical cardioversion to ac-
celerate restoration of sinus rhythm in patients with
a first-detected episode of AF. (Level of Evidence: C)
(See Tables 6, 7, and 8 for recommended drugs.)
2. Electrical cardioversion in patients with persistent
AF when early recurrence is unlikely. (Level of
Evidence: C)
3. Repeated cardioversion followed by prophylactic
drug therapy in patients who relapse to AF without
antiarrhythmic medication after successful cardio-
version. (Level of Evidence: C)
Class IIb
1. Pharmacological agents for cardioversion to sinus
rhythm in patients with persistent AF. (Level of
Evidence: C) (See Tables 6, 7, and 8 for recom-
mended drugs.)
2. Out-of-hospital administration of pharmacological
agents for cardioversion of first-detected, paroxys-
mal, or persistent AF in patients without heart
disease or when the safety of the drug in the
particular patient has been verified. (Level of Evi-
dence: C) (See Table 8.)
Class III
1. Electrical cardioversion in patients who display
spontaneous alternation between AF and sinus
rhythm over short periods of time. (Level of Evi-
dence: C)
2. Additional cardioversion in patients with short
periods of sinus rhythm who relapse to AF despite
multiple cardioversion procedures and prophylactic
antiarrhythmic drug treatment. (Level of Evidence:
C)
E. Maintenance of Sinus Rhythm
1. Pharmacological Therapy to Prevent Recurrence of AF.
A. GOALS OF TREATMENT. Maintenance of sinus rhythm is
relevant in patients with paroxysmal AF (in whom episodes
terminate spontaneously) and persistent AF (in whom
electrical or pharmacological cardioversion is necessary to
restore sinus rhythm). Whether paroxysmal or persistent,
AF is a chronic disorder, and recurrence is likely at some
point in most patients (Figs. 13 and 14) (303,304,388).
Most patients with AF will therefore need prophylactic
treatment with antiarrhythmic drugs if sinus rhythm must
be maintained.
The goal of maintenance therapy is suppression of symp-
toms and sometimes prevention of tachycardia-induced
cardiomyopathy due to AF. It is not yet known whether
maintenance of sinus rhythm prevents thromboembolism,
HF, or death (178,305). Because the clinical factors that
predispose a patient to recurrent AF (advanced age, history
of HF, hypertension, LA enlargement, and LV dysfunction)
are also risk factors for thromboembolism, the risk of stroke
may not be reduced by correction of the rhythm. Pharma-
cological maintenance of sinus rhythm may reduce morbid-
ity in patients with HF (227,306), but one observational
study demonstrated that the strategy of serial cardioversion
of persistent AF did not prevent complications (307).
Pharmacological therapy to maintain sinus rhythm is indi-
cated in patients who have troublesome symptoms related to
paroxysmal AF or recurrence after cardioversion and who
can tolerate antiarrhythmic drugs.
Throughout this document, reference is made to the
Vaughan Williams classification of antiarrhythmic drugs
(308), which has been modified to include drugs that
Figure 14. Hypothetical illustration of cardioversion failure. Three types of
recurrences after electrical cardioversion of persistent AF are shown. The
efficacy of drugs varies in enhancement of shock conversion and suppres-
sion of recurrences. ECV indicates external cardioversion; IRAF, first
recurrence of AF after cardioversion; and SR, sinus rhythm. Modified with
permission from van Gelder IC, et al. Am J Cardiol Vol. 84, Pharmaco-
logic versus direct-current electrical cardioversion of atrial flutter and
fibrillation, pp. 147R–151R. 1999, with permission from Excerpta Medica
Inc. (388).
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became available after the original classification was devel-
oped (Table 9).
B. END POINTS IN ANTIARRHYTHMIC DRUG STUDIES. Over
the past decades, various antiarrhythmic drugs have been
investigated for maintenance of sinus rhythm in patients
with AF. The number and quality of studies with each drug
are limited (few meet current standards of good clinical
practice), and end points vary. In studies of paroxysmal AF,
the proportion of patients without recurrence at the end of
follow-up, the time to first recurrence, the number of
recurrences over a specified interval (an example of arrhyth-
mia burden), or combinations of these data have been
reported. The arrhythmia burden and quality-of-life assess-
ments from the patient’s viewpoint have not been quantified
consistently in studies of maintenance antiarrhythmic ther-
apy.
In studies of persistent AF, the proportion of patients in
sinus rhythm at the end of follow-up is a useful end point,
but this is a less useful measure in studies of paroxysmal AF.
Most studies involving patients with persistent AF used
electrical cardioversion to restore sinus rhythm, with anti-
arrhythmic drug prophylaxis started before or after electrical
cardioversion. Because transtelephonic monitoring reveals
clustering of the majority of recurrences in the first few
weeks after cardioversion (309,310), the median time to first
recurrence may not differ between drug and placebo. Be-
cause recurrent AF tends to persist, neither the interval
between recurrences nor the number of episodes in a given
period of time (arrhythmia burden) represents a suitable end
point unless a serial cardioversion strategy is used.
Given these differences, the appropriate end points for
evaluation of treatment efficacy in patients with paroxysmal
and persistent AF have little in common. This hampers
evaluation of treatment strategies aimed at maintenance of
sinus rhythm in cohorts containing both paroxysmal and
persistent AF patients. Studies of mixed cohorts have not
contributed heavily to the development of these guidelines.
Recurrence of AF is not equivalent to treatment failure.
In several studies (311,312), patients with recurrent AF
often chose to continue treatment with a drug, perhaps
because episodes of AF were less frequent, shorter, or
associated with milder symptoms. A reduction in arrhyth-
mia burden may constitute therapeutic success for some
patients, whereas any recurrence of AF may seem intolera-
ble to others. Assessment based on time to recurrence in
paroxysmal AF or the number of patients in sinus rhythm
after cardioversion in persistent AF may overlook poten-
tially valuable treatment strategies. The duration of
follow-up varied considerably among studies and was gen-
erally insufficient to permit meaningful extrapolation to
years of treatment in this often lifelong cardiac rhythm
disorder.
Available studies are far from uniform in many other
respects as well. Underlying heart disease or extracardiac
disease is present in 80% of patients with persistent AF, but
this is not always described in sufficient detail. It is also not
always clear when patients had a first episode of AF and
whether it was recent or persistent AF, and the frequency of
previous episodes and previous electrical cardioversions are
not uniformly described. The efficacy of treatment for atrial
flutter and AF is usually not reported separately. Controlled
trials of antiarrhythmic drugs usually contain few high-risk
patients (those at risk of drug-induced HF, proarrhythmia,
or conduction disturbances), and this should be kept in
mind in applying the recommendations below.
C. PREDICTORS OF RECURRENT AF AFTER RESTORATION OF
SINUS RHYTHM. Most patients with AF, except those with
postoperative AF, eventually experience recurrence. Risk
factors for frequent recurrence of paroxysmal AF (more than
1 episode per month) include female gender and underlying
heart disease (313). In one study of patients with persistent
AF, the 4-year arrhythmia-free survival rate was less than
10% after single-shock electrical cardioversion without pro-
phylactic drug therapy (304). Predictors of recurrences
within that interval included hypertension, age greater than
55 years, and AF duration greater than 3 months. Even
serial cardioversions and prophylactic drug therapy resulted
in freedom from recurrent AF in only approximately 30% of
patients in the same study (304). With this serial approach,
predictors of recurrence included age greater than 70 years,
AF duration greater than 3 months, and HF (304). Other
risk factors for recurrent AF include atrial enlargement and
rheumatic heart disease; some of the above parameters are
interrelated (e.g., duration of AF and atrial size).
2. General Approach to Antiarrhythmic Drug Therapy.
Before any antiarrhythmic agent is administered, reversible
cardiovascular and noncardiovascular precipitants of AF
Table 9. Vaughan Williams Classification of Antiarrhythmic
Drug Actions
Type IA
Disopyramide
Procainamide
Quinidine
Type IB
Lidocaine
Mexiletine
Type IC
Flecainide
Moricizine
Propafenone
Type II
Beta-blockers (e.g., propranolol)
Type III
Amiodarone
Bretylium
Dofetilide
Ibutilide
Sotalol
Type IV
Calcium-channel antagonists (e.g., verapamil and diltiazem)
Modified with permission from Vaughn Williams EM. A classification of antiar-
rhythmic action as reassessed after a decade of new drugs. J Clin Pharmacol
1984;24:129–47, © 1984 by Sage Publications Inc. (308) to include compounds
introduced after publication of the original classification.
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should be addressed. Most of these relate to CAD, valvular
heart disease, hypertension, and HF. Those who develop
AF in association with alcohol intake should practice
abstinence. Prophylactic drug treatment is not usually indi-
cated in case of a first-detected episode of AF. Antiarrhythmic
drugs may also be avoided in patients with infrequent and
well-tolerated paroxysmal AF. Similarly, when recurrences are
infrequent and tolerated, patients experiencing breakthrough
arrhythmias may not require a change in antiarrhythmic drug
therapy. In patients who develop AF only during exercise,
administration of a beta-blocker may be effective, but a single
specific inciting cause accounts for all episodes of AF in
relatively few patients, and a majority will not sustain sinus
rhythm without antiarrhythmic drug treatment. Selection of an
appropriate agent is based first on safety and is tailored to any
underlying heart disease that may be present, as well as the
number and pattern of previous episodes of AF (314).
In patients with lone AF, a beta-blocker may be tried
first, but flecainide, propafenone, and sotalol are particularly
effective. Amiodarone and dofetilide are recommended as
alternative therapy. Quinidine, procainamide, and disopyr-
amide are not favored unless amiodarone fails or is contra-
indicated. For patients with vagally induced AF, however,
the anticholinergic activity of long-acting disopyramide
makes it a relatively attractive choice. Flecainide and ami-
odarone represent secondary and tertiary treatment options,
respectively, in this situation, whereas propafenone is not
recommended because its (weak) intrinsic beta-blocking activ-
ity may aggravate vagally mediated paroxysmal AF. In patients
with adrenergically mediated AF, beta-blockers represent first-
line treatment, followed by sotalol and amiodarone. In patients
with adrenergically mediated lone AF, amiodarone should be
chosen later in the sequence of drug therapy (Fig. 11).
When treatment with a single drug fails, combinations of
antiarrhythmic drugs may be tried. Useful combinations
include a beta-blocker, sotalol or amiodarone, plus a type IC
agent. A drug that is initially safe may become proarrhyth-
mic when the patient develops CAD or HF or starts other
medication that in combination may be arrhythmogenic.
Thus, the patient should be alerted to the potential signif-
icance of such symptoms as syncope, angina pectoris, or
dyspnea and warned about the use of noncardiac drugs that
can prolong the QT interval. A useful source of information
is the Internet site http://www.torsades.org. Monitoring of
antiarrhythmic drug treatment varies with the agent in-
volved and with patient factors. Prospective trial data on
upper limits of drug-induced increased in QRS duration or
QT prolongation are not available. The following recom-
mendations are the consensus of the writing committee.
With type IC drugs, QRS widening should not be permit-
ted to exceed 150% of the pretreatment QRS duration.
Exercise testing may be helpful to detect QRS widening
that occurs only at rapid heart rates (use-dependent con-
duction slowing). For type IA or type III drugs, with the
possible exception of amiodarone, the corrected QT interval
in sinus rhythm should remain below 520 ms. During
follow-up, plasma potassium and magnesium levels and
renal function should be checked periodically, because renal
insufficiency leads to drug accumulation and predisposes to
proarrhythmia. In individual patients, serial noninvasive
tests may be appropriate to reevaluate LV function, espe-
cially if clinical HF develops during treatment of AF.
3. Pharmacological Agents to Maintain Sinus Rhythm.
Fourteen controlled trials of drug prophylaxis involving pa-
tients with paroxysmal AF have been published, and there have
been 22 published trials of drug prophylaxis for maintenance of
sinus rhythm in patients with persistent AF. Comparative data
are not sufficient to permit subclassification by drug or etiology.
Individual drugs, listed alphabetically, are described below, and
dosages for maintenance of sinus rhythm are given in Table 10.
A. AMIODARONE. Available evidence suggests that amioda-
rone is effective for maintenance of sinus rhythm in patients
with AF but is associated with a relatively high incidence of
side effects compared with placebo (315). Amiodarone is
usually used as a second-line or last-resort agent. Of the 403
patients in the CTAF study (316), most had first-time
paroxysmal (46%) or persistent (54%, duration less than 6
months) AF. AF was considered persistent when more than
half the previous episodes had required pharmacological or
electrical intervention. This definition implies that many of
the patients designated as having persistent AF actually had
spontaneously terminating paroxysmal AF. Amiodarone
prevented further attacks beyond the first month in 69% of
patients, significantly more than did propafenone or sotalol
(each of which achieved complete suppression in 39% of 101
patients). Nevertheless, 11% of the patients assigned to
sotalol or propafenone stopped treatment because of side
effects after a mean of 468 days, compared with 18% of
patients given amiodarone. A placebo-controlled study of
amiodarone and sotalol that predominantly involved pa-
tients with paroxysmal AF (317) produced results similar to
those in the CTAF study. Other uncontrolled, observa-
tional studies in patients with paroxysmal AF refractory to 1
or more type I agents support the antiarrhythmic efficacy of
amiodarone (318–320).
The selection of a pharmacological agent should be based
on the arrhythmia burden, type of underlying heart disease,
severity of symptoms, risk of side effects, and patient
preferences. Considering the paucity of adequate data from
randomized trials, as well as its side effect profile, amioda-
rone should only be used cautiously as a first-line agent in
paroxysmal AF. An exception is its use in patients with HF,
for whom amiodarone appears to offer distinct advantages
over other agents in terms of relative risks and benefits.
There are scant prospective comparative data available on
the use of amiodarone to maintain sinus rhythm in patients
with persistent AF, but a favorable outcome has been
reported when amiodarone was given as a last-resort agent
in uncontrolled studies. Amiodarone is particularly useful in
AF complicated by HF, but its use is limited by potentially
severe extracardiac side effects. The use of low-dose amio-
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darone (200 mg daily or less) may be effective and may be
associated with fewer side effects (218,316,322).
To date, only a few randomized studies have been
performed with amiodarone after cardioversion in patients
with persistent AF. Amiodarone was tested as a first-line
agent in a study confined to postcardioversion patients
(322). After electrical cardioversion, but before randomiza-
tion, patients were stratified according to age, duration of
AF, mitral valve disease, and cardiac surgery. After 6
months, amiodarone was more effective than quinidine;
83% of patients remained in sinus rhythm with amiodarone
vs. 43% who were given quinidine. Amiodarone therapy was
associated with fewer side effects than quinidine over this
interval, but side effects tend to occur after more prolonged
treatment with amiodarone. In a single-crossover study of
32 patients randomized to amiodarone or quinidine (218) in
which patients with persistent AF for more than 3 weeks
were treated with amiodarone when pharmacological con-
version did not occur with quinidine (electrical cardiover-
sion was not used), amiodarone was better tolerated, and
considering the patients whose treatment crossed over, it
was far more effective in achieving conversion of AF and
long-term maintenance of sinus rhythm. After 9 months, 18
(67%) of 27 amiodarone-treated patients were in sinus
rhythm vs. 2 (12%) of 17 patients taking quinidine.
Among uncontrolled studies (223,318,319,323–326), one
involved 89 patients with persistent AF for whom previous
treatments had failed; actuarially, 53% of these patients were
in sinus rhythm after 3 years of amiodarone therapy (323).
In another study (318) of 110 patients with refractory AF or
atrial flutter for whom a median of 2 type I agents had failed
(57 with paroxysmal AF) and who were followed up for 5
years, amiodarone (268 plus or minus 100 mg daily) was
associated with recurrence in 9% of patients with persistent
AF and 40% of those with paroxysmal AF. Several other
uncontrolled studies support the use of amiodarone as a
last-resort agent (319,324–326). In one, a dose of 200 mg
per day appeared to be effective in patients for whom
cardioversion had failed; 52% underwent repeated cardio-
version with success for 12 months (223).
B. BETA-BLOCKERS. One randomized, open-label, crossover
study showed that atenolol 50 mg once daily was as effective
as sotalol 80 mg twice daily and better than placebo at
suppressing ECG-documented episodes of AF, reducing
their duration and associated symptoms (327). The study
involved stable, nonpostoperative patients. The dose of
sotalol was lower than that generally used for suppression of
recurrent AF, and both drugs were well tolerated. Beta-
blockers have the advantage of controlling the ventricular
rate in the event AF recurs during treatment, and they
thereby reduce or abolish associated symptoms, but the
patient’s unawareness of recurrent AF may be a disadvan-
tage in certain cases. These agents may benefit postoperative
patients but may aggravate vagally mediated AF. One
placebo-controlled study (328) of 394 patients found meto-
prolol to be moderately effective in preventing postshock
recurrences of AF (reduced to 49% vs. 60%, respectively).
C. DIGOXIN. The evidence available does not support a role
for digitalis in suppressing recurrent AF in most patients.
The lack of an AV blocking effect during sympathetic
stimulation results in poor rate control with digoxin, and
hence its use does not usually reduce symptoms associated
with recurrent paroxysmal AF (22).
D. DISOPYRAMIDE. Several small randomized studies sup-
port the efficacy of disopyramide to prevent recurrent AF
after electrical cardioversion. One study comparing
Table 10. Typical Doses of Drugs Used to Maintain Sinus Rhythm in Patients With
Atrial Fibrillation**
Drug* Daily Dosage Potential Adverse Effects
Amiodarone† 100–400 mg Photosensitivity, pulmonary toxicity, polyneuropathy,
GI upset, bradycardia, torsade de pointes (rare),
hepatic toxicity, thyroid dysfunction
Disopyramide 400–750 mg Torsade de pointes, HF, glaucoma, urinary retention,
dry mouth
Dofetilide‡ 500–1000 mcg Torsade de pointes
Flecainide 200–300 mg Ventricular tachycardia, congestive HF, enhanced AV nodal
conduction (conversion to atrial flutter)
Procainamide 1000–4000 mg Torsade de pointes, lupus-like syndrome, GI symptoms
Propafenone 450–900 mg Ventricular tachycardia, congestive HF, enhanced AV nodal
conduction (conversion to atrial flutter)
Quinidine 600–1500 mg Torsade de pointes, GI upset, enhanced AV nodal
conduction
Sotalol‡ 240–320 mg Torsade de pointes, congestive HF, bradycardia,
exacerbation of chronic obstructive or bronchospastic
lung disease
GI indicates gastrointestinal; AV, atrioventricular; and HF, heart failure.
*Drugs are listed alphabetically.
**The drugs and doses given here have been determined by consensus based on published studies.
†A loading dose of 600 mg per day is usually given for one month or 1000 mg per day over 1 week.
‡Dose should be adjusted for renal function and QT-interval response during in-hospital initiation phase.
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propafenone and disopyramide showed equal efficacy, but
propafenone was better tolerated (329). Treatment with
disopyramide for more than 3 months after cardioversion
was associated with an excellent long-term outcome in an
uncontrolled study (98 of 106 patients were free of recurrent
AF; of these, 67% remained in sinus rhythm after a mean of
6.7 years). Although the duration of AF was more than 12
months in most of these patients, few had significant
underlying cardiac disease other than previously treated
thyrotoxicosis. It is not clear, therefore, whether disopyr-
amide was the critical factor in suppressing AF (330).
Disopyramide has negative inotropic and negative dromo-
tropic effects that respectively may cause HF or precipitate
AV block (329–333).
E. DOFETILIDE. Several large-scale, double-blind, random-
ized studies support the efficacy of dofetilide for prevention
of AF or atrial flutter (261,334). To reduce the risks of
proarrhythmia, dofetilide should be initiated in the hospital
at a dose titrated to renal function and the QT interval. This
provides a measure of safety in the event of early proar-
rhythmic toxicity. Combined results from 966 patients in
the SAFIRE-D (Symptomatic Atrial Fibrillation Investiga-
tive Research on Dofetilide) and EMERALD studies found
dofetilide treatment to be associated with conversion to
sinus rhythm, and this effect was dose related: 6%, 10%, and
30% of patients responded within 72 h to 125, 250, and 500
mcg twice a day, respectively (261,334). Most (87%) con-
versions occurred within 30 h after treatment was initiated.
The incidence of torsade de pointes was 0.8%. Four of 5 of
these incidents occurred in the first 3 days. In SAFIRE-D,
dofetilide was associated with 40%, 52%, and 66% of
patients in sinus rhythm at 6 months in the 125-, 250-, and
500-mcg-daily dosage groups, respectively, compared with
21% with placebo (261). In EMERALD, suppression of
recurrence of AF by dofetilide was also dose dependent:
51%, 57%, and 71% of patients were in sinus rhythm with
125, 250, and 500 mg daily, respectively, compared with
approximately 25% with placebo and 60% with sotalol
(334).
F. FLECAINIDE. Two placebo-controlled studies (311,335)
found flecainide to be effective in postponing the first
recurrence of AF and the overall time spent in AF; and
other randomized studies (336,337) found its efficacy to be
comparable to that of quinidine, with fewer side effects.
Efficacy is further supported by uncontrolled studies
(312,338).
Van Gelder et al. (339) showed that time to recurrence of
AF was significantly longer with flecainide than without
treatment, and severe ventricular proarrhythmia or sudden
death was not observed with a mean dose of 199 mg daily.
Side effects occurred in 5 patients (9%) and were predom-
inantly related to negative dromotropism, with or without
syncope. Compared with long-acting quinidine (1,100 mg
daily), flecainide (200 mg daily) was superior in preventing
recurrent AF after cardioversion and was associated with
fewer side effects, but 1 patient died suddenly a month after
entry, presumably due to proarrhythmia (339).
G. MORIZICINE. Although few data are presently available
regarding the efficacy of moricizine (340), further studies
may define a role for its use in patients with AF.
H. PROCAINAMIDE. No adequate studies are available.
Long-term treatment with procainamide is frequently asso-
ciated with development of antinuclear antibodies and is
occasionally associated with arthralgias or agranulocytosis.
I. PROPAFENONE. The UK PSVT (paroxysmal supraven-
tricular tachycardia) study was a large, randomized, placebo-
controlled trial of propafenone in which transtelephonic
monitoring was used to detect and document relapses of AF
(341). The primary end point was time to first recurrence or
adverse event. A dose of 300 mg twice daily was effective;
300 mg 3 times a day was even more effective but caused
more frequent side effects. In one small, placebo-controlled
study (342), only those patients who tolerated an initial
average propafenone dose of 688 mg per day were random-
ized to the drug group. Compared with placebo,
propafenone reduced the percentage of days in AF from
51% to 27%. Propafenone was more effective than quinidine
in another randomized comparison (343). In an open-label
randomized study involving 100 AF patients (approximately
half with paroxysmal and half with persistent AF),
propafenone and sotalol were equally effective in maintain-
ing sinus rhythm (30% vs. 37% of patients in sinus rhythm
at 12 months, respectively) (344). The pattern of AF
(paroxysmal or persistent), LA size, and previously unsuc-
cessful drug therapy did not predict the response, but
statistical power was quite limited. Other uncontrolled
studies, usually involving selected patients previously refrac-
tory to other antiarrhythmic drugs, also support the efficacy
of propafenone (345–349).
Like other highly effective type IC drugs, propafenone
should not be used in patients with ischemic heart disease or
LV dysfunction. Close follow-up is necessary to avoid
adverse effects due to changes in cardiac condition (e.g.,
development of ischemia or HF).
In a randomized study, propafenone and disopyramide
appeared to be equally effective in preventing postcardiover-
sion AF, but propafenone was better tolerated. As men-
tioned previously, in the study by Reimold et al. (344),
propafenone was as effective as sotalol. The effect of
propafenone in the CTAF study (316) is discussed above. A
few observational studies involving mixed cohorts of pa-
tients with paroxysmal and persistent AF have shown
propafenone to be effective in terms of maintenance of sinus
rhythm and reduction of arrhythmia-related complaints
(348).
J. QUINIDINE. Quinidine has not been evaluated extensively
in patients with paroxysmal AF but appears to be approxi-
mately as effective as type IC drugs (336,337,350). In one
study (343), quinidine was less effective than propafenone
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(22% of patients were attack free with quinidine vs. 50%
with propafenone). Side effects are more prominent than
with other antiarrhythmic drugs, and proarrhythmia is a
particular concern. A meta-analysis involving patients
treated with quinidine to maintain sinus rhythm after
cardioversion of AF showed an increase in mortality com-
pared with placebo, but this was based on a total of 12
deaths (351).
A meta-analysis of 6 trials found quinidine to be superior
to no treatment (50% vs. 25% of patients, respectively,
remained in sinus rhythm over a 1-year period). Total
mortality was significantly higher among patients given
quinidine (12 of 413 patients; 2.9%) than among those not
given quinidine (3 of 387 patients; 0.8%) (351). In a registry
analysis (352), 6 of 570 patients less than 65 years old died
suddenly shortly after restoration of sinus rhythm while
taking quinidine. Up to 30% of patients taking quinidine
experience intolerable side effects, most commonly diarrhea.
Other investigators (353) found sotalol and quinidine to be
equally effective for maintaining sinus rhythm after electrical
cardioversion of AF. Sotalol but not quinidine reduced heart
rate significantly in patients with recurrent AF, contributing
to fewer symptoms with sotalol therapy (278,333,351,353–
361).
K. SOTALOL. Sotalol is not effective for conversion of AF to
sinus rhythm, but it may be used to prevent AF. To date, 2
placebo-controlled studies (362,363) have been published
involving AF patients who were in sinus rhythm at entry
and who had at least 1 documented prior episode of AF.
Patients considered at risk of proarrhythmia, HF, or AV
conduction disturbances were excluded. Whether any of
these patients had undergone previous electrical cardiover-
sion was not reported. Sotalol appeared to be safe and
effective at doses ranging from 80 to 160 mg twice daily in
these carefully selected patient populations (316,344,362).
In another study (344), sotalol and propafenone appeared
to be equally effective for maintenance of normal sinus
rhythm. In the CTAF study, sotalol and propafenone
(separately) were less effective than amiodarone in terms of
the number of patients without documented recurrence of
AF. The difference between outcomes with these drugs was
less marked when the number of patients continuing treat-
ment without side effects was considered. In an uncontrolled
study of a stepped-care approach using propafenone and,
after failure of propafenone, sotalol in refractory patients,
paroxysmal AF occurred in nearly 50% of patients, but only
27% of patients with persistent AF converted to sinus
rhythm at 6 months (349).
In a multicenter study, sotalol was as effective as slow-
release quinidine sulfate (353) in preventing recurrent AF,
was better tolerated than quinidine, and was more effective
in suppressing symptoms in patients who relapsed into AF,
probably because it induces a slower ventricular rate. Several
studies found sotalol and the combination of quinidine and
verapamil to be equally effective after cardioversion of AF,
although significant ventricular arrhythmias (including tor-
sade de pointes) were more frequent with quinidine
(250,364).
L. VERAPAMIL AND DILTIAZEM. There is no evidence to
support the antiarrhythmic efficacy of calcium channel
antagonist drugs in patients with paroxysmal AF, but they
reduce heart rate during an attack such that symptoms may
disappear despite recurrences of AF.
4. Out-of-Hospital Initiation of Antiarrhythmic Drugs
in Patients With AF. Recommendations for out-of-
hospital initiation or intermittent use of antiarrhythmic
drugs differ for patients with paroxysmal and persistent AF.
The aims also differ from those listed in Table 5. In patients
with paroxysmal AF, the aims are to stop an attack
(“pill-in-the-pocket” approach), to prevent recurrences, or a
combination of both. In patients with persistent AF, the
aims of out-of-hospital drug initiation are to achieve phar-
macological cardioversion of AF, thereby obviating the need
for electrical cardioversion, or to enhance the success of
electrical cardioversion (by lowering the defibrillation
threshold) and prevent early recurrence of AF. Preadmission
treatment may also be designed to ensure adequate plasma
concentrations of the drug at the moment recurrences are
most likely to occur (beginning after electrical cardiover-
sion), because the pharmacokinetics of most antiarrhythmic
drugs are such that peak plasma concentrations do not
develop for several days.
Few prospective data are available on the safety of
outpatient initiation of antiarrhythmic drug therapy. The
most worrisome problem is proarrhythmia (Table 11),
which rarely occurs in patients without HF who have
normal ventricular function and baseline QT intervals
(100,365), and who do not have profound bradycardia. In
these patients, as long as sinus or AV node dysfunction is
not suspected, propafenone or flecainide may be initiated
out of the hospital. Sudden death related to idiopathic
ventricular fibrillation in a structurally normal heart may
occur in patients with the Brugada syndrome, an inherited
cardiac disease characterized by ST-segment elevation in
the right precordial ECG leads and frequently accompanied
by right bundle-branch block. Cases in which administra-
tion of type I antiarrhythmic drugs have unmasked this
condition have been reported (366,367). Before therapy
with these agents is begun, a beta-blocker or calcium
channel antagonist should be given to prevent rapid AV
conduction or 1:1 AV conduction if atrial flutter develops
(368–372). Because termination of paroxysmal AF with
flecainide or propafenone may be associated with bradycar-
dia due to sinus node or AV node dysfunction, an initial
conversion trial should be undertaken in the hospital before
a patient is declared fit for outpatient “pill-in-the pocket”
use of these agents for conversion of subsequent recurrences.
Out-of-hospital drug termination should be avoided in
patients with symptomatic sick sinus syndrome, AV con-
duction disturbances, or bundle-branch block. Table 12 lists
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other factors associated with proarrhythmic toxicity to type
IC agents.
Sotalol may be initiated in outpatients with little or no
heart disease as long as the baseline uncorrected QT interval
is less than 450 ms, serum electrolytes are normal, and none
of the type III drug–related proarrhythmia risk factors are
present (Table 12). Safety is greatest when sotalol is started
when the patient is in sinus rhythm. Amiodarone can
usually be given safely on an outpatient basis, even in
patients with persistent AF (323), but in-hospital loading
may be more appropriate when earlier restoration of sinus
rhythm is needed, as in patients with HF. Some loading
regimens involve giving either 600 mg per day for 4 weeks
(323) or 1 g per day for 1 week (223), followed by lower
maintenance doses. Quinidine, procainamide, and disopyr-
amide should generally not be started out of hospital, but an
exception may be made for disopyramide in patients without
heart disease in whom the QT interval is normal. Currently,
the standards for use of dofetilide do not permit out-of-
hospital initiation. These recommendations are general
guidelines regarding out-of-hospital initiation of drug ther-
apy, but the decision should be individualized for each
patient.
Transtelephonic monitoring or other ECG surveillance
methods may be used to monitor conduction disturbances as
pharmacological antiarrhythmic therapy is initiated in pa-
tients with AF. Specifically, the PR interval (flecainide,
propafenone, sotalol, and amiodarone), QRS duration (fle-
cainide and propafenone), and QT interval (sotalol, amio-
darone, and disopyramide) should be measured. As a gen-
Table 11. Types of Proarrhythmia During Treatment With Various Antiarrhythmic Drugs for
Atrial Fibrillation or Atrial Flutter According to the Vaughan Williams Classification
A. Ventricular proarrhythmia
c Torsade de pointes (VW type IA and type III drugs)
c Sustained monomorphic ventricular tachycardia (usually VW type IC drugs)
c Sustained polymorphic ventricular tachycardia/VF without long QT (VW types IA, IC, and III drugs)
B. Atrial proarrhythmia
c Provocation of recurrence (probably VW types IA, IC, and III drugs)
c Conversion of AF to flutter (usually VW type IC drugs)
c Increase of defibrillation threshold (a potential problem with VW type IC drugs)
C. Abnormalities of conduction or impulse formation
c Acceleration of ventricular rate during AF (VW type IA and type IC drugs)
c Accelerate conduction over accessory pathway (digoxin, intravenous verapamil, or diltiazem)
c Sinus node dysfunction, atrioventricular block (almost all drugs)
VW indicates the Vaughan Williams classification of antiarrhythmic drugs (308). VF indicates ventricular fibrillation; AF, atrial
fibrillation.
Table 12. Factors Predisposing to Drug-Induced Ventricular Proarrhythmia
VW Type IA and Type III Agents VW Type IC Agents
Long QT interval (QTc greater than 460 ms) Wide QRS duration (more than 120 ms)
Long QT-interval syndrome Associated VT
Structural heart disease, LVH Structural heart disease
Depressed LV function* Depressed LV function*
Hypokalemia/hypomagnesemia*
Female gender
Renal dysfunction*
Bradycardia* Rapid ventricular response rate*
1. (Drug-induced) sinus node disease or AV
block
2. (Drug-induced) conversion of AF to sinus
rhythm
3. Ectopy producing short-long RR sequences
1. During exercise
2. During rapid AV conduction
Rapid dose increase Rapid dose increase
High dose (sotalol, dofetilide), drug accumulation* High dose, drug accumulation*
Addition of drugs* Addition of drugs*
1. Diuretics 1. Negative inotropic drugs
2. Other QT-prolonging antiarrhythmic drugs
3. Non-antiarrhythmic drugs listed in: http://
www.torsades.org
Previous proarrhythmia
After initiation of drug
Excessive QT lengthening Excessive (more than 150%) QRS widening
*Some of these factors may develop later after initiation of drug treatment.
VW indicates Vaughan Williams classification (308); QTc, corrected QT interval; VT, ventricular tachycardia; LVH, left
ventricular hypertrophy; LV, left ventricular; AV, atrioventricular; AF, atrial fibrillation.
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eral rule, antiarrhythmic drugs should be started at a
relatively low dose with upward titration as needed, and the
ECG should be reassessed as each dose change is made. The
dose of other medication used for rate control should be
reduced approximately 6 weeks after initiation of amioda-
rone and stopped if the rate slows excessively. Concomitant
drug therapies (Table 10) should be monitored closely, and
both the patient and the physician should be alert to
possible deleterious drug interactions.
5. Recurrence of AF After Cardioversion: Implications
for Drug Treatment. Although it has long been known
that most recurrences of AF occur within the first month
after electrical cardioversion, recent research with internal
atrial cardioversion (373), as well as day-to-day postconver-
sion studies (309), have established several patterns of
recurrence (Fig. 14). In some cases, there is complete failure
of direct-current countershock to elicit even a single isolated
sinus or ectopic atrial beat, tantamount to a high atrial
defibrillation threshold. In others, AF reappears within 1
to 2 minutes after a period of sinus rhythm (374,375).
Sometimes recurrence is delayed from 1 day to 2 weeks
(309) or more after the shock. Complete shock failure
and immediate recurrences occur in approximately 25%
of patients undergoing electrical cardioversion, and sub-
acute recurrences occur within 2 weeks in about an equal
proportion (374).
Although beta-blockers are unlikely to prevent complete
shock failure (lower the defibrillation threshold) or suppress
immediate or late recurrences of AF, they may reduce
subacute recurrences (328). Conversely, type III drug effects
may be less effective for suppression of subacute recurrences
than for reducing late recurrences of AF (Table 13).
Controlled studies are needed to determine the most effec-
tive treatment of immediate and subacute recurrences, but
available data suggest that starting pharmacological therapy
before electrical cardioversion may enhance immediate suc-
cess and suppress early recurrences. As a corollary, it seems
appropriate to establish therapeutic plasma drug concentra-
tions at the time of cardioversion and for a few weeks
thereafter to optimize the chance of success. After cardio-
version to sinus rhythm, patients receiving drugs that
prolong the QT interval should be observed in the hospital
for 24 to 48 h to evaluate the effects of heart rate slowing
and to allow for prompt intervention in the event that
torsade de pointes develops.
Pretreatment with pharmacological agents may be started
out of hospital (see Section VIII-E-4, Out-of-Hospital
Initiation of Antiarrhythmic Drugs in Patients With AF) or
in hospital, immediately before electrical cardioversion. The
primary aims are to enhance conversion (e.g., by lowering
the cardioversion threshold) and prevent recurrent AF. The
risks of pretreatment include the possibility of a paradoxical
increase in the defibrillation threshold, as has occurred with
flecainide (339); accelerated ventricular rate during loading
with type IA or IC drugs in the absence of an AV nodal
blocking agent (368–372,376); and ventricular proarrhyth-
mia (Table 11). A loading dose of quinidine (1,200 mg 24 h
before electrical cardioversion) was associated with a signif-
icant reduction in the number of shocks given and a
decreased energy requirement in patients with persistent
AF. Quinidine prevented immediate recurrences in almost
all of 25 cases compared with 7 of 25 controls (374). When
quinidine was administered for approximately 3 days and
then patients who did not convert to sinus rhythm were
randomized to withdraw or continue quinidine (600 to
800 mg 3 times a day), there was no difference in defibril-
lation threshold between patients in whom quinidine was
continued or withdrawn (278). In-hospital treatment with
oral propafenone started 2 days before electrical cardiover-
sion did not influence either the mean defibrillation thresh-
old or the rate of conversion compared with placebo (84%
vs. 82%, respectively), but propafenone completely sup-
pressed immediate recurrences (within 10 minutes), so that
84% versus 65% of patients were in sinus rhythm at the end
Table 13. Pharmacological Treatment Before Cardioversion in Patients With Persistent Atrial Fibrillation: Effects of Various
Antiarrhythmic Drugs on Acute and Subacute Outcome of Transthoracic Direct Current Shock
Enhance Conversion
by DC Shock and
Prevent IRAF*
Suppress SRAF and
Maintenance Therapy Class
Recommendation
Class
Level of
Evidence
Effective Amiodarone
Flecainide
Ibutilide
Propafenone
Propafenone1verapamil
Quinidine
Sotalol
All drugs in recommendation Class I
(except ibutilide) plus beta-blockers
I B
Uncertain/unknown Beta-blockers
Disopyramide
Diltiazem
Dofetilide
Procainamide
Verapamil
Diltiazem
Dofetilide
Verapamil
IIb B
All drugs (except beta-blockers and amiodarone) should be initiated in hospital. IRAF indicates immediate recurrence of atrial fibrillation; SRAF, subacute recurrence of atrial
fibrillation; and DC, direct current.
*Drugs are listed alphabetically within each class of recommendation.
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of the procedure and 74% vs. 53% were in sinus rhythm
after 2 days (245).
Propafenone combined with verapamil prevented imme-
diate recurrences of AF after cardioversion, and prophylaxis
against subacute recurrences was enhanced by this combi-
nation given for 3 days before and 3 days after the shock
(310). In a study of 100 patients randomly assigned to
electrical cardioversion with or without pretreatment with
the type III antiarrhythmic drug ibutilide, 36 of 50 patients
in the control group were successfully converted to sinus
rhythm compared with all 50 patients in the group treated
with ibutilide. In the 14 patients in whom electrical cardio-
version was initially unsuccessful, sinus rhythm was subse-
quently restored when electrical cardioversion was repeated
after treatment with ibutilide (377). Others described sim-
ilar results with ibutilide (378). Amiodarone pretreatment
also appears to be effective in patients for whom an initial
attempt at electrical cardioversion fails (223,379). Standard
therapy with dofetilide includes pretreatment that may
produce conversion before the electrical procedure and may
decrease the cardioversion threshold, but whether the drug
enhances shock conversion or reduces immediate recur-
rences is not known. Magnesium supplementation does not
appear to enhance cardioversion (380).
Pretreatment with pharmacological agents is most appro-
priate in patients who have previously failed to respond to
electrical cardioversion and in those who developed imme-
diate or subacute recurrence of AF. In patients with late
recurrence and those undergoing initial cardioversion of
persistent AF, pretreatment is optional.
6. Selection of Antiarrhythmic Agents in Patients With
Certain Cardiac Diseases.
A. HEART FAILURE. Patients with congestive HF are partic-
ularly prone to the ventricular proarrhythmic effects of
antiarrhythmic drugs related to underlying myocardial dys-
function and electrolyte disturbances. Randomized trials
have demonstrated the safety of amiodarone and dofetilide
(given separately) in patients with HF (227,381), and these
are the recommended drugs for maintenance of sinus
rhythm.
In a subgroup analysis of data from the CHF-STAT
study (Congestive Heart Failure Survival Trial of Antiar-
rhythmic Therapy) (306), amiodarone reduced the inci-
dence of AF over 4 years to 4% from 8% with placebo in
patients with HF. In those patients who had AF, conversion
to sinus rhythm occurred in 31% of 51 patients taking
amiodarone vs. only 8% with placebo, and this was associ-
ated with significantly better survival. A trial of 1,518
patients with symptomatic HF who were randomized to
dofetilide or placebo established the clinical advantage of
antifibrillatory treatment in HF (227). Dofetilide, initiated
in hospital, was associated with a lower incidence of AF
(1.9%, 11 of 556 patients) than placebo (6.6%, 35 of 534
patients) after an average of 18 months. With dofetilide, 25
cases of torsade de pointes occurred, three fourths of which
occurred within 3 days after treatment was begun. Mortality
was equal in both groups (41% and 42%), but dofetilide was
associated with a significantly reduced hospital readmission
rate for HF.
B. CORONARY ARTERY DISEASE. In stable patients with
CAD, beta-blockers may be considered first, but their use is
supported by only 2 studies (327,328), and the data on their
efficacy for maintenance of sinus rhythm in patients with
persistent AF after cardioversion are not convincing (328).
Sotalol has substantial beta-blocking activity and may there-
fore be chosen as the initial antiarrhythmic agent in AF
patients with ischemic heart disease because it is associated
with less long-term toxicity than amiodarone. Both sotalol
and amiodarone have reasonable short-term safety profiles,
and amiodarone may be preferred in patients with HF
(382–384). Flecainide (385) and propafenone are not rec-
ommended in these situations. Quinidine, procainamide,
and disopyramide may be considered as third-line treatment
choices in patients with CAD. Given the results of the
DIAMOND-MI trial (Danish Investigations of Arrhyth-
mias and Mortality on Dofetilide in Myocardial Infarction),
dofetilide may be considered as a second-line rather than a
third-line antiarrhythmic agent, but this study involved
selected post-MI patients in whom the antiarrhythmic
benefit balanced the risk of proarrhythmic toxicity. In a
straightforward CAD population without MI or HF, it is
uncertain whether benefit will outweigh risk, and more
experience with the use of dofetilide as a third-line agent is
needed before it can be advocated as a second-line agent in
these patients.
C. HYPERTENSIVE HEART DISEASE. Patients with LV hy-
pertrophy may be at increased risk of developing torsade de
pointes related to early ventricular afterdepolarizations
(314,386,387). Thus, a drug that does not prolong the QT
interval is preferable as first-line therapy, and in the absence
of CAD or marked ventricular hypertrophy (LV wall
thickness greater than or equal to 1.4 cm), propafenone and
flecainide are reasonable choices. Proarrhythmia with one
agent does not predict this type of response to another type
of pharmacological agent. For example, patients with LV
hypertrophy who develop torsade de pointes during treat-
ment with a type III agent may tolerate a type IC agent
uneventfully. Amiodarone prolongs the QT interval but
carries a very low risk of ventricular proarrhythmia; its
extracardiac toxicity profile relegates it to second-line ther-
apy in these individuals, but amiodarone becomes first-line
therapy when marked LV hypertrophy is present. When
amiodarone and sotalol either fail or are inappropriate,
disopyramide, quinidine, or procainamide may be used as
alternatives.
D. WPW SYNDROME. Radiofrequency ablation of the acces-
sory pathway is usually the preferred therapy for patients
with preexcitation syndromes and AF. Antiarrhythmic
drugs may be useful in selected cases. Digoxin should be
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avoided because of the risk of paradoxical acceleration of the
ventricular rate during AF in some patients with accessory
pathways. Beta-blockers do not decrease conduction over
accessory pathways during preexcited periods of AF and
could cause hypotension or other complications in patients
with tenuous hemodynamics.
Recommendations for Pharmacological Therapy to
Maintain Sinus Rhythm
Pharmacological management strategies or algorithms to
maintain sinus rhythm in patients with AF (Figs. 9, 10, 11,
and 12) are based on available evidence and extrapolated
from experience with these agents in other situations.
Class I
1. Base selection of pharmacological therapy to main-
tain sinus rhythm in patients with disabling or
otherwise troublesome symptoms during AF pre-
dominantly on safety. (Level of Evidence: B)
2. Treat precipitating or reversible causes of AF be-
fore initiation of antiarrhythmic drug therapy.
(Level of Evidence: C)
Class IIa
1. Administer pharmacological therapy to maintain
sinus rhythm to prevent progression of tachycardia-
induced cardiomyopathy due to AF. (Level of Evi-
dence: C)
2. Infrequent and well-tolerated recurrence of AF may
in some cases be deemed a successful outcome of
antiarrhythmic drug therapy. (Level of Evidence: C)
3. Outpatient initiation of antiarrhythmic drug treat-
ment is appropriate in selected patients. (Level of
Evidence: C)
Class IIb
1. Administer pharmacological therapy to maintain
sinus rhythm in asymptomatic patients to prevent
atrial remodeling. (Level of Evidence: C)
2. Administer pharmacological therapy to maintain
sinus rhythm to prevent thromboembolism or HF
in selected patients. (Level of Evidence: C)
3. Administer combinations of antiarrhythmic agents
to maintain sinus rhythm when single-drug therapy
fails. (Level of Evidence: C)
Class III
1. Use of a particular pharmacological agent to main-
tain sinus rhythm in patients with well-defined
proarrhythmia risk factors for that agent. (Level of
Evidence: A)
2. Use of pharmacological therapy to maintain sinus
rhythm in patients with advanced sinus node or AV
node dysfunction in the absence of a functioning
electronic cardiac pacemaker. (Level of Evidence: C)
7. Nonpharmacological Correction of AF. The limited
efficacy and proarrhythmic risks of antiarrhythmic drug
therapies have led to the exploration of a wide spectrum of
alternative nonpharmacological therapies for AF.
A. SURGICAL ABLATION. Based on mapping studies of ani-
mal and human AF, Cox (58,81,82,389) developed a
surgical procedure (maze operation) that controls AF in
more than 90% of selected patients. The mechanism by
which the procedure prevents recurrent AF has not been
established conclusively, but the creation of barriers to
conduction within the RA and LA limits the amount of
myocardium available to propagate reentrant wave fronts,
thereby inhibiting sustained AF. Incisions encircling the
pulmonary veins may prevent initiation of AF by isolating
potentially arrhythmogenic foci within or near the pulmo-
nary veins from the remainder of the atria or by isolating
atrial regions with the shortest refractory periods. Modifi-
cations of the Cox maze operation involve encircling the
pulmonary veins by surgical incisions within the LA and
radial incisions in both atria that join the mitral and
tricuspid valve annuli (390–392).
Surgical operations for AF have been combined success-
fully with operative correction of a variety of structural
cardiac conditions. In patients with highly symptomatic AF
who require open-heart operations for valvular, ischemic,
and congenital heart disease, consideration should be given
to performing a concomitant maze operation for AF or
atrial flutter, although this may entail additional risk. The
mortality rate of an isolated maze operation is less than 1%,
but mortality is higher when the procedure is combined
with other types of operative repair. The morbidity associ-
ated with the maze operation includes consequences com-
mon to median sternotomy and cardiopulmonary bypass, as
well as a risk of short-term fluid retention (due to reduced
release of atrial natriuretic peptide), transient reduction in
LA and RA transport function, and early postoperative
atrial tachyarrhythmias. In addition, when the blood supply
to the sinus node is disrupted, sinus node dysfunction may
require permanent pacemaker implantation. Progressive it-
erations of these operations have reduced the risk of this
complication to less than 10%. Echocardiographic studies
suggest that LA and RA transport function is regained
postoperatively in more than 90% of patients.
B. CATHETER ABLATION. Given the success of surgical
approaches to AF, several catheter ablation strategies have
been designed to produce similar effects (393–395). Abla-
tion strategies limited to the RA produce marginal improve-
ment (393), whereas linear ablation in the LA has been
more successful in controlling AF. Improvement in as many
as 70% to 80% of selected patients with medically refractory
AF has been reported with these investigational procedures
(395). It has also been recognized that the pulmonary veins
are a common location of rapidly depolarizing arrhythmo-
genic foci that induce paroxysmal AF (48,49,85,396–398).
The recognition that foci triggering AF often originate
within the pulmonary veins has led to ablation strategies
that target this zone or electrically isolate the pulmonary
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vein from the LA. Other sites of arrhythmogenic foci that
may initiate AF have been found in the superior vena cava,
the RA and LA, and the coronary sinus. Ablation of these
foci eliminates or reduces the frequency of recurrent AF in
more than 60% of patients, but the risk of recurrent AF after
a focal ablation procedure is still 30% to 50% over the first
year and even higher when more than 1 pulmonary vein is
involved. Thus, many patients continue to require antiar-
rhythmic drug therapy after ablative therapy of AF (399).
Potential complications of catheter ablation for AF include
systemic embolism, pulmonary vein stenosis, pericardial
effusion, cardiac tamponade, and phrenic nerve paralysis.
Thus, although these procedures have produced promising
results, they have not yet been widely applied.
Atrial flutter may develop not only as a distinct arrhyth-
mia but also during antiarrhythmic drug therapy of AF,
especially with type IC agents. Catheter ablation is more
effective than antiarrhythmic drugs for treatment of atrial
flutter, reducing the recurrence rate from 93% to 5% when
used as first-line therapy (400). In addition, the risk of
developing AF may also be lower after catheter ablation of
atrial flutter than with pharmacological therapy (29% vs.
60% over the first year).
C. SUPPRESSION OF AF BY PACING. Several studies have
examined the role of atrial pacing, either from the RA alone
or from more than 1 atrial site, to prevent recurrent
paroxysmal AF. In patients with standard indications for
pacemaker therapy, the risk of AF is lower with atrial than
with ventricular pacing (401). Despite this observation, the
utility of atrial pacing as a treatment for paroxysmal AF in
patients without conventional indications for pacing was
not proven in a large controlled trial (402). It has been
suggested that the frequency of AF may be lower with
dual-site atrial pacing than with single-site pacing (403). A
randomized trial of biatrial pacing to prevent recurrent AF
(SynbiaPace [Synchronous Biatrial Pacing Therapy]) re-
ported no significant benefit, but a larger trial of dual-site
RA pacing (406) is in progress. Although atrial-based
pacing is associated with a lower risk of AF and stroke than
ventricular-based pacing for patients requiring pacemakers
for bradyarrhythmias, the use of pacing as a primary therapy
for prevention of recurrent AF has not been validated.
D. INTERNAL ATRIAL DEFIBRILLATORS. There has been an
interest in internal cardioversion of AF for the past 10 years.
Early work using a sheep model (283,407) showed that
delivery of a synchronous shock between the high RA and
coronary sinus was effective for the termination of AF. A
clinical trial of a low-energy transvenous atrial cardioverter/
defibrillator that used a 3/3-ms biphasic waveform shock
synchronized to the R wave established that internal car-
dioversion was safe, although the energy required in patients
with persistent AF was relatively high (a mean of 3.5 J) (6).
An intense amount of basic and clinical research ensued as
investigators attempted to find shock waveforms that would
reduce the energy requirements for cardioversion, thereby
making the shock tolerable to awake patients.
One implantable cardioverter/defibrillator capable of
atrial sensing and defibrillation as well as ventricular sensing
and pacing was evaluated in 290 AF patients (408). Each
had experienced failed therapy with 4 antiarrhythmic drugs.
The mean LV ejection fraction was greater than 0.50. In
total, 614 episodes of AF were treated with 1,497 shocks, a
mean of 2.4 shocks per episode. The conversion rate to sinus
rhythm was 93%. The data also suggested that as sponta-
neous episodes were treated quickly, the interval between
episodes of AF lengthened.
Another device with dual-chamber sensing, pacing, and
cardioversion capabilities and a maximum output of 27 J has
both atrial and ventricular cardioversion/defibrillation capa-
bilities. The device, which weighs 93 g, was designed to
treat both atrial and ventricular arrhythmias with pacing
modalities before delivering low-energy shocks. A number
of investigators are pursuing other techniques to terminate
AF by pacing, but the efficacy of this technique may be
limited to atrial tachycardia and atrial flutter. Because these
units record the number of AF episodes, they provide a very
accurate representation of AF control.
An important limitation of this procedure, unrelated to
safety or efficacy, is that discharge energy greater than 1 J is
uncomfortable to most patients, and the mean cardioversion
threshold in the earlier trial was approximately 3 J. Shocks
at this amplitude are generally intolerable without sedation
in a medical setting, which makes the routine use of the
device in its current form not widely acceptable. Another
weakness is that some systems do not use atrium-based
pacing as a means of maintaining sinus rhythm after atrial
cardioversion. Currently, potential candidates for atrial car-
dioverters/defibrillators (such as those with infrequent epi-
sodes of poorly tolerated AF) are usually also suitable for
catheter ablation.
E. EVOLVING STRATEGIES FOR NONPHARMACOLOGICAL
CORRECTION OF AF. The current absence of a single drug
or procedure that can safely and effectively cure AF has
engendered the development of a wide array of nonphar-
macological approaches. Although each has limitations,
these techniques may bring clinical improvement to a large
number of patients in the future. In some patients, non-
pharmacological therapies may render AF responsive to
previously ineffective pharmacological agents. It is also likely
that combinations of approaches may be required in treating
AF in selected patients. For example, an electronic pace-
maker may be a useful adjunct to antiarrhythmic drug
therapy in patients with sinus node dysfunction to permit
administration of an effective agent that could not otherwise
be given because of unacceptable bradycardia.
F. Rate Control During AF
1. Pharmacological Approaches. An alternative to main-
tenance of sinus rhythm in patients with paroxysmal or
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persistent AF is control of the ventricular rate. In a recent
randomized trial, the therapeutic strategies of rate vs.
rhythm control yielded similar clinical results with respect to
symptoms in patients with AF, but exercise tolerance was
better with rhythm control (179). The results of other
studies comparing these 2 strategies are not yet available
(178,305).
A. CRITERIA FOR RATE CONTROL. The adequacy of rate
control during AF may be judged from clinical symptoms
and ECG recordings. Control of the heart rate at rest does
not ensure that the rate is well regulated during exercise, and
excessive rate acceleration may occur during even mild
exercise in patients with AF whose heart rates are well
controlled at rest (409,410).
Criteria for rate control vary with patient age. The rate is
generally considered controlled when the ventricular re-
sponse ranges between 60 and 80 beats per minute at rest
and between 90 and 115 beats per minute during moderate
exercise (410,411). Atwood et al. (412) proposed consider-
ing the circadian pattern and the mean rate over a 24-h
period on Holter recording. Exercise testing can also be
used to evaluate heart rate during submaximal or maximal
exercise. Heart rate variability during AF provides addi-
tional information about the status of the autonomic ner-
vous system, which may have independent prognostic im-
plications (413–415).
B. HEMODYNAMIC AND CLINICAL CONSEQUENCES OF A
RAPID VENTRICULAR RESPONSE TO AF. Patients who de-
velop rapid ventricular rates during an episode of AF may be
highly symptomatic. If a rapid ventricular response is
associated with symptomatic hypotension, angina, or con-
gestive HF, prompt medical management is required, and
cardioversion should be considered. When sustained, an
uncontrolled ventricular response may result in deterioration
of ventricular function (tachycardia-related cardiomyopa-
thy), which is reversible when the heart rate is brought
under control (416,417).
C. PHARMACOLOGICAL INTERVENTIONS FOR RATE CON-
TROL. Negative chronotropic therapy of AF is based mainly
on depression of conduction across the AV node. The
effective refractory period of the AV node is closely corre-
lated with ventricular rates during AF, and drugs that
prolong the effective refractory period of the AV node are
generally effective. Another pharmacological determinant of
the ventricular response is cholinergic activity (410). Sinus
bradycardia and heart block may occur in some patients with
paroxysmal AF, particularly the elderly, as an unwanted
effect of pharmacological intervention with beta-blockers,
digitalis glycosides, or calcium channel antagonists.
D. PHARMACOLOGICAL AGENTS TO CONTROL HEART RATE
IN PATIENTS WITH ACUTE AF. The following agents may be
administered to achieve control of the ventricular response
to AF in an emergency setting (Table 14).
Digoxin. Although intravenous digoxin may effectively
slow the ventricular rate at rest, there is a delay of at least 60
minutes before onset of a therapeutic effect in most patients,
and a peak effect does not develop for up to 6 h. Digoxin is
no more effective than placebo in converting AF to sinus
rhythm (255,257,258) and may prolong the duration of AF
(255,418). The efficacy of digoxin is reduced in states of
high sympathetic tone, a common precipitant of paroxysmal
AF. In a review of 139 episodes of paroxysmal AF recorded
on Holter monitoring, there was no difference in the
ventricular rates of patients taking digoxin and those not
taking this medication (418). Other investigators, however,
have found that digoxin reduces the frequency and severity
of AF recurrence (22). Furthermore, the combination of
digoxin and atenolol has been shown to be effective for
ventricular rate control (419). Given the availability of more
effective agents, digoxin is no longer first-line therapy for
management of acute AF, except in patients with HF or LV
dysfunction. In an uncontrolled study, parenteral magne-
sium sulfate in combination with digoxin appeared useful
Table 14. Intravenous Pharmacological Agents for Heart Rate Control in Patients With Atrial Fibrillation
Drug* Loading Dose Onset Maintenance Dose Major Side Effects
Class
Recommendation
Diltiazem 0.25 mg/kg IV over 2 min 2–7 min 5–15 mg per hour infusion Hypotension, heart block, HF I†
Esmolol‡ 0.5 mg/kg over 1 min 5 min 0.05–0.2 mgzkg21zmin21 Hypotension, heart block,
bradycardia, asthma, HF
I
Metoprolol‡ 2.5–5 mg IV bolus over 2 min; up
to 3 doses
5 min NA Hypotension, heart block,
bradycardia, asthma, HF
I†
Propranolol‡ 0.15 mg/kg IV 5 min NA Hypotension, heart block,
bradycardia, asthma, HF
I†
Verapamil 0.075–0.15 mg/kg IV over 2 min 3–5 min NA Hypotension, heart block, HF I†
Digoxin 0.25 mg IV each 2 h, up to 1.5 mg 2 h 0.125–0.25 mg daily Digitalis toxicity, heart block,
bradycardia
IIb**
HF indicates heart failure.
*Drugs are listed alphabetically within each class of recommendation.
**Type I in congestive HF.
†Type IIb in congestive HF.
‡Only representative members of the type of beta-adrenergic antagonist drugs are included in the table, but other, similar agents could be used for this indication in appropriate
doses.
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for the acute management of rapid ventricular rates in
patients with AF (420).
Nondihydropyridine Calcium Antagonists. The most com-
monly used calcium channel antagonist agents for treatment
of AF are verapamil and diltiazem. Intravenously, each drug
is effective in emergency settings (421,422), but the response
is transient, and repeated doses or a continuous intravenous
infusion may be required to maintain heart rate control.
These agents, particularly verapamil, generally should not be
used in patients with HF due to systolic dysfunction.
Management of Patients With WPW Syndrome. Intrave-
nous agents such as digitalis and most especially calcium
antagonists that slow AV nodal conduction are contraindi-
cated in patients with WPW syndrome. Anterograde con-
duction along the accessory pathway during AF is facilitated
when these agents are given (423,424), and this may result
in acceleration of the ventricular rate, hypotension, or
degeneration to ventricular fibrillation. When antiarrhyth-
mic medication is needed in hemodynamically stable pa-
tients, intravenous type I or type III agents may generally be
used. When the arrhythmia is associated with hemodynamic
compromise, however, early direct-current cardioversion
should be performed.
Beta-Blockers. Intravenous beta-blockade with proprano-
lol, atenolol, metoprolol, or esmolol may help to control the
rate of ventricular response to AF in specific settings.
Beta-blockers may be particularly useful in states of high
adrenergic tone (e.g., postoperative AF). Among patients
with AF after noncardiac surgery, intravenous esmolol given
in an intensive care unit produced a more rapid conversion
to sinus rhythm than did intravenous diltiazem, but rates
after 2 and 12 h were similar with each treatment (425).
Other Antiarrhythmic Agents. Amiodarone has both sym-
patholytic and calcium antagonistic properties, depresses
AV conduction, and is effective in controlling the ventric-
ular rate in patients with AF. Intravenous amiodarone is
effective and well tolerated in critically ill patients who
develop rapid atrial tachyarrhythmias refractory to conven-
tional treatment but has not been sufficiently evaluated in
this indication. Amiodarone is considered a suitable alter-
native agent for heart rate control when conventional
measures are ineffective (426). New antiarrhythmic drugs
(e.g., dofetilide and ibutilide) are effective for acute conver-
sion of atrial flutter and AF but are not effective for
controlling the ventricular rate.
E. PHARMACOLOGICAL AGENTS TO CONTROL HEART RATE
IN PATIENTS WITH PERSISTENT AF. When restoration of
sinus rhythm is not possible or is not attempted in patients
with AF, control of the ventricular rate is essential. Drugs
that block AV nodal conduction can be used to achieve rate
control both at rest and during exercise or other types of
cardiovascular stress (Table 15). Specific agents, listed
alphabetically, are discussed below.
Beta-Blockers. For long-term use, beta-blockade is a safe
therapy to control heart rate in AF patients and antagonizes
the effects of increased sympathetic tone. In 7 of 12
comparisons with placebo, beta-blockers were effective at
controlling resting heart rate. The effect was drug specific,
with nadolol and atenolol being most efficacious. All 9
comparisons demonstrated good rate control with beta-
blockers, but exercise tolerance was compromised in 3 of 9
studies (427). Sotalol, a nonselective beta-blocking drug
with type III antiarrhythmic activity, provides excellent rate
control during AF recurrence (428). Atenolol provided
better control of exercise-induced tachycardia than digoxin
alone (429). Patients taking beta-blockers may experience
excessively slow rates at rest. Beta-blockers should be
initiated gradually in patients with HF (430).
Digoxin. In contrast with its lack of rate control effect in
acute AF, digoxin is generally effective for rate control in
persistent AF, particularly when congestive HF is present
Table 15. Orally Administered Pharmacological Agents for Heart Rate Control in Patients With Atrial Fibrillation
Drug* Loading Dose Onset Usual Maintenance Dose** Major Side Effects Recommendation
Digoxin 0.25 mg PO each 2 h;
up to 1.5 mg
2 h 0.125–0.375 mg daily Digitalis toxicity, heart block, bradycardia I
Diltiazem NA 2–4 h 120–360 mg daily in divided
doses; slow release
available
Hypotension, heart block, HF I
Metoprolol† NA 4–6 h 25–100 mg BID Hypotension, heart block, bradycardia,
asthma, HF
I
Propranolol† NA 60–90 min 80–240 mg daily in divided
doses
Hypotension, heart block, bradycardia,
asthma, HF
I
Verapamil NA 1–2 h 120–360 mg daily in divided
doses; slow release
available
Hypotension, heart block, HF, digoxin
interaction
I
Amiodarone 800 mg daily for 1 wk
600 mg daily for 1 wk
400 mg daily for 4–6 wk
1–3 wk 200 mg daily Pulmonary toxicity, skin discoloration,
hypothyroidism, corneal deposits, optic
neuropathy, warfarin interaction,
proarrhythmia
IIb
HF indicates heart failure; PO, by mouth; NA, not applicable; HF, heart failure; and BID, twice a day.
*Drugs are listed alphabetically within each class of recommendation.
**Recommended maintenance dosages are the usual ones necessary, but higher doses may be appropriate in some patients.
†The table includes representative members of the type of beta-blocker drugs, but other, similar agents could be used for this indication in appropriate doses.
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(416). According to a recent meta-analysis (427), digoxin
administered alone slows the resting heart rate more than
placebo, but it has been known for several generations that
digitalis does not slow heart rate during exercise in patients
with AF (431). Recent data indicate that digoxin lowers the
ventricular rate in patients with recent-onset AF without
overt HF as well (257), but the effect is modest, perhaps
resulting from a vagotonic effect on the AV node.
Nondihydropyridine Calcium Antagonists. The negative
inotropic effect of oral calcium antagonists requires that they
be used cautiously in patients with HF. Calcium antagonists
are preferred over beta-blockers for long-term use in pa-
tients with chronic obstructive pulmonary disease. Vera-
pamil and diltiazem reduced heart rate both at rest and
during exercise significantly better than placebo in several
trials, with preserved or improved exercise tolerance in most
patients (427). Investigational data also show that calcium
channel antagonists prevent electrical remodeling of atrial
tissue (421).
Combination Therapy. Combinations of these agents may
often be required to achieve adequate rate control, but care
should be taken to avoid excessive slowing. Addition of
other drugs to digoxin is commonly required to control AV
nodal conduction during exercise and to achieve consistent,
adequate heart rate control. The combination of digoxin
and atenolol produces a synergistic effect on the AV node
(419), and pindolol combined with digoxin offered better
rate protection than digoxin alone or combined with vera-
pamil during exercise, with less effect on resting heart rate
(424). In general, the combination of digoxin and beta-
blockers appears to be more effective than the combination
of digoxin and diltiazem (419).
Other Agents. Clonidine reduces standing ventricular re-
sponse by 15% to 20% and may have value in hypertensive
patients with AF (432). The antiarrhythmic agent
propafenone exerts mild beta-blocking effects and may slow
conduction across the AV node, but this is seldom sufficient
to control heart rate in patients with AF. Should the atrial
rhythm become slower and more regular, AV conduction
may accelerate, and another agent is generally recommended
in addition to propafenone to slow AV node conduction.
Drug interaction may result in a rise in serum digoxin level
when propafenone is given concurrently. Oral amiodarone
has not been investigated properly in this indication and
should not be used as a first-line agent because of the side
effects associated with its chronic administration. Oral
amiodarone also interacts with digoxin, raising serum con-
centrations of the latter.
2. Nonpharmacological Regulation of AV Nodal Con-
duction and Pacing. Pacing at a rate that approximates the
mean ventricular rate during spontaneous AV conduction
can regulate the ventricular rhythm during AF (433).
Because ventricular pacing prolongs the AV nodal refractory
period as a result of concealed retrograde penetration, it
eliminates ventricular cycles longer than the pacing cycle
length and may reduce the number of short ventricular
cycles related to rapid AV conduction during AF. As a
result, ventricular pacing may be used as a strategy to reduce
the irregularity of the ventricular rhythm (102). This mo-
dality may be useful for patients with marked variability in
ventricular rates and for those who develop resting brady-
cardia during treatment with medications prescribed to
control rapid ventricular rates with exertion. The precise
role of pacemaker therapy to regulate the ventricular rate in
patients with AF, however, remains controversial.
A. CONCLUSIONS. A summary of recommendations for use
of pharmacological agents to control the rate of ventricular
response to AF is given in Table 16. A combination of drugs
is often necessary to achieve rate control in AF patients in
the acute and chronic settings. Therapy may require careful
dose titration, and some patients may develop symptomatic
bradycardia requiring permanent pacing. When pharmaco-
logical intervention fails to prevent recurrences of AF or to
control heart rate, nonpharmacological therapy may be
considered.
3. Nonpharmacological/AV Nodal Ablation. AV nodal
ablation and permanent pacemaker implantation provide a
highly effective means of improving symptoms in selected
patients with AF (182,183,185,187). In general, patients
most likely to benefit from this strategy are those who
experience symptoms related to a rapid ventricular rate
during AF that cannot be controlled adequately with anti-
arrhythmic or negative chronotropic medications. AV nodal
ablation may be especially useful for patients with an
excessive ventricular rate that induces a tachycardia-
mediated decline in ventricular systolic function despite
appropriate medical therapy. A meta-analysis of 21 studies
published between 1989 and 1998 that included a total of
1,181 patients concluded that AV nodal ablation and
permanent pacemaker implantation significantly improved
cardiac symptom scores, quality-of-life measures, and
healthcare utilization for patients with highly symptomatic
AF that was refractory to medical treatment (187). In the
Ablate and Pace Trial, 156 patients with medically refrac-
tory AF were prospectively enrolled in a registry to deter-
mine the effects of this strategy on quality of life, exercise
capacity, and ventricular function over a period of 1 year
after ablation (183). Significant improvement in quality of
life was measured after AV nodal ablation and permanent
Table 16. Summary of Recommendations for Use of
Pharmacological Agents to Control the Rate of Ventricular
Response to Atrial Fibrillation
Drug*
Route of
Administration
Type of
Recommendation
Level of
Evidence
Diltiazem Intravenous I A
Esmolol Intravenous I A
Verapamil Intravenous or oral I A
Other beta-
blockers
Intravenous or oral I B
Digoxin Intravenous or oral IIa B
*The doses of medications used in these studies may not be the same as those
recommended by the manufacturers.
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pacemaker implantation. For patients with impaired LV
function before ablation, this treatment significantly im-
proved LV ejection fraction. Two small randomized trials
compared the effects of AV nodal ablation with antiarrhyth-
mic medications on quality of life and symptoms in patients
with paroxysmal (185) and persistent (182) AF. Signifi-
cantly more patients with both forms of AF experienced
improvement in symptoms and quality of life after AV
nodal ablation than with antiarrhythmic medication ther-
apy.
The use of catheter ablation to modify AV nodal con-
duction by eliminating posterior atrial inputs to the AV
node has been reported to decrease the ventricular rate
during AF and to improve cardiac symptoms without
requiring pacemaker implantation (434,435). This tech-
nique has several limitations, including the inadvertent
induction of complete AV block and a relatively high risk of
increasing ventricular rate over the first 6 months after
ablation. Two small randomized trials comparing the strat-
egies of complete AV nodal ablation and permanent pace-
maker implantation with AV nodal modification have
demonstrated improved symptom relief with complete in-
terruption of AV nodal conduction. Thus, AV nodal mod-
ification without pacemaker implantation is only rarely used
for patients with rapid ventricular rates during AF. Com-
plications of AV nodal ablation include those of pacemaker
implantation, as well as ventricular arrhythmias, relatively
rare instances of worsened LV function, thromboembolism
associated with interruption of anticoagulation, and a
greater rate of progression from paroxysmal to persistent
AF. The 1-year mortality rate after AV nodal ablation and
permanent pacemaker implantation is approximately 6.3%
(95% confidence interval [CI] 5.5% to 7.2%), with a risk of
sudden death of approximately 2.0% (95% CI 1.5% to
2.6%). Although the relation of sudden death to this
procedure remains controversial, it has been suggested that
programming the pacemaker to a higher nominal rate (80 to
90 bpm) for the first month after ablation may reduce the
risk.
Although the symptomatic benefits of AV nodal ablation
have been clearly demonstrated, the limitations of this
technique include the persistent need for anticoagulation,
loss of AV synchrony, and lifelong pacemaker dependency.
There is a small but real risk of sudden death due largely to
torsade de pointes (436). In addition, ablation of the AV
conduction system may preclude or limit the later use of
newer nonpharmacological treatments. Patients with im-
paired diastolic ventricular compliance who are most depen-
dent on AV synchrony for maintenance of cardiac output
(such as those with HCM or restrictive cardiomyopathies)
may experience persistent symptoms after AV nodal abla-
tion and permanent pacemaker implantation. Thus, patients
must be counseled regarding each of these considerations
before proceeding with this irreversible treatment.
Recommendations for Heart Rate Control in Patients
With AF
Class I
1. Measure heart rate response both at rest and during
exercise in patients with persistent or permanent
AF and control the rate with pharmacological
agents (using a beta-blocker or calcium channel
antagonist in most cases) to the physiological range.
(Level of Evidence: C)
2. Administer intravenous beta-blockers or calcium
channel antagonists (verapamil, diltiazem) in the
acute setting to slow the ventricular response to AF
in the absence of conduction over an accessory
pathway, exercising caution in patients with hypo-
tension or HF. (Level of Evidence: B)
3. Perform immediate electrical cardioversion in pa-
tients with acute paroxysmal AF and a rapid ven-
tricular response associated with acute MI, symp-
tomatic hypotension, angina, or cardiac failure that
does not respond promptly to pharmacological
measures. (Level of Evidence: C) (See Section
VIII-D, Recommendations for Pharmacological or
Electrical Cardioversion of AF.)
Class IIa
1. Administer a combination of digoxin and a beta-
blocker or calcium channel antagonist to control
the heart rate at rest and during exercise in patients
with AF. The choice of medication should be
individualized and the dose modulated to avoid
bradycardia. (Level of Evidence: C)
2. Employ nonpharmacological therapy to control
heart rate when pharmacological therapy is insuffi-
cient. (Level of Evidence: C)
Class IIb
1. Administer digoxin as the sole agent to control
heart rate at rest in patients with persistent AF.
(Level of Evidence: B)
2. Administer intravenous quinidine, procainamide,
disopyramide, ibutilide, or amiodarone to hemody-
namically stable patients with AF involving con-
duction over an accessory pathway. (Level of Evi-
dence: B)
3. Immediate cardioversion is required when very
rapid tachycardias or hemodynamic instability oc-
curs in patients with AF involving conduction over
an accessory pathway. (Level of Evidence: B)
Class III
1. Administer digitalis as the sole agent to control a
rapid rate of ventricular response to AF in patients
with paroxysmal AF. (Level of Evidence: B)
2. Catheter ablation without prior medical therapy to
control AF. (Level of Evidence: C)
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G. Preventing Thromboembolism
1. Risk Stratification.
A. EPIDEMIOLOGICAL DATA. The rate of stroke in patients
with AF is related to coexistent cardiovascular disease
(10,28,165,166). In a small, retrospective, population-based
study in Olmsted County, Minnesota, over 3 decades, the
15-year cumulative stroke rate in people with lone AF
(defined as those younger than 60 years of age with no
clinical history or echocardiographic signs of cardiopulmo-
nary disease) was 1.3% (10). Conversely, in the Framingham
Study (20), the age-adjusted stroke rate over a mean
follow-up period of 11 years was 28.2% in those with lone
AF, more liberally defined to include patients with a history
of hypertension or cardiomegaly on chest roentgenography,
compared with 6.8% in normal controls (20). In the Stroke
Prevention in Atrial Fibrillation (SPAF) study, the annual-
ized rate of ischemic stroke was similar in those with
recurrent (3.2%) and permanent (3.3%) AF (437). Those
with prior stroke or transient ischemic attack have a rate of
subsequent stroke of 10% to 12% per year despite aspirin
use, and these patients benefit substantially from treatment
with adjusted-dose oral anticoagulation (438,439). In addi-
tion to prior thromboembolism, HF, hypertension, increas-
ing age, and diabetes mellitus have consistently emerged as
independent risk factors for ischemic stroke in nonvalvular
AF (28,163,165,440,441). Others, such as female gender,
systolic blood pressure greater than 160 mmHg, and LV
dysfunction, have been variably linked to stroke
(163,167,442). The relative risk for ischemic stroke associ-
ated with specific clinical features, derived from a collabo-
rative analysis of participants given no antithrombotic ther-
apy in the control groups of 5 randomized trials, is given in
Table 17. Nearly half of AF-associated strokes occur in
patients over age 75 years (Fig. 15), and AF is the most
frequent cause of disabling stroke in elderly women
(14,440,442). Older people are widely thought to be at
increased risk for anticoagulant-related bleeding (443), and
they are less likely to be treated with oral anticoagulation,
even in situations for which it has been proven efficacious, in
part because of concern about the risk of bleeding (444).
Special consideration of these older patients is therefore a
critical aspect of effective stroke prophylaxis (440).
Several reports suggest that patients with AF in the
setting of thyrotoxicosis, which is often associated with
decompensated congestive HF, are also at high risk (445–
447), although the mechanism underlying this enhanced
embolic potential is not clear (121,448,449). The notion of
increased thromboembolic risk in thyrotoxic AF has been
challenged on the basis of comparison of patients with
thyrotoxicosis in AF with those in sinus rhythm; logistic
regression analysis found only age to be an independent
predictor of cerebral ischemic events (199). Although 13%
of patients with AF had ischemic cerebrovascular events
(6.4% per year) compared with 3% of those in normal sinus
rhythm (1.7% per year) (121,169,200), there was no adjust-
ment for duration of observation or time to event. When
transient ischemic attacks are discounted, the increased risk
of stroke in patients with AF reached statistical significance
(p 5 0.03) (199). Although it remains controversial whether
patients with AF associated with thyrotoxicosis are at
increased risk of thromboembolic cerebrovascular events
Table 17. Risk Factors for Ischemic Stroke and Systemic
Embolism in Patients With Nonvalvular Atrial Fibrillation
Risk Factors (Control Groups)
Relative
Risk
Previous stroke or TIA 2.5
History of hypertension 1.6
Congestive heart failure 1.4
Advanced age (continuous, per decade) 1.4
Diabetes mellitus 1.7
Coronary artery disease 1.5
TIA indicates transient ischemic attack. Data derived from collaborative analysis of 5
primary prevention trials (28). As a group, patients with nonvalvular atrial fibrillation
carry about a 6-fold increased risk of thromboembolism compared with patients in
sinus rhythm.
Relative risk refers to comparison with atrial fibrillation patients without these risk
factors.
Figure 15. Stroke rates in relation to age among patients with atrial fibrillation in the Framingham Heart Study. Data are from Wolf et al. (23).
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(450), the authors of these guidelines favor treatment with
anticoagulant medication in the absence of a specific con-
traindication, at least until a euthyroid state has been
restored and congestive HF has been corrected.
Atrial fibrillation is a frequent complication of HCM.
Studies of patients with HCM and AF (451) have consis-
tently reported a high incidence of stroke and systemic
embolism (452– 455). These retrospective longitudinal
studies report stroke or systemic embolism in 20% to 40% of
patients with HCM and AF followed up for a mean of 4 to
11 years, for a thromboembolism rate of 2.4% to 7.1% per
year. In addition to AF, other factors associated with
systemic embolism in patients with HCM include advanced
age (455), hypertension (453), mitral annular calcification,
and LA enlargement (453). On multivariate analysis, age
and AF were independent predictors of thromboembolism
(455). Although no randomized studies of anticoagulant
therapy have been reported, the incidence of thromboem-
bolism in patients with HCM and AF is high, warranting
consideration of anticoagulant therapy.
B. ROLE OF ECHOCARDIOGRAPHY IN RISK STRATIFICATION.
Transthoracic Echocardiography In patients with nonval-
vular AF, correlations in placebo-assigned participants in
randomized clinical trials of antithrombotic therapy deter-
mined the independent predictive value of transthoracic
echocardiography for thromboembolic events (166,456).
Fibrocalcific disease in the mitral annulus was a predictor of
thromboembolism in the BATAF trial (Boston Area Anti-
coagulation Trial for Atrial Fibrillation) (456) but not in the
SPAF study, in which the predictive values of LA size and
LV function were independent of clinical features (166).
Meta-analysis of 3 randomized trials of antithrombotic
therapy found moderate to severe LV dysfunction to be the
only independent echocardiographic predictor of stroke in
patients with AF when clinical features were also considered
(457). The diameter of the LA was a less useful predictor of
ischemic events (457).
Secondary analyses of aspirin-assigned patients in multi-
center trials of antithrombotic therapy in nonvalvular AF
have yielded variable results regarding the role of trans-
thoracic echocardiography in predicting thromboembolic
risk (29,121). Secondary analysis of aspirin-assigned pa-
tients (receiving 325 mg per day) in the SPAF I and II
studies detected several independent clinical and trans-
thoracic echocardiographic features for thromboembolism.
The only independent echocardiographic feature, however,
was LV fractional shortening less than 25% by M-mode
echocardiography when combined with recent (less than
100 days) congestive HF. Independent clinical risk factors
were prior thromboembolism, age (over 75 years in women),
and systolic hypertension (greater than 160 mmHg on 2
consecutive measurements). The risk-stratification scheme
derived from this analysis was the basis for the SPAF-III
study. Although risk stratification included an echocardio-
graphic criterion, clinical features were clearly the dominant
factors. Among the 2,012 aspirin-assigned patients from all
3 SPAF trials, including 290 in SPAF-III assigned to a
relatively ineffective, fixed-dose combination of aspirin plus
warfarin (1 to 3 mg per day; initial international normalized
ratio [INR] of 1.2 to 1.5), no transthoracic echocardio-
graphic parameter was independently predictive of throm-
boembolism. The Embolism in Left Atrial Thrombi
(ELAT) study group evaluated 409 outpatients with non-
valvular AF treated with aspirin (160 mg per day) by both
transthoracic echocardiography and TEE at study entry.
Although LV fractional shortening was associated with
thromboembolic events by univariate analysis, no indepen-
dent echocardiographic predictors of thromboembolism
were identified (169).
Transesophageal Echocardiography. TEE is the most sen-
sitive and specific imaging technique for detection of LA
and LAA thrombus, far surpassing transthoracic echocar-
diography (121). This modality also permits superior eval-
uation for other causes of cardiogenic embolism (200), as
well as a means of measuring LAA function (199). Several
TEE features have been associated with thromboembolism
(including such LA/LAA abnormalities as thrombus, re-
duced flow velocity, and spontaneous echo contrast) and
atheromatous disease of the aorta (156,458).
Detection of LA/LAA thrombus stands as a contraindi-
cation to elective cardioversion of AF. The absence of
detectable thrombus, however, does not preclude thrombo-
embolism after cardioversion if patients do not receive
anticoagulation therapy (205,459). A TEE-guided strategy
for elective cardioversion of AF has been reported to result
in comparable outcomes for thromboembolism and death
compared with conventional anticoagulation for 3 weeks
before and 4 weeks after cardioversion (201) (see Section
VIII-G-3, Conversion to Sinus Rhythm and Thromboem-
bolism). Hence, transthoracic echocardiography is valuable
for defining the origin of AF (e.g., detecting rheumatic
mitral valve disease or HCM), and TEE may provide
additional information for stratifying thromboembolic risk.
Among high-risk AF patients, the following echocardio-
graphic findings have been associated with thromboembo-
lism: impaired LV systolic function on transthoracic echo-
cardiography, thrombus, dense spontaneous echo contrast
or reduced velocity of blood flow in the LAA, and complex
atheromatous plaque in the thoracic aorta on TEE. Other
echocardiographic signs, such as the diameter of the LA and
fibrocalcific endocardial abnormalities, have been variably
associated with thromboembolism and may interact with
other factors. Oral anticoagulation effectively lowers the risk
of stroke in AF patients with these features. Whether the
absence of these abnormalities identifies a low-risk group of
patients with other clinical risk factors who could safely
avoid anticoagulation has not been established.
C. THERAPEUTIC IMPLICATIONS. The efficacy and safety of
oral anticoagulation and aspirin for prevention of stroke in
patients with AF have been well characterized (460). The
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selection of appropriate antithrombotic therapy is discussed
below in the context of thromboembolic risk (Tables 18 and
19). Atrial fibrillation patients with low rates of stroke when
treated with aspirin may not gain sufficient benefit from
anticoagulation to outweigh the attendant risks and the
need for close medical monitoring required during oral
anticoagulation therapy (457,461). Estimating the risk of
stroke for individual AF patients is a crucial factor in the
decision to provide anticoagulation therapy to individual
patients with AF (29), and accurate prediction of stroke risk
to individualize antithrombotic management has become
the salient clinical issue. The threshold risk of stroke that
warrants anticoagulation of AF patients is controversial.
Those whose stroke risk is less than or equal to 2% per year
when taking aspirin do not benefit substantially from
alternative treatment with oral anticoagulation, with anti-
coagulation of more than 100 patients for 1 year required to
prevent 1 stroke (460). For high-risk AF patients with
stroke rates greater than or equal to 6% per year with aspirin
therapy, the comparable number needed to treat is 25 or
fewer, which strongly favors the use of adjusted-dose oral
anticoagulation. Opinion remains divided about routine use
of oral anticoagulation for those with intermediate levels of
stroke risk (greater than 2% or less than 6% per year).
Three clinical schemes have been proposed recently to
stratify the risk of ischemic stroke in AF patients that are
directly or indirectly based on analyses of prospectively
monitored cohorts of participants in clinical trials in which
antithrombotic therapy was controlled (441,457,462). One
set of criteria is based on multivariate pooled analysis of
Table 18. Published Risk-Stratification Schemes for Primary* Prevention of Thromboembolism in Patients With Nonvalvular
Atrial Fibrillation
Source High Risk Intermediate Risk Low Risk
Atrial Fibrillation Investigators (185)† Age greater than or equal to 65 years
History of hypertension
Coronary artery disease
Diabetes
Age less than 65 years
No high-risk features
American College of Chest Physicians (473) Age greater than 75 years
History of hypertension
Left ventricular dysfunction‡
More than 1 intermediate risk factor
Age 65–75 years
Diabetes
Coronary artery disease
Thyrotoxicosis
Age less than 65 years
No risk factors
Stroke Prevention in Atrial Fibrillation (468) Women greater than 75 years
Systolic BP greater than 160 mm Hg
Left ventricular dysfunction†
History of hypertension
No high-risk features
No high-risk features
No history of hypertension
BP indicates blood pressure. Patients are classified on the basis of the presence or absence of any risk factor.
Adapted with permission from Am J Med, Vol. 109, Pearce et al., Assessment of these schemes for stratifying stroke risk in patients with nonvalvular atrial fibrillation, pp.
45–51, © 2000, with permission, from Excerpta Medica, Inc.
*Patients with AF and prior thromboembolism are at high risk of stroke, and anticoagulation is indicated for secondary prevention in such cases.
†Did not distinguish high-risk from intermediate-risk patients.
‡Left ventricular dysfunction refers to moderate to severe wall motion abnormality assessed globally by 2-dimensional echocardiography, reduced ejection fraction, fractional
shortening less than 0.25 by M-mode echocardiography, or clinical heart failure.
Table 19. Risk-Based Approach to Antithrombotic Therapy in Patients With Atrial Fibrillation
Patient Features Antithrombotic Therapy
Grade of
Recommendation
Age less than 60 years, no heart disease
(lone AF)
Aspirin (325 mg per day) or no therapy I
Age less than 60 years, heart disease but no
risk factors*
Aspirin (325 mg per day) I
Age greater than or equal to 60 years, no
risk factors*
Aspirin (325 mg per day) I
Age greater than or equal to 60 years with
diabetes mellitus or CAD
Oral anticoagulation (INR 2.0–3.0) I
Addition of aspirin, 81–162 mg per day is
optional
IIb
Age greater than or equal to 75 years,
especially women
Oral anticoagulation (INR ’2.0) I
HF
LV ejection fraction less than or equal to
0.35, thyrotoxicosis, and hypertension
Oral anticoagulation (INR 2.0–3.0) I
Rheumatic heart disease
(mitral stenosis)
Prosthetic heart valves
Prior thromboembolism
Persistent atrial thrombus on TEE
Oral anticoagulation
(INR 2.5–3.5 or higher may be
appropriate)
I
AF indicates atrial fibrillation; HF, heart failure; INR, international normalized ratio; LV, left ventricular; CAD, coronary artery
disease; and TEE, transesophageal echocardiography.
*Risk factors for thromboembolism include HF, LV ejection fraction less than 0.35, and history of hypertension.
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1,593 participants assigned to the control or placebo groups
of 5 randomized primary prevention trials in which 106
ischemic strokes occurred over a mean follow-up of 1.4 years
(28). This scheme divides patients into 2 strata, distinguish-
ing low-risk patients from those at intermediate or high
risk. Echocardiographic features were not considered ini-
tially, but subsequent analysis of 3 of these trials identified
abnormal LV systolic function as an independent predictor
of stroke (457). The SPAF study criteria were based on
multivariate analysis of 854 participants assigned aspirin in
the SPAF-I and -II clinical trials who were followed up for
a mean of 2.3 years, during which 68 ischemic strokes were
observed. A third set of criteria was developed by expert
consensus (462) based on consideration of the 2 foregoing
schemes and other available data to classify patients into
low-, intermediate-, and high-risk groups (Table 18).
Each of these schemes is predictive of stroke, but the
differences between them are potentially important for
patient management. Both the criteria derived by collabo-
rative analysis of concurrent primary prevention trials (28)
and those developed by expert consensus (462) identify a
smaller proportion of patients with a lower risk of stroke
than those classified as low risk on the basis of the SPAF
study criteria (463). The SPAF study scheme also desig-
nates some male patients over age 75 years as low risk,
whereas the other schemes classify all patients over age 75
years as high risk.
Although stratification of stroke risk identifies AF pa-
tients who benefit most and least from lifelong anticoagu-
lation, the threshold for use of anticoagulation is controver-
sial. Opinion is particularly divided about anticoagulation
for those at intermediate risk for stroke (3% to 5% per year).
Some advocate routinely providing anticoagulation to those
with stroke rates in this range (464), whereas others favor
selective anticoagulation of those at intermediate risk, with
weight given to individual bleeding risks and patient pref-
erences (29,463). The threshold of benefit at which AF
patients choose anticoagulation varies; some at intermediate
risk elect anticoagulation, whereas others do not (465).
The risk of thromboembolism for patients with chronic
atrial flutter has been variably reported but is generally
estimated as higher than for patients with sinus rhythm and
less than for those with persistent or permanent AF. On the
basis of multivariate analysis, Wood et al. (466) reported
hypertension as the only significant correlate of previous
thromboembolism for patients with chronic atrial flutter.
Biblo et al. (467) recently reviewed 8 years of retrospective
data on 749,988 hospitalized older patients, including 17,413
with atrial flutter and 337,428 with AF. The overall stroke risk
ratio for patients with atrial flutter was 1.406 compared with
the control group; for patients with AF, the relative risk was
1.642. Coexisting HF, rheumatic heart disease, and hyperten-
sion predicted an episode of AF in patients with atrial flutter.
Risk ratios for patients with these comorbid conditions were
1.243, 1.464, and 1.333, respectively (467).
As a chronic arrhythmia, atrial flutter is uncommon, and
the risk of thromboembolism is not as well established as it
is for AF. Until more robust data become available, and
although the overall thromboembolic risk associated with
atrial flutter may be lower than with AF, it seems prudent to
estimate risk by use of similar stratification criteria.
2. Antithrombotic Strategies for Prevention of Ischemic
Stroke and Systemic Embolism. Before 1990, antithrom-
botic therapy for prevention of ischemic stroke and systemic
embolism in patients with AF was limited mainly to those
with rheumatic heart disease and prosthetic heart valves
(14). Anticoagulation was also accepted therapy for patients
who had sustained ischemic stroke to prevent recurrence but
was often delayed to avoid hemorrhagic transformation.
Some advocated anticoagulation of patients with thyrotox-
icosis or other conditions associated with cardiomyopathy
and AF. Five large randomized trials published between
1989 and 1992 evaluated oral anticoagulation, and 2 tested
aspirin for primary prevention of thromboembolism in
patients with nonvalvular AF (32,456,468,469) (Fig. 16 and
Table 20). A sixth trial focused on secondary prevention
among patients who had survived nondisabling stroke or
transient cerebral ischemic attack (439). Meta-analysis ac-
cording to the principle of intention to treat showed that
adjusted-dose oral anticoagulation is highly efficacious for
prevention of all stroke (both ischemic and hemorrhagic),
with a risk reduction of 61% (95% CI 47% to 71%) vs.
placebo (460) (Fig. 17). This reduction was similar for both
primary and secondary prevention and for both disabling
and nondisabling strokes. Excluding patients not undergo-
ing oral anticoagulation at the time of stroke, the preventive
efficacy of oral anticoagulation exceeded 80%. Four of these
trials were placebo controlled; of the 2 that were double
blinded with regard to anticoagulation (469), one was
stopped early because of external evidence that oral antico-
agulation was superior to placebo. In 3 of the trials, oral
Figure 16. Antithrombotic therapy for prevention of stroke (ischemic and
hemorrhagic) in patients with nonvalvular AF: adjusted-dose warfarin
compared with placebo. Adapted with permission from Hart et al.
(163,460) Ann Intern Med 1999;131:492–501. (The American College of
Physicians–American Society of Internal Medicine is not responsible for
the accuracy of the translation.)
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anticoagulant dosing was regulated according to the pro-
thrombin time ratio; 2 used the INR, with target ranges of
2.5 to 4.0 and 2 to 3, respectively. These trials are summa-
rized in Table 20. The duration of follow-up in these trials
was generally between 1 and 2 years; the longest was 2.2
years, whereas in clinical practice, the need for antithrom-
botic therapy in patients with AF typically extends over
much longer periods.
Anticoagulation increases the frequency and severity of
major extracranial and intracranial hemorrhage, however,
and all of these trials excluded patients considered at high
risk of bleeding. Patient age and the intensity of anticoag-
ulation are the most powerful predictors of major bleeding
(470–473). Trial participants, at an average age of 69 years,
were carefully selected and managed. It is thus unclear
whether the relatively low rates of major hemorrhage also
apply to AF patients in clinical practice, who have a mean
age of about 75 years and whose anticoagulation therapy is
less closely regulated (37,474).
The target intensity of anticoagulation involves a balance
between prevention of ischemic stroke and avoidance of
hemorrhagic complications. Targeting the lowest adequate
intensity of anticoagulation to minimize the risk of bleeding
is particularly important for elderly AF patients. Maximum
protection against ischemic stroke in AF is probably
achieved with an INR range of 2.0 to 3.0 (438,475,476),
whereas an INR range of 1.6 to 2.5 appears to be associated
with incomplete efficacy, estimated at approximately 80% of
that achieved with higher-intensity anticoagulation (Fig.
17) (475,477). Two randomized trials with a target INR of
1.4 to 2.8 (estimated mean achieved INR 2.0 to 2.1) found
the largest relative risk reductions for ischemic stroke. A
trial in which AF patients with prior stroke or transient
ischemic attack were randomly assigned to target INR
ranges of 2.2 to 3.5 vs. 1.5 to 2.1 found a greater rate of
major hemorrhage with the higher intensity (478). For
patients with nonvalvular AF, an INR of 1.6 to 3.0 is
efficacious and relatively safe. For primary prevention in
most AF patients under age 75 years and for secondary
prevention, an INR of 2.5 (target range 2.0 to 3.0) seems
reasonable. A target INR of 2.0 (target range 1.6 to 2.5) is
recommended for primary prevention in patients more than
75 years old. In clinical trials, INRs achieved during
follow-up were more often below than above the target
range. Low-intensity anticoagulation requires special efforts
to minimize time spent below the target range, during
which stroke protection is sharply reduced.
From time to time, it may be necessary to interrupt oral
anticoagulant therapy in preparation for elective surgical
procedures. In patients with mechanical prosthetic heart
valves, it is generally appropriate to substitute unfraction-
ated or low-molecular-weight heparin to prevent thrombo-
Table 20. Randomized Trials of Antithrombotic Therapy in Patients With Nonvalvular Atrial Fibrillation
Trials Reference
Year
Published
No. of
Patients Interventions
Large Published Trials
Copenhagen Atrial Fibrillation, Aspirin, Anticoagulation I
(AFASAK I)
468 1989 1,007 OA, ASA, placebo
Copenhagen Atrial Fibrillation, Aspirin, Anticoagulation II
(AFASAK II)
487 1998 677 OA, ASA, OA*1ASA,
OA*
Stroke Prevention in Atrial Fibrillation I (SPAF I) 32 1991 1,330 OA, ASA, placebo
Stroke Prevention in Atrial Fibrillation II (SPAF II) 488 1994 1,100 OA, ASA
Stroke Prevention in Atrial Fibrillation III (SPAF III) 438 1996 1,044 OA, OA*1ASA
Boston Area Anticoagulation Trial for Atrial Fibrillation
(BAATAF)
456 1990 420 OA, control
Canadian Atrial Fibrillation Anticoagulation (CAFA) 489 1991 378 OA, placebo
Stroke Prevention in Nonrheumatic Atrial Fibrillation
(SPINAF)
469 1992 571 OA, placebo
European Atrial Fibrillation Trial (EAFT) 439 1993 1,007 OA, ASA, placebo
Studio Italiano Fibrillazione Atriale (SIFA) 490 1997 916 OA, indobufen
Minidose Warfarin in Nonrheumatic Atrial Fibrillation 491 1998 303 OA, OA*
Prevention of Arterial Thromboembolism in Atrial
Fibrillation (PATAF)
461 1999 729 OA, OA*, ASA
Small or pilot trials
Harenberg et al. 492 1993 75 LMW heparin, control
Low-dose Aspirin, Stroke, Atrial Fibrillation (LASAF) 493 1996 285 ASA, placebo
Subgroups with AF in other trials
European Stroke Prevention Study II (ESPS II) 494 1997 429 ASA, dipyridamole, placebo
Ongoing or unpublished AF trials
French Aspirin Coumarin Collaborative Study . . . . . . OA, OA1ASA
Swedish Atrial Fibrillation Trial . . . . . . . . .
Stroke Prevention using an Oral Thrombin Inhibitor in
Atrial Fibrillation (SPORTIF)
. . . . . . OA, thrombin inhibitor
AF indicates atrial fibrillation; OA, oral anticoagulation; OA*, low-dose oral anticoagulation; ASA, aspirin; LMW, low-molecular-weight.
Adapted with permission from Hart et al. (460) Ann Intern Med 1999;131:492–501. (The American College of Physicians–American Society of Internal Medicine is not
responsible for the accuracy of the translation.)
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sis (479,480). In patients with AF who do not have
mechanical valves, based on extrapolation from the annual
rate of thromboembolism in patients with nonvalvular AF,
it is the consensus of the writing group that anticoagulation
may be interrupted for a period of up to 1 week for surgical
or diagnostic procedures that carry a risk of bleeding,
without substituting heparin. In high-risk patients, or when
a series of procedures requires interruption of oral antico-
agulant therapy for a period longer than 1 week, unfraction-
ated or low-molecular-weight heparin may be administered
intravenously or subcutaneously, respectively.
The use of low-molecular-weight heparins instead of
unfractionated heparin in patients with AF is based largely
on extrapolation from venous thromboembolic disease
states. In general, low-molecular-weight heparins have sev-
eral pharmacological advantages over unfractionated hepa-
rin. These include a longer half-life, more predictable
bioavailability (greater than 90% after subcutaneous injec-
tion), predictable clearance (enabling once- or twice-daily
subcutaneous administration), and predictable antithrom-
botic response based on body weight, which permits fixed-
dose treatment without laboratory monitoring except under
special circumstances such as obesity, renal insufficiency, or
pregnancy (481). Treatment with low-molecular-weight
heparins is associated with a lower risk of heparin-induced
thrombocytopenia than unfractionated heparin (482). The
favorable properties of low-molecular-weight heparins may
simplify the treatment of AF in acute situations and shorten
or eliminate the need for hospitalization to initiate antico-
agulation. Self-administration of low-molecular-weight he-
parins out of hospital by patients with AF is a promising
approach that may result in cost savings in conjunction with
elective cardioversion (483).
Aspirin offers only modest protection against stroke for
patients with AF (Fig. 18). Meta-analysis of 5 randomized
trials showed a stroke reduction of 19% (95% CI 2% to 34%)
(460). The effect of aspirin on stroke in these trials was less
consistent than that of oral anticoagulation (460,484).
Differences in patient features may have influenced aspirin
efficacy. For example, aspirin reduced stroke occurrence by
33% in primary prevention studies (in which the stroke rate
with placebo averaged 5% per year) vs. 11% for secondary
prevention trials (in which the stroke rate with placebo
averaged 14% per year) (460). Aspirin may be more effica-
cious for AF patients with hypertension or diabetes
(484,485) and for reduction of noncardioembolic vs. cardio-
embolic ischemic strokes in AF patients (119). Cardioem-
bolic strokes are, on average, more disabling than noncar-
dioembolic strokes (155). Aspirin appears to prevent
nondisabling strokes more often than disabling strokes
(460); thus, the greater the risk of disabling cardioembolic
stroke in a population of AF patients, the less protection
afforded by aspirin (155).
In summary, adjusted-dose oral anticoagulation is more
efficacious than aspirin for prevention of stroke in patients
with AF, as suggested by indirect comparisons and by a 33%
risk reduction (95% CI 13% to 49%) in a meta-analysis of 5
randomized trials (460). Randomized trials involving high-
risk AF patients (stroke rates greater than 6% per year) show
larger relative risk reductions by adjusted-dose oral antico-
agulation relative to aspirin (Fig. 18), whereas the relative
risk reductions are consistently smaller in trials of AF
patients with lower stroke rates. Accordingly, oral antico-
agulation may be most beneficial for AF patients at higher
intrinsic thromboembolic risk, offering only modest reduc-
tions over aspirin in both the relative risk and absolute rates
of stroke for AF patients at low risk. Individual risk varies
over time, so the need for anticoagulation must be reeval-
uated at regular intervals in all patients with AF.
The combination of low-dose oral anticoagulation (INR
Figure 17. Adjusted odds ratios for ischemic stroke and intracranial bleeding in relation to intensity of anticoagulation in randomized trials of
antithrombotic therapy for patients with atrial fibrillation. Adapted with permission from Hylek et al. (472,475).
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less than 1.5) with aspirin adds little protection against
stroke compared with aspirin alone in patients with AF
(438). Combining aspirin with an oral anticoagulant at
higher anticoagulation intensities may accentuate intracra-
nial hemorrhage, particularly in elderly AF patients (486).
For AF patients who sustain cardioembolic events while
receiving low-intensity anticoagulation, the anticoagulation
intensity should be increased to a maximum target INR of
3 to 3.5 rather than routinely adding antiplatelet agents,
pending further data.
An emerging surgical option, not yet sufficiently investi-
gated to allow general clinical application, is obliteration of
the LAA to remove a principal nidus of thrombus formation
in patients with AF who cannot safely undergo anticoagu-
lation. In addition to direct surgical amputation or trunca-
tion of appendage, several methods are under development
to achieve this with intravascular catheters or transpericar-
dial approaches. These must presently be considered inves-
tigational, and indications for this type of intervention have
not been established convincingly.
Recommendations for Antithrombotic Therapy in
Patients With AF
Class I
1. Administer antithrombotic therapy (oral anticoag-
ulation or aspirin) to all patients with AF, except
those with lone AF, to prevent thromboembolism.
(Level of Evidence: A)
2. Individualize the selection of the antithrombotic
agent, based upon assessment of the absolute risks
of stroke and bleeding and the relative risk and
benefit for a particular patient. (Level of Evidence:
A)
3. Chronic oral anticoagulant therapy in a dose ad-
justed to achieve a target intensity INR of 2 to 3 in
patients at high risk of stroke, unless contraindi-
cated. (Level of Evidence: A)
a. The need for anticoagulation should be reeval-
uated at regular intervals. (Level of Evidence: A)
b. INR should be determined at least weekly dur-
ing the initiation of oral anticoagulation therapy
and monthly when the patient is stable. (Level of
Evidence: A)
4. Aspirin in a dose of 325 mg daily as an alternative
in low-risk patients or in those with certain contra-
indications to oral anticoagulation. (Level of Evi-
dence: A)
5. Oral anticoagulation for patients with AF who have
rheumatic mitral valve disease or prosthetic heart
valves (mechanical or tissue valves). (Level of Evi-
dence: B)
a. Base the target intensity of anticoagulation on
the particular type of prosthesis, but not less
than INR 2 to 3. (Level of Evidence: B)
Class IIa
1. Target a lower INR of 2 (range 1.6 to 2.5) for
primary prevention of ischemic stroke and systemic
embolism in patients over 75 years old considered at
increased risk of bleeding complications but with-
out frank contraindications to oral anticoagulant
therapy. (Level of Evidence: C)
2. Manage antithrombotic therapy for patients with
atrial flutter, in general, as for those with AF. (Level
of Evidence: C)
3. Select antithrombotic therapy using the same cri-
teria irrespective of the pattern of AF (i.e., for
patients with paroxysmal, persistent, or permanent
AF). (Level of Evidence: B)
Figure 18. Antithrombotic therapy for prevention of stroke (ischemic and hemorrhagic) in patients with nonvalvular AF: warfarin compared with aspirin
and aspirin compared with placebo. Adapted with permission from Hart et al. (163,460) Ann Intern Med 1999;131:492–501. (The American College of
Physicians–American Society of Internal Medicine is not responsible for the accuracy of the translation.)
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Class IIb
1. Interrupt anticoagulation for a period of up to 1
week for surgical or diagnostic procedures that
carry a risk of bleeding, without substituting hepa-
rin in patients with AF who do not have mechanical
prosthetic heart valves. (Level of Evidence: C)
2. Administer unfractionated or low-molecular-
weight heparin intravenously or subcutaneously,
respectively in selected high-risk patients or when a
series of procedures requires interruption of oral
anticoagulant therapy for a period longer than 1
week. (Level of Evidence: C)
3. Manage patients with CAD with anticoagulation
(INR 2 to 3) based on the same criteria used for
patients without CAD. (Level of Evidence: C)
a. A low dose of aspirin (less than 100 mg per day)
or clopidogrel (75 mg per day) may be given
concurrently with anticoagulation, but these
strategies have not been evaluated sufficiently
and may be associated with an increased risk of
bleeding. (Level of Evidence: C)
4. Treatment with aspirin is optional for primary
prevention of stroke in patients under 60 years of
age without heart disease or risk factors for throm-
boembolism (lone AF). (Level of Evidence: C)
Class III
Long-term anticoagulation for stroke prevention in
patients under 60 years of age without heart disease
(lone AF) and without risk factors for thromboembo-
lism. (Level of Evidence: C)
3. Conversion to Sinus Rhythm and Thromboembolism.
Randomized studies of antithrombotic therapy are lacking
for patients undergoing cardioversion of AF or atrial flutter,
but the risk of thromboembolism was between 1% and 5% in
case-control series (292,495). Risk was nearer the lower end of
this spectrum when anticoagulation pretreatment (INR 2 to 3)
(29) was given for 3 to 4 weeks before and after conversion
(100,297). It is now common practice to administer anticoag-
ulant drugs to patients with AF of more than 2 days’ duration
when they are prepared for cardioversion. Manning et al. (195)
suggested that TEE might be used to identify patients without
LAA thrombi who do not require anticoagulation, but a
subsequent investigation (205) and meta-analysis of several
clinical studies found this approach to be unreliable (496).
If most AF-associated strokes result from embolism of
stasis-induced thrombi from the LAA, then restoration and
maintenance of atrial contraction should logically reduce
thromboembolic risk. LV function can improve after car-
dioversion (497), potentially lowering embolic risk and
improving cerebral hemodynamics (498). There is no solid
clinical evidence that cardioversion followed by prolonged
maintenance of sinus rhythm effectively reduces thrombo-
embolism in AF patients. It is thus unclear at present
whether efforts to restore and maintain sinus rhythm are
justified for the specific purpose of preventing stroke.
Conversion of AF to sinus rhythm results in transient
mechanical dysfunction of the LA and LAA (459) known as
“stunning,” which can occur after spontaneous, pharmaco-
logical (499,500), or electrical (500–502) conversion of AF
or after radiofrequency catheter ablation of atrial flutter
(503) and which may be associated with spontaneous echo
contrast (459). Recovery of mechanical function may be
delayed for several weeks, depending in part on the duration
of AF before restoration of sinus rhythm (110,504,505).
This could explain why some patients with no demonstrable
LA thrombus on TEE before cardioversion subsequently
experience thromboembolic events (205). Presumably,
thrombus forms during the period of stunning and is
expelled after the return of mechanical function, which
explains the clustering of thromboembolic events in the first
10 days after cardioversion (506).
Patients in whom LAA thrombus is identified by TEE
appear to be at high risk of thromboembolism after cardio-
version of AF or atrial flutter, and they should be treated
with anticoagulation for at least 3 to 4 weeks before and
after either pharmacological or electrical cardioversion. In a
multicenter study of 1,222 patients with either AF persist-
ing longer than 2 days or atrial flutter and previous AF (201)
who were randomized to a TEE-guided or conventional
strategy, one group underwent anticoagulation with heparin
briefly before and with warfarin for 4 weeks after cardiover-
sion. Cardioversion was postponed when thrombus was
identified, and warfarin was administered for 3 weeks before
TEE was repeated. The other group received anticoagula-
tion for 3 weeks before and 4 weeks after cardioversion.
Both approaches were associated with a comparably low risk
of stroke (0.81% with the TEE approach and 0.50% with
the conventional approach) after 8 weeks of follow-up, and
the risk of major bleeding did not differ significantly. There
were no differences in the proportion of cardioverted sub-
jects, and thus the clinical benefit of the TEE approach was
limited to saving time before cardioversion.
In contrast to the perceived low rate of thromboembolism
in patients with chronic atrial flutter, stroke or systemic
embolism at the time of cardioversion to sinus rhythm has
been reported often (507–509), and anticoagulation should
be considered with either the conventional or TEE-guided
strategy. TEE-guided cardioversion of atrial flutter has been
performed with a low rate of systemic embolism, particularly
when patients are stratified for other risk factors on the basis
of clinical and/or TEE features (339,340).
Anticoagulation is recommended for 3 to 4 weeks before
and after cardioversion for patients with AF of unknown
duration or with AF for more than 48 h. Although LA
thrombus and systemic embolism have been documented in
patients with AF of shorter duration, the need for antico-
agulation is less clear. When acute AF produces hemody-
namic instability in the form of angina pectoris, MI, shock,
or pulmonary edema, immediate cardioversion should not
be delayed to achieve therapeutic anticoagulation. Never-
theless, intravenous heparin or low-molecular-weight hep-
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arin should be initiated before cardioversion by synchronous
direct-current countershock or intravenous antiarrhythmic
medication.
Protection against late embolism may require continua-
tion of anticoagulation for a more extended period after the
procedure, and the duration of anticoagulation after cardio-
version depends both on the likelihood that AF will recur in
an individual patient and on the patient’s intrinsic risk of
thromboembolism. Late events are probably due to both the
development of thrombus as a consequence of atrial stunning
and the delayed recovery of atrial contraction after cardiover-
sion. Berger and Schweitzer (506) pooled data from 32 studies
on the timing of clinical thromboembolic events after cardio-
version of AF or atrial flutter, 98% of which occurred within 10
days. These data support the use of anticoagulation for at least
2 weeks after cardioversion, but they have not been verified by
prospective randomized studies.
Recommendations for Antithrombotic Therapy to
Prevent Ischemic Stroke and Systemic Embolism in
Patients With AF Undergoing Cardioversion
Class I
1. Administer anticoagulation therapy regardless of
the method (electrical or pharmacological) used to
restore sinus rhythm. (Level of Evidence: B)
2. Anticoagulate patients with AF lasting more than
48 h or of unknown duration, for at least 3 to 4
weeks before and after cardioversion (INR 2 to 3).
(Level of Evidence: B)
3. Perform immediate cardioversion in patients with
acute (recent onset) AF accompanied by symptoms
or signs of hemodynamic instability resulting in
angina pectoris, MI, shock, or pulmonary edema,
without waiting for prior anticoagulation. (Level of
Evidence: C)
a. If not contraindicated, administer heparin con-
currently by an initial intravenous bolus injec-
tion followed by a continuous infusion in a dose
adjusted to prolong the activated partial throm-
boplastin time at 1.5 to 2 times the reference
control value. (Level of Evidence: C)
b. Next, provide oral anticoagulation (INR 2 to 3)
for a period of at least 3 to 4 weeks, as for
patients undergoing elective cardioversion.
(Level of Evidence: C)
c. Limited data from recent studies support subcu-
taneous administration of low-molecular-weight
heparin in this indication. (Level of Evidence: C)
4. Screening for the presence of thrombus in the LA
or LAA by TEE is an alternative for routine
preanticoagulation in candidates for cardioversion
of AF. (Level of Evidence: B)
a. Anticoagulate patients in whom no thrombus is
identified in the form of intravenous unfraction-
ated heparin by an initial bolus injection before
cardioversion, followed by a continuous infusion
in a dose adjusted to prolong the activated
partial thromboplastin time at 1.5 to 2 times the
reference control value. (Level of Evidence: B)
b. Next, provide oral anticoagulation (INR 2 to 3)
for a period of at least 3 to 4 weeks, as for
patients undergoing elective cardioversion.
(Level of Evidence: B)
c. Limited data are available to support the subcu-
taneous administration of low-molecular-weight
heparin in this indication. (Level of Evidence: C)
d. Treat patients in whom thrombus is identified
by TEE with oral anticoagulation (INR 2 to 3)
for at least 3 to 4 weeks before and after resto-
ration of sinus rhythm. (Level of Evidence: B)
Class IIb
1. Cardioversion without TEE guidance during the
first 48 h after the onset of AF. (Level of Evidence: C)
a. In these cases, anticoagulation before and after
cardioversion is optional, depending on assessment
of risk. (Level of Evidence: C)
2. Anticoagulate patients with atrial flutter undergo-
ing cardioversion in the same way as for patients
with AF. (Level of Evidence: C)
H. Special Considerations
1. Postoperative AF. Although AF may occur after
noncardiac surgery, the incidence of atrial arrhythmias
including AF after open heart surgery is between 20% and
50% (510–512), depending on definitions and methods of
detection. The incidence of postoperative AF is growing,
perhaps more because of the age of surgical patients than
because of technical factors, and this increases patient
morbidity and hospital costs.
A. CLINICAL AND PATHOPHYSIOLOGICAL CORRELATES.
Postoperative AF usually occurs within the first 5 days of
cardiac surgery, with a peak incidence on day 2. The
dysrhythmia usually runs a self-correcting course, and more
than 90% of patients have resumed sinus rhythm by 6 to 8
weeks after surgery (513), a rate of spontaneous resolution
higher than for other forms of AF. A number of studies
have addressed clinical conditions that may predict postop-
erative AF with conflicting results, related in part to sample
size (511,514–518). The most reproducible factor is age.
Other independent predictors—most of which are clinically
obvious—include valvular heart disease, chronic lung dis-
ease, atrial enlargement, and preoperative atrial arrhythmias
(Table 21). In many cases, however, none of these features
are present. It is likely that the collagen content of the atria
of older patients is greater than in younger individuals (519).
This may serve as a substrate on which various intraopera-
tive and postoperative factors act to trigger AF after cardiac
surgery (520) (Table 21). Among these factors are pericar-
ditis (521) and increased sympathetic tone.
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B. PREVENTION OF POSTOPERATIVE AF. It is important to
consider prophylactic treatment of patients at greatest risk
of developing postoperative AF. Over the past decade,
pretreatment with beta-blockers decreased the incidence of
AF in several clinical trials from 40% to 20% in patients
undergoing coronary artery bypass graft (CABG) surgery
and from 60% to 30% in those undergoing valvular proce-
dures (512,513,522). In a meta-analysis of 24 trials (512)
limited to CABG patients with ejection fraction greater
than 30%, prophylactic beta-blockade protected against
development of supraventricular tachycardia (summary odds
ratio of 0.28, 95% CI 0.21 to 0.36).
Sotalol, which in its dl-racemic form has both beta-
blocking and type III antiarrhythmic activity, is effective for
prophylaxis against postoperative AF. In one study (523)
comparing sotalol 120 mg per day with metoprolol 75 mg
per day, AF developed in 16% of patients given sotalol vs.
32% of those treated with metoprolol (p 5 0.01). This
finding was confirmed in a smaller study (524) in which
sotalol (80 or 120 mg twice a day) reduced postoperative AF
compared with beta-blocker or placebo (12.5% vs. 38%), but
not in another large study (208) that found little difference
between sotalol and beta-blocker treatment.
When the prophylactic value of amiodarone 600 mg per
day initiated at least 7 days preoperatively was evaluated in
124 patients undergoing cardiac surgery, the incidence of
AF was 25% in the treated group compared with 53% with
placebo (p 5 0.003) (525). This approach is impractical
unless patients are identified and treatment started at least a
week before surgery. The Amiodarone Reduction in Coro-
nary Heart (ARCH) trial found that postoperative admin-
istration of intravenous amiodarone (1 g per day for 2 days)
reduced the incidence of postoperative AF from 47% to 35%
vs. placebo in 300 patients (p 5 0.01). The higher overall
incidence of postoperative AF and more modest prophylac-
tic effect than in other studies may have been related in part
to less frequent use of beta-blockers (526).
Pretreatment with either digoxin or verapamil does not
prevent postoperative AF (512,527,528). Results with pro-
cainamide have been inconsistent, and this drug is not
widely used for prevention of postoperative AF (529). Other
agents, such as disopyramide (526) or flecainide (529), have
not been studied extensively because of concerns about the
risks associated with type IC agents in patients with
coronary disease.
Single-chamber and biatrial overdrive pacing have been
used to prevent postoperative AF. In a recent randomized
trial, postoperative biatrial pacing reduced the incidence of
AF to 13% from 36% with LA pacing, 33% with RA
pacing, and 42% without pacing in 132 patients undergoing
CABG. Hospital length of stay was also abbreviated in the
biatrial pacing group (530). Prophylactic atrial pacing to
prevent postoperative AF requires further investigation
before specific recommendations for its use can be made.
C. TREATMENT OF POSTOPERATIVE AF. Because of comor-
bidity including adrenergic stress, it may be difficult to
control the ventricular rate in patients with postoperative
AF. This can be accomplished with a beta-blocker, and
short-acting agents are particularly useful when hemody-
namic instability is a concern. Other AV nodal blocking
agents, such as calcium channel antagonist agents, can be
used as alternative therapy, but digoxin is less effective when
adrenergic tone is high. Intravenous amiodarone has been
associated with improved hemodynamics in this setting
(426).
Given the self-limited course of postoperative AF, elec-
trical cardioversion is usually unnecessary except when the
dysrhythmia develops in the immediate postoperative (hy-
pothermic) period. In the highly symptomatic or poorly
controlled patient, cardioversion may be performed with the
same precautions regarding anticoagulation as in nonsurgi-
cal cases. A variety of pharmacological agents, including
amiodarone (531,532), procainamide (533,534), ibutilide,
and sotalol, may be used to convert AF to sinus rhythm.
Although a type III agent (e.g., ibutilide) was more effective
than placebo in one study for treatment of postoperative AF
(535), oral sotalol is appealing in this situation because its
beta-blocking action slows the ventricular rate and proar-
rhythmic toxicity is relatively infrequent, but this agent
appears to be less effective than the others for cardioversion.
A number of studies have shown an increased risk of
stroke in post-CABG patients, so anticoagulation with
heparin or an oral anticoagulant is appropriate when AF
persists more than 48 h (536,537). However, this entails
special challenges because of the greater potential for bleed-
ing in surgical patients. The choice of drug, heparin and/or
an oral anticoagulant, must be based on the individual
clinical situation.
Atrial flutter is less common than AF after cardiac
surgery (538). Pharmacological therapy for patients with
atrial flutter is similar to that for patients with AF. Preven-
tion of postoperative atrial flutter is as difficult as prevention
of AF.
Table 21. Multivariate Predictors of Postoperative Atrial
Arrhythmias in Patients Undergoing Myocardial
Revascularization Surgery
Advanced age
Male gender
Digoxin
Peripheral arterial disease
Chronic lung disease
Valvular heart disease
Left atrial enlargement
Previous cardiac surgery
Discontinuation of beta-blocker medication
Preoperative atrial tachyarrhythmias
Pericarditis
Elevated postoperative adrenergic tone
Adapted with permission from the Society of Thoracic Surgeons (The Annals of
Thoracic Surgery 1993;56:539–49) (511).
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Recommendations for Prevention and Management of
Postoperative AF
Class I
1. Treat patients undergoing cardiac surgery with an
oral beta-blocker to prevent postoperative AF, un-
less contraindicated. (Level of Evidence: A)
2. In patients who develop postoperative AF, achieve
rate control by administration of AV nodal blocking
agents. (Level of Evidence: B)
Class IIa
1. Administer sotalol or amiodarone prophylactically
to patients at increased risk of developing postop-
erative AF. (Level of Evidence: B)
2. Restore sinus rhythm in patients who develop
postoperative AF by pharmacological cardioversion
with ibutilide or direct-current cardioversion, as
recommended for nonsurgical patients. (Level of
Evidence: B)
3. In patients with recurrent or refractory postopera-
tive AF, attempt maintenance of sinus rhythm by
administration of antiarrhythmic medications, as
recommended for patients with CAD who develop
AF. (Level of Evidence: B)
4. Administer antithrombotic medication in patients
who develop postoperative AF, as recommended for
nonsurgical patients. (Level of Evidence: B)
2. Acute MI. Estimates of the incidence of AF in patients
with acute MI vary depending on the population sampled.
In the Cooperative Cardiovascular Project, 22% of Medi-
care patients aged greater than or equal to 65 years hospi-
talized for acute MI had AF (171). In the TRACE
(Trandolapril Cardiac Evaluation) study of patients with
LV dysfunction associated with acute MI, 21% had AF
(539). Lower rates of AF were observed in patients selected
for other prospective trials, such as GUSTO-I (Global
Utilization of Streptokinase and Tissue Plasminogen Acti-
vator for Occluded Coronary Arteries), in which the inci-
dence was 10.4% (540), but this may reflect the younger age
of patients who present with acute MI associated with
ST-segment elevation on the ECG. AF is more commonly
associated with acute MI in those who are older, have
higher Killip class, and have LV dysfunction.
Atrial fibrillation is an independent risk factor for in-
creased in-hospital mortality in the setting of acute MI
(25.3% with AF vs. 16.0% without AF), 30-day mortality
(29.3% vs. 19.1%), and 1-year mortality (48.3% vs. 32.7%)
(171); patients who developed AF during hospitalization
had a worse prognosis than those with AF on admission
(171). Stroke rates are also increased in patients with MI
and AF compared with those without AF (540). Outcomes
appear to have improved in the thrombolytic era for patients
with AF and acute MI compared with experience between
1981 and 1983 (541), but a stroke rate of 3.1% in the setting
of AF and acute MI (540) emphasizes the importance of
this association even in the era of thrombolysis.
Specific recommendations for therapy of AF in the
setting of acute MI are primarily based on consensus,
because no adequate trials have tested alternate strategies.
Urgent electrical cardioversion is appropriate for patients
presenting with AF related to acute MI, intractable ischemia,
or hemodynamic instability. Intravenous administration of a
beta-blocker and digoxin is also indicated for rate control in
patients with acute MI to reduce myocardial oxygen demands.
Anticoagulants are indicated in those with large anterior
infarcts and in survivors of acute MI with persistent AF. ACE
inhibition appears to reduce the incidence of AF in patients
with LV dysfunction after acute MI (539).
Management decisions have been summarized in the
ACC/AHA Guidelines for the Management of Patients
With Acute Myocardial Infarction (542) and are reflected in
the consensus recommendations as follows.
Recommendations for Management of Patients With
AF and Acute MI
Class I
1. Electrical cardioversion for patients with severe
hemodynamic compromise or intractable ischemia.
(Level of Evidence: C)
2. Intravenous administration of digitalis or amioda-
rone to slow a rapid ventricular response and
improve LV function. (Level of Evidence: C)
3. Intravenous beta-blockers to slow a rapid ventric-
ular response in patients without clinical LV dys-
function, bronchospastic disease, or AV block.
(Level of Evidence: C)
4. Heparin for patients with AF and acute MI, unless
contraindications to anticoagulation are present.
(Level of Evidence: C)
Class III
Administer type IC antiarrhythmic drugs in patients with
AF in the setting of acute MI. (Level of Evidence: C)
There have been no controlled studies of cardioversion,
antiarrhythmic drugs, or other interventions to maintain
sinus rhythm for stable patients with AF in acute MI.
Physicians should apply the guidelines for management
outlined elsewhere in this document with emphasis on
recognition of AF and risk stratification and should recog-
nize the significance of the dysrhythmia as an independent
predictor of poor long-term outcome in patients with acute
MI (543,544).
3. WPW Preexcitation Syndromes. Atrial fibrillation may
induce ventricular fibrillation and sudden death in patients
with the WPW syndrome when atrial impulses are con-
ducted antegrade across a bypass tract. This complication is
feared but infrequent. The incidence of sudden death ranges
from 0 to 0.6% per year in patients with WPW
(370,485,510,545). In contrast, a large population-based
study in Olmsted County, Minnesota, found 4 newly
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diagnosed cases of WPW per 100,000 population per year;
only 2 sudden deaths occurred over 1,338 patient-years of
follow-up. Among 113 patients with WPW, 6 had docu-
mented AF and 3 had atrial flutter. Patients with WPW
syndrome at high risk of sudden death are those with short
antegrade bypass tract refractory periods (less than 250 ms)
and short R-R intervals during preexcited AF (180 plus or
minus 29 ms) (97,546). In patients prone to ventricular
fibrillation, there is also a higher incidence of multiple
pathways (97).
Catheter ablation of bypass tracts should be considered
for most symptomatic patients with WPW (547), particu-
larly those who have had documented AF or syncope (suggest-
ing rapid heart rate) or those with a short bypass tract refractory
period. Ablation of the bypass tract will not necessarily prevent
the occurrence of AF, especially in older patients, and addi-
tional pharmacological therapy may be required.
Patients with WPW in whom AF occurs with a rapid
ventricular response associated with hemodynamic instabil-
ity should be cardioverted immediately because of the high
risk of developing ventricular fibrillation. When a patient
with a preexcited tachycardia is clinically stable, intravenous
procainamide may be given to convert the atrial mechanism
to sinus rhythm. It is critically important to avoid agents
with the potential to increase the refractoriness of the AV
node, which could encourage preferential conduction over
the accessory pathway. Specifically, administration of AV
nodal blocking agents such as digoxin, diltiazem, or vera-
pamil is contraindicated. Beta-blockers are ineffective in this
situation, and their administration by the intravenous route
may have adverse hemodynamic effects. Intravenous aden-
osine may be used when the QRS complex is narrow (less
than 120 ms duration) during the tachycardia, because this
indicates that antegrade conduction is occurring through the
AV node.
Recommendations for Management of AF and
Ventricular Preexcitation
Class I
1. Catheter ablation of the accessory pathway in symp-
tomatic patients with AF who have WPW syn-
drome, particularly those with syncope due to rapid
heart rate or those with a short bypass tract refrac-
tory period. (Level of Evidence: B)
2. Immediate electrical cardioversion to prevent ventric-
ular fibrillation in patients with WPW in whom AF
occurs with a rapid ventricular response associated
with hemodynamic instability. (Level of Evidence: B)
3. Intravenous procainamide or ibutilide in an at-
tempt to restore sinus rhythm in patients with
WPW in whom AF occurs without hemodynamic
instability in association with a wide QRS complex
on the ECG (greater than or equal to 120 ms
duration). (Level of Evidence: C)
Class IIb
Administer intravenous quinidine, procainamide, diso-
pyramide, ibutilide, or amiodarone to hemodynamically
stable patients with AF involving conduction over an
accessory pathway. (Level of Evidence: B)
a. Immediate cardioversion is required when very
rapid tachycardias or hemodynamic instability oc-
curs in patients with AF involving conduction over
an accessory pathway. (Level of Evidence: B)
Class III
Intravenous administration of beta-blocking agents,
digitalis glycosides, diltiazem, or verapamil in pa-
tients with WPW syndrome who have preexcited
ventricular activation in AF. (Level of Evidence: B)
4. Hyperthyroidism. AF occurs in 10% to 25% of patients
with hyperthyroidism, more commonly in men and the
elderly than in women or patients less than 75 years old
(548,549). Treatment is primarily directed toward restoring
a euthyroid state, which is usually associated with a spon-
taneous reversion to sinus rhythm. Antiarrhythmic drugs
and electrical cardioversion are generally unsuccessful while
the thyrotoxic condition persists (550,551). Beta-blockers
are somewhat effective in controlling the ventricular rate in
this situation, and aggressive treatment with intravenous
beta-blockers is particularly important in cases of thyroid
storm, for which high doses may be required. Calcium
channel antagonists may also be useful (551). Although
specific evidence is lacking in AF caused by hyperthyroid-
ism, oral anticoagulation is recommended to prevent sys-
temic embolism (552).
Recommendations for Management of AF in Patients
With Hyperthyroidism
Class I
1. Administer a beta-blocker as necessary to control
the rate of ventricular response in patients with AF
complicating thyrotoxicosis, unless contraindi-
cated. (Level of Evidence: B)
2. In circumstances when a beta-blocker cannot be
used, administer a calcium channel antagonist (dil-
tiazem or verapamil) to control the ventricular rate.
(Level of Evidence: B)
3. In patients with AF associated with thyrotoxicosis,
use oral anticoagulation (INR 2 to 3) to prevent
thromboembolism, as recommended for AF pa-
tients with other risk factors for stroke. (Level of
Evidence: C)
a. Once a euthyroid state is restored, recommen-
dations for antithrombotic prophylaxis are the
same as for patients without hyperthyroidism.
(Level of Evidence: C)
5. Pregnancy. Atrial fibrillation is rare during pregnancy
(553) and is usually associated with another underlying
cause, such as mitral stenosis (554), congenital heart disease
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(555), or hyperthyroidism (556). A rapid ventricular re-
sponse to AF can have serious hemodynamic consequences
for both the mother and the fetus.
In a pregnant woman who develops AF, diagnosis and
treatment of the underlying condition causing the dysrhyth-
mia is the first priority. The ventricular rate should be
controlled with digoxin, a beta-blocker, or a calcium chan-
nel antagonist (557–559). All currently available antiar-
rhythmic drugs have the potential to cross the placenta and
to be excreted in breast milk and should be avoided if
possible. Quinidine (558), mexiletine (560), sotalol (561),
flecainide (561), and amiodarone (559,562–564) have all
been used successfully during pregnancy in a relatively small
number of cases. Quinidine has the longest record of safety
in pregnant women and remains the agent of choice for
pharmacological cardioversion of AF in this situation
(308,558). In the event of hemodynamic embarrassment,
electrical cardioversion can be performed without fetal
damage (565).
The role of anticoagulation to prevent systemic arterial
embolism has not been systematically studied in pregnant
patients with AF, but the dysrhythmia is frequently associ-
ated with conditions that carry a high risk of thromboem-
bolism, including congenital or valvular heart disease. Con-
sideration should be given to avoiding warfarin because it
crosses the placental barrier and is associated with terato-
genic embryopathy in the first trimester and with fetal
hemorrhage in the later stages of pregnancy (566–572). The
preferred anticoagulant is heparin, which does not cross the
placenta. The value of subcutaneous unfractionated heparin
or low-molecular-weight heparin in preventing ischemic
stroke in patients with AF has not been proven, however,
and the use of these agents is based predominantly on
experience in patients with prosthetic heart valves or venous
thromboembolism.
Recommendations for Management of AF During
Pregnancy
Class I
1. Control the rate of ventricular response with
digoxin, a beta-blocker, or a calcium channel an-
tagonist. (Level of Evidence: C)
2. Electrical cardioversion in patients who become
hemodynamically unstable due to the dysrhythmia.
(Level of Evidence: C)
3. Administer antithrombotic therapy (anticoagulant
or aspirin) throughout pregnancy to all patients
with AF (except those with lone AF). (Level of
Evidence: C)
Class IIb
1. Attempt pharmacological cardioversion by admin-
istration of quinidine, procainamide, or sotalol in
hemodynamically stable patients who develop AF
during pregnancy. (Level of Evidence: C)
2. Administer heparin to patients with risk factors for
thromboembolism during the first trimester and
last month of pregnancy. Unfractionated heparin
may be administered either by continuous intrave-
nous infusion in a dose sufficient to prolong the
activated partial thromboplastin time to 1.5 to 2
times the control (reference) value or by intermit-
tent subcutaneous injection in a dose of 10,000 to
20,000 units every 12 h, adjusted to prolong the
mid-interval (6 h after injection) activated partial
thromboplastin time to 1.5 times control. (Level of
Evidence: B)
a. Limited data are available to support the sub-
cutaneous administration of low-molecular-
weight heparin for this indication. (Level of
Evidence: C)
3. Administer an oral anticoagulant during the second
trimester to patients at high thromboembolic risk.
(Level of Evidence: C)
6. Hypertrophic Cardiomyopathy. Opinions differ re-
garding the clinical significance of AF in the setting of
HCM. In a retrospective series of 52 patients studied
between 1960 and 1985, 89% of patients who developed AF
experienced clinical deterioration that was ameliorated by
restoration of sinus rhythm (164). In a multivariate analysis
of a population-based cohort of 37 patients with HCM who
experienced an annual cardiac mortality rate of 5%, AF was
associated with decreased survival (445). A lower annual
mortality rate (1.3%) was observed in a single-center retro-
spective study of 277 patients with HCM. The prevalence
of AF was 18%; among the 50 cases with AF, 15 deaths
were recorded, a third of which were attributed to stroke
(446). The natural history of HCM is better defined in the
combined experience of 3 large centers, which included 717
cases followed up for a mean of 8 plus or minus 7 years.
Eighty-six deaths (12%) occurred, of which 51% were
sudden death (mean age 45 plus or minus 20 years); death
was attributable to HF in 36% of patients (mean age 56 plus
or minus 19 years) and to stroke in 13% (mean age 73 plus
or minus 14 years). Ten of the 11 fatal strokes were
associated with AF. Although most of the sudden deaths
were attributed to ventricular arrhythmias, cardiogenic
stroke may have been underestimated as a contributory
mechanism (573).
There have been no systematic studies of the treatment of
AF in patients with HCM, but various antiarrhythmic
agents, including disopyramide, propafenone, and amioda-
rone, have been used. Some authors advocate administration
of amiodarone both to prevent episodes of AF and to
modulate the rate of ventricular response (574). The use of
electrical pacing to prevent AF has not been studied, but the
high incidence of ischemic stroke in patients with HCM
who develop AF justifies efforts to restore and maintain
sinus rhythm and to use anticoagulant medication.
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Recommendations for Management of AF in Patients
With HCM
Class I
Treat patients with HCM who develop AF with oral
anticoagulation (INR 2 to 3) as recommended for
other high-risk patients for prevention of thromboem-
bolism. (Level of Evidence: B)
Class IIa
Antiarrhythmic medications to prevent recurrences.
Available data are insufficient to recommend one agent
over another in this situation, but disopyramide and
amiodarone are generally preferred. (Level of Evidence:
C)
7. Pulmonary Diseases. Supraventricular arrhythmias, in-
cluding AF, are common in patients with chronic obstruc-
tive lung disease (575,576) and have adverse prognostic
implications in patients with acute exacerbations of chronic
obstructive pulmonary disease (577). Treatment of the
underlying lung disease and correction of hypoxia and
acid-base imbalance are of primary importance. Theophyl-
line and beta-adrenergic agonists, which are commonly used
to relieve bronchospasm in these patients, can precipitate
AF and make it difficult to control the rate of ventricular
response. Beta-blockers, sotalol, propafenone, and adeno-
sine are contraindicated in patients with bronchospasm and
wheezing. Rate control can usually be achieved safely with
calcium channel antagonists (578); digoxin offers no advan-
tage over calcium channel antagonists in this situation.
Pharmacological antiarrhythmic therapy and electrical car-
dioversion may be ineffective against AF until respiratory
decompensation has been corrected. Intravenous flecainide
may be efficacious in restoring sinus rhythm in some
patients (232). Electrical cardioversion may be attempted in
hemodynamically unstable patients. In resistant cases, AV
nodal ablation and ventricular pacing may be necessary to
control the ventricular rate. The role of anticoagulation in
patients with AF due to chronic obstructive lung disease has
not been studied specifically.
Recommendations for Management of AF in Patients
With Pulmonary Diseases
Class I
1. In patients who develop AF during an acute pul-
monary illness or exacerbation of chronic pulmo-
nary disease, correction of hypoxemia and acidosis
are the primary therapeutic measures. (Level of
Evidence: C)
2. In patients with obstructive pulmonary disease who
develop AF, a calcium channel antagonist agent
(diltiazem or verapamil) is preferred for ventricular
rate control. (Level of Evidence: C)
3. Attempt electrical cardioversion in patients with
pulmonary disease who become hemodynamically
unstable owing to AF. (Level of Evidence: C)
Class III
1. Use of theophylline and beta-adrenergic agonist
agents in patients with bronchospastic lung disease
who develop AF. (Level of Evidence: C)
2. Use of beta-blockers, sotalol, propafenone, and
adenosine in patients with obstructive lung disease
who develop AF. (Level of Evidence: C)
I. Primary Prevention
Although measures aimed at the primary prevention of AF
have not been widely investigated, 2 randomized trials have
demonstrated that atrial or AV synchronous pacing reduces
the incidence of subsequent AF in patients with bradycardia
compared with ventricular pacing (401,579,580). Whether
this merely reflects avoidance of AF induced by ventricular
pacing or actual prevention of AF by atrial or AV synchro-
nous pacing is not known, because no difference emerged
until 2 years after pacemaker implantation in the recently
published Canadian Trial of Physiologic Pacing (580).
Another potential avenue for primary prevention has been
suggested by a secondary analysis of a placebo-controlled
trial of the angiotensin converting enzyme inhibitor tran-
dolapril in survivors of acute MI, which found a lower
incidence of AF in treated patients (26). Given the associ-
ation between hypertension and AF, it would be helpful to
know whether some types of antihypertensive therapy are
superior to others for prevention of AF and whether
controlling blood pressure itself can reduce the incidence of
AF. It may be that some of the benefit of treating hyper-
tension with respect to lowering the incidence of stroke may
be due to the prevention of AF. (See Section V, Pathophys-
iological Mechanisms). Insufficient data are available at this
time to permit recommendations for primary prevention of
AF in populations at risk.
IX. PROPOSED MANAGEMENT STRATEGIES
A. Overview of Algorithms for Management of Patients
With AF
Management of patients with AF requires knowledge of its
pattern of presentation (paroxysmal, persistent, or perma-
nent) and decisions about restoration and maintenance of
sinus rhythm, control of the ventricular rate, and anticoag-
ulation. These issues are addressed in the various manage-
ment algorithms for each presentation of AF (Figs. 9, 10,
11, and 12).
1. Newly Discovered AF (Fig. 9). It is not always clear
whether the initial presentation of AF is actually the patient’s
first episode, particularly in those with minimal or no symp-
toms of the dysrhythmia, so both are considered together. In
patients who have self-limited episodes of AF, antiarrhyth-
mic drugs to prevent recurrence are usually unnecessary
unless AF is associated with severe symptoms related to
hypotension, myocardial ischemia, or HF. Whether these
individuals require long-term or even short-term anticoag-
ulation is not clear, and the decision must be individualized
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for each patient based on the intrinsic risk of thromboem-
bolism. When AF persists, one option is to accept progres-
sion to permanent AF, with attention to antithrombotic
therapy and control of the ventricular rate. Although it may
seem reasonable to make at least one attempt to restore
sinus rhythm, this may not be in the best interest of all
patients. An example is the older man without risk factors
for thromboembolism in whom asymptomatic AF is dis-
covered on routine examination and control of the ventric-
ular rate is readily achieved. Here, the potential toxicity of
antiarrhythmic drugs may outweigh the benefit of restora-
tion of sinus rhythm. If the decision is made to attempt to
restore and maintain sinus rhythm, anticoagulation and rate
control are important before cardioversion. Although long-
term antiarrhythmic therapy may not be needed to prevent
recurrent AF after cardioversion, short-term therapy may be
beneficial. In patients with AF of more than 3 months’
duration, early recurrence is common after cardioversion.
Antiarrhythmic medication may be initiated before cardio-
version (after adequate anticoagulation) in such cases to
reduce the likelihood of recurrence, and the duration of drug
therapy would be brief (e.g., 1 month).
2. Recurrent Paroxysmal AF (Figs. 10, 11). In patients
who experience brief or minimally symptomatic recurrences
of paroxysmal AF, it is reasonable to avoid antiarrhythmic
drugs, but troublesome symptoms generally call for suppres-
sive antiarrhythmic therapy. Rate control and prevention of
thromboembolism are appropriate in both situations. In any
given patient, several different antiarrhythmic drugs may be
effective, and thus the initial selection is based mainly on
safety (Fig. 11). For individuals with no or minimal struc-
tural heart disease, flecainide, propafenone, and sotalol are
recommended as initial antiarrhythmic therapy because they
are generally well tolerated and are essentially devoid of
extracardiac organ toxicity. When one or another of these
drugs is ineffective or is associated with side effects, then
second or third-line choices include amiodarone, dofetilide,
disopyramide, procainamide, and quinidine, which have
greater potential for adverse reactions. A nonpharmacologi-
cal approach may be appropriate for some patients, and this
should be considered before amiodarone therapy is insti-
tuted. Occasionally, a consistent initiating factor may be
found, such as vagally mediated AF (in which case drugs
such as disopyramide or flecainide are appropriate initial
agents) or adrenergically induced AF (for which beta-
blockers or sotalol is suggested).
Many patients with organic heart disease can be broadly
categorized into those with HF, CAD, or hypertension.
Other types of heart disease can be associated with AF, and
the clinician must determine which of these categories best
fits the individual patient. For patients with HF, safety data
support the selection of amiodarone or dofetilide to main-
tain sinus rhythm. Patients with ischemic heart disease
often require beta-blocker medication, and sotalol, a drug
with both beta-blocking activity and primary antiarrhythmic
efficacy, is considered first, unless the patient has HF.
Amiodarone and dofetilide are considered secondary agents,
and the clinician may consider disopyramide, procainamide,
or quinidine on an individual basis. In patients with hyper-
tension without LV hypertrophy, drugs such as flecainide
and propafenone, which do not prolong repolarization and
the QT interval, may offer a safety advantage and are
recommended first. If these agents either prove ineffective or
produce side effects, then amiodarone, dofetilide, or sotalol
represent appropriate secondary choices. Disopyramide,
procainamide, and quinidine are considered third-line
agents in this situation. Hypertrophied myocardium may be
prone to proarrhythmic toxicity and development of the
torsade de pointes type of ventricular tachycardia. Amioda-
rone is suggested as first-line therapy in patients with LV
hypertrophy (wall thickness greater than or equal to 1.4 cm)
because of its relative safety compared with several other
agents. Because neither ECG nor echocardiography invari-
ably detects LV hypertrophy as defined by measurement of
myocardial mass, clinicians may face a conundrum. The
selection of antiarrhythmic drugs for patients with a history
of hypertension is compounded by the dearth of prospective,
controlled trials comparing the safety and efficacy of drug
therapy for AF.
The scarcity of data from randomized trials of antiar-
rhythmic medications for treatment of patients with AF
applies generally to all patient groups. Accordingly, the
drug-selection algorithm presented here has been developed
as a consensus of experts and is particularly subject to
revision as additional evidence emerges in this field.
3. Recurrent Persistent AF (Figs. 11, 12). Patients with
minimal or no symptoms referable to AF who have under-
gone at least 1 attempt to restore sinus rhythm may remain
in AF after its second occurrence, with therapy for rate
control and prevention of thromboembolism as needed.
Alternatively, those with symptoms favoring sinus rhythm
should be treated with an antiarrhythmic agent (in addition
to medications for rate control and anticoagulation) before
cardioversion. The selection of an antiarrhythmic drug
should be based on the same algorithm used for patients
with recurrent paroxysmal AF.
4. Permanent AF (Fig. 12). Permanent AF is the desig-
nation given to cases in which sinus rhythm cannot be
sustained after cardioversion of AF or when the patient and
physician have decided to allow AF to continue without
further efforts to restore sinus rhythm. It is important to
maintain control of the ventricular rate and to use anti-
thrombotic therapy, as outlined elsewhere in this document,
for all patients in this category.
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